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Abstract 
Background: Allergen-specific immunotherapy is an effective treatment for seasonal allergic 
rhinitis. Clinical trials may be confounded by variable allergen exposure. Nasal allergen 
provocation might provide a useful surrogate to assess the efficacy of immunotherapy and 
identify biomarkers of response.   
Objective: Nasal allergen provocation was used to assess the efficacy of allergen 
immunotherapy and identify local and systemic immune biomarkers.  
Methods:  Dose and time course responses to grass-pollen nasal provocations were studied 
in 20 allergic individuals. Different matrices were compared for absorption and isolation of 
nasal mucosal fluid for immunoassay of inflammatory mediators. Optimised techniques were 
then applied to cat-allergen nasal provocation in 18 allergic individuals, along with 
assessment of in vitro basophil allergen-induced activation. Finally, in a cross-sectional study, 
responses to grass-pollen provocation were compared in 14 untreated grass-pollen allergics, 
18 immunotherapy-treated patients, and 14 non-atopic controls.  
Results: Nasal responses to allergen were dose-dependent. Symptoms peaked at 5 minutes 
post challenge; overall, there was no distinct late-phase clinical response. Nasal fluid tryptase 
peaked at 5 minutes; IL-4, -5, -9, -13 and eotaxin peaked at 8 hours. Basophil allergen-induced 
activation in vitro was enhanced at 6 hours compared to pre-challenge.  
Grass-pollen immunotherapy-treated patients had lower symptom scores (45% lower, 
p=0.04) and higher peak nasal inspiratory flow, PNIF (54% higher, p=0.02) after challenge than 
untreated-allergics. They had reduced early (27% lower, p=0.0007) and late (51% lower, 
p<0.0001) skin responses, and lower retrospective seasonal symptom scores (60% lower, 
p<0.0001). Nasal challenge response correlated with seasonal symptoms (symptoms: r=0.52, 
p<0.003; PNIF: r=-0.57, p<0.001). Immunotherapy-treated patients had reduced nasal fluid IL-
4, IL-9 and eotaxin (p<0.05), and trends for reduced IL-13 and tryptase levels (p=0.07).   
Conclusions: Nasal allergen challenge is sensitive in the detection of clinical and biological 
effects of allergen immunotherapy and may be a useful surrogate marker of treatment 
efficacy in future studies.  
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1. Introduction 
1.1 Allergic rhinitis 
Rhinitis means inflammation of the nasal mucosa. It is clinically defined as symptoms including 
nose running (rhinorrhoea), blocking/congestion, itching, and sneezing for two or more 
consecutive days, with symptoms usually lasting for more than an hour (Bousquet J, 2001). 
Allergic rhinitis (AR) is mediated by interaction of allergen with mast cell-bound allergen-
specific IgE antibodies in the nasal mucosa. In the UK, it has traditionally been classified as 
either perennial, in response to allergens, such as house dust mite, present throughout the 
year, or seasonal, caused by allergens, typically pollens, present for only limited months of 
the year. International consensus since 2001 has been for a move away from these historic 
classifications, dividing instead according to both duration of symptoms and their severity, 
particularly with regards to impact on daily life (Bousquet J, 2001).  
1.1.1 Epidemiology 
Allergic rhinitis is a common problem in the UK, with reported prevalence of 10.1% and 15.3% 
in 6-7 and 13-14 year olds, respectively (Asher MI, 2006), and 23.6-29.2% in adults aged 20-
44 (Burney P, 1996; Bauchau and Durham, 2004). Peak prevalence appears to occur in the 3rd 
and 4th decades (Eriksson J, 2010; Blomme K, 2013), with some evidence for remission in 
allergic sensitisation during adult life (Warm K, 2012). Prevalence in the UK and Western 
Europe has increased dramatically over the past 4-5 decades (Brabeck L, 2004; Gupta R, 2007).  
Some studies indicate a plateau may have been reached (Asher MI, 2006; Gupta R, 2007; 
Björkstén B, 2007; Braun-Fahrlander C, 2004), but others report continued increases since the 
1990s (McNeill G, 2009; Duggan EM, 2012; Ghouri N, 2008). Worldwide, there appears to be 
a correlation between economic and industrial development and the prevalence of allergic 
rhinitis (Asher MI, 2006; Katerlaris CH, 2011); post-communist Eastern Europe has seen 
increased prevalence (von Mutius E, 1998).  
Allergic rhinitis adversely affects sufferers’ quality of life, impairing work and education 
performance (Blanc PD, 2001; Juniper EF, 1994; Walker S, 2007), sleep quality (Meltzer EO, 
2009), mood (Meltzer EO, 2012) and cognitive function (Marshall and Colon, 1993), as well as 
causing embarrassment (Marshall and Colon, 1993). The economic burden of allergic rhinitis 
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is substantial, running into billions of dollars per year in the United States alone, including 
direct healthcare costs – physician visits and prescription medication - as well as the indirect 
costs resulting from impaired work performance (Reed SD, 2004; Meltzer and Bukstein, 2011).  
1.1.2 Aetiology 
Genetic predisposition is the most important factor in the development of allergic rhinitis (van 
Beijsterveldt CE, 2007; Rasanen M, 1998), but identification of specific susceptibility genes 
has proved difficult. The development of large scale, genome wide association studies (GWAS) 
has allowed identification of several candidate loci and genes for asthma and atopic 
dermatitis (Moffatt MF, 2007; Moffatt MF, 2010; Paternoster L, 2012). To date, only one such 
GWAS has been carried out for AR (Ramasamy A, 2011). Future studies may further elucidate 
specific risk genes. Of note, classical genetic change (i.e. change in DNA nucleotide sequence) 
is unable to account for the rapid increase in prevalence of AR seen in recent years, suggesting 
environmental factors (and possible gene-environment interactions) are important. 
Epigenetic modifications, such as DNA methylation, may be involved in the mechanism of 
gene-environment interactions in allergic diseases (Kabesch M, 2014). 
Epidemiological evidence suggests various environmental factors are relevant, particularly in 
early life: smaller family size, urban environments and reduced exposure to infectious disease 
appear to increase the risk of developing rhinitis (Strachan DP, 1989; Riedler J, 2001; 
Matricardi PM, 2002); rural environments, early life farm animal exposure, unpasteurised 
milk consumption and other aspects of an anthroposophic lifestyle may confer protection 
(Loss G, 2011; Sozanska B, 2013; Beasley R, 2008) – in general supportive of Strachan’s so-
called ‘hygiene hypothesis’ (Strachan DP, 1989). Investigation of other early life factors has 
provided less clear cut, or frankly conflicting data, such as the effects of breast feeding and 
domestic pet exposure (Hesselmar B, 1999; Brunekreef B, 2012; Björkstén B, 2011; Kellberger 
J, 2012).  
Whilst certain occupations are linked to the development of rhinitis - bakers, furriers, 
veterinarians, livestock workers (Hytonen M, 1997), many of the environmental exposures 
occurring in adult life have a less well-defined effect, including cigarette smoking, air-
pollution, vitamin D levels, alcohol and physical activity. It has been postulated that climate 
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change is leading to longer pollination periods and may lead to a further increase in rhinitis 
prevalence in coming decades (Kim SH, 2011).  
1.1.3.a Immunology of allergic rhinitis 
Allergic sensitisation is a prerequisite in the development of allergic rhinitis. Evidence of 
sensitisation can generally be detected systemically – in serum or on skin testing – but there 
also appears to be a cohort of individuals who only manifest allergen-specific IgE at the 
mucosa itself, so-called local allergic rhinitis (Rondon C, 2009). Development of sensitisation 
is likely to be dependent on intrinsic factors – genetic predisposition and, perhaps, epigenetic 
modifications – and extrinsic factors including dose, timing, route and duration of allergen 
exposure (Custovic A, 2015). Allergen is deposited at the mucosa and is taken-up by antigen 
presenting cells, particularly dendritic cells. These cells are subsequently able to migrate to 
regional lymph nodes before presenting peptide fragments to T cells on MHC class II 
molecules (Wheatley and Togias, 2015). In order to induce a significant response, additional 
stimuli and an appropriate inflammatory milieu are likely required. This may be provided by 
activation of the epithelium by, for example, intrinsic allergen protease activity (as in the case 
of house dust mite) and/or ligation of innate immune receptors by viral and bacterial 
anitgens, or even by pollutants, particularly particulate matter. The epithelium is a source of 
cytoknies and chemokines, with recent evidence from murine studies and human studies of 
the lower airway implicating mediators including TSLP, IL-25 and IL-33 (Gregory LG, 2013; 
Saglani S, 2013; Jackson DJ, 2013). These epithelial-derived cytokines appear to promote Th2 
polarisation via direct effects on antigen presenting cells and by activation of type 2 innate 
lymphoid cells with a high capacity for secretion of IL-4 and IL-13 in particular. Evidence for a 
definitive role for these cytokines in allergic rhinitis, as opposed to asthma or nasal polyps, is 
still lacking (Scadding G, 2014). Priming of dendritic cells and a Th2-rich environment promote 
the development of Th2 cells from non-polarised (Th0) T cells following engagement of 
allergen peptide on MHC class II with the requisite T-cell receptors (TCRs) in the context of 
co-stimulation with CD80/86 on the APC surface binding to CD20 on the T-cell. Further T-cell 
derived IL-4 and IL-13 help promote B-cell class-switching to IgE following T-cell – B-cell 
interaction in regional lymph nodes, resulting in production of IgE secreting plasma cells. 
These antibodies subsequently may bind to high-affinity IgE receptors (FcϵR1) on the surface 
of mast cells and basophils, as well as low affinity receptors (FcϵRII) on antigen presenting 
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cells. This results in the local mucosa being primed for an inflammatory, allergic response on 
subsequent allergen exposure (Sin and Togias, 2011).  
1.1.3.b Pathophysiology 
The basic mechanisms of allergic rhinitis, following re-exposure to allergen in a sensitised 
individual, are illustrated in Figure 1. At the nasal mucosa, allergen molecules bind and cross-
link allergen-specific surface IgE on mast cells, causing degranulation. In the normal state, IgE 
is bound to the tetrameric high affinity receptor, FcεR1, forming a stable complex on the cell 
surface. The α subunit of FcεR1 is responsible for IgE binding, the βγ2 complex responsible for 
signal transduction. Studies of basophils (the circulating equivalent of the tissue-resident 
mast cell), suggest anywhere between 6,000 and 600,000 surface bound IgE molecules may 
be present, with the density proportional to serum IgE. An allergen must have two or more 
IgE binding sites (being at least divalent or in dimeric form) to enable FcεR1 cross-linking and 
surface clustering. Studies suggest that clustering of as little as 1% of surface FcεR1 may be 
sufficient to induce degranulation (Wu LC, 2011; Knol EF, 2006; Kambayashi and Koretzky, 
2007). 
Following degranulation, pre-formed mediators such as histamine stimulate sensory nerve 
endings within seconds, causing itch and sneezing, and promote dilatation of local vasculature 
and glandular secretion, causing obstruction and rhinorrhoea, respectively. Prostaglandin D2 
(PGD2) is a vasodilator, contributing to nasal obstruction, but also acts on CRTH2 
(chemoattractant homologous receptor expressed on Th2 cells) and promotes influx of T-
cells, eosinophils, and basophils. Newly-synthesised mediators, including leukotrienes, as well 
as chemokines and cytokines, contribute to a delayed eosinophil and Th2 T-cell predominant 
inflammation - the late phase response - characterised by nasal obstruction and 
hyperreactivity (Hansen I, 2004). Leukotrienes C4, D4 and E4 act at cysteinyl leukotriene 
recptors (CysLT1 and CysLT2) to promote dilatation and permeability of local capillary beds, 
mucus secretion and leukocyte activation. Mast cell-derived cytokines including IL-4 and IL-
13 promote further IgE production and mucus secretion, whilst IL-5 promotes eosinophil 
survival and activation. Other factors including IL-6, IL-8 and TNF-α promote upregulation of 
adhesion molecules on endothelial cells, such as VCAM-1, and further leukocyte recruitment. 
Hence mast cells also play a significant role in mediating the late phase allergic response. 
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Basophils have been shown to accumulate during the LPR, releasing mediators such as 
histamine (Naclerio R, 1985), IL-4 and IL-13 (Pawankar R, 2011). They may subsequently have 
a role in further allergen presentation given that they express MHC class II molecules and 
CD80/86 (Barnes PJ, 2011). Recruitment of T-cells, eosinophils and basophils is mediated by 
chemokines released from activated epithelial cells and dendritic cells including TARC (thymus 
and activation-regulated chemokine/CCL17), MDC (macrophage-derived chemokine/CCL22), 
eotaxin-1 (CCL11) and RANTES (regulated on activation, normal T cell expressed and 
secreted/CCL5) (Barnes PJ, 2011; Pewankar R, 2011). Stem cell factor (SCF), released from the 
epithelium, is important in maintaining mast cells in the airway mucosa. Allergen is also 
encountered by antigen presenting cells in the mucosa on re-exposure. The primary cell 
involved is the dendritic cell, but other cells including macrophages, mast cells, eosinophils 
and basophils may also contribute (Barnes PJ, 2011). Subsequent presentation of peptide 
fragments to T cells may lead to further stimulation of the Th2 response and encourage B cell 
class switching and secretion of IgE, as well as stimulating eosinophil recruitment and mucous 
secretion, via interleukins 4, 5 and 13. Evidence for these IgE-independent mechanisms is 
provided by the finding that administration of allergen peptide fragments into the skin can 
lead to isolated late phase asthmatic responses in the absence of an early phase response 
(Oldfield WL, 2002).  
Eosinophils are a cardinal feature of allergic inflammation. Whilst they secrete cysteinyl 
leukotrienes and various cytokines and may act as antigen presenting cells, their main effects 
are seen through the release of highly cationic and basic proteins from intracellular granules 
including ECP (eosinophil cationic protein), MBP (major basic protein) and EDN (eosinophil-
derived neurotoxin). They may also generate reactive oxygen species through the action of 
eosinophil peroxidase. Whilst these substances have roles in fighting both helminth and viral 
infections, in the context of allergic rhinitis and other forms of allergic inflammation, they 
contribute to cell toxicity, tissue damage and inflammation (Liao W, 2015). In the context of 
asthma, eosinophilia is associated with severe exacerbations and often found within the lungs 
at autopsy in deaths from acute asthma.  
Additional mechanisms are likely to be relevant. These include neuro-immune interactions, 
such as release of neuropeptides (substance P, calcitonin gene-related peptide) and 
neurokinins from sensory nerve endings in response to inflammatory mediators (Van Gerven 
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L, 2012). The role of the epithelium, particularly its interaction with newly-defined type 2 
innate lymphoid cells (ILC2), has been scrutinised in murine asthma and allergy models 
(Licona-Limón P, 2013; Lloyd CM, 2010) as well as in human asthma (Ying S, 2008; Saglani S, 
2013). Further research is needed to confirm the relevance of epithelial-derived cytokines 
such as TSLP, IL-33 and IL-25 as well as ILC2 cells in allergic rhinitis (Scadding G, 2014).  
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1.1.4 Diagnosis 
Allergic rhinitis presents with symptoms including rhinorrhoea, blocking/congestion, itching, 
and sneezing. In seasonal allergic rhinitis induced by pollens or moulds itching, sneezing and 
anterior rhinorrhoea may be predominant features. Conversely, with chronic allergen 
exposure, for example to house dust mite, nasal blockage and post nasal drip may be more 
problematic. The presence of eye symptoms – allergic rhinoconjunctivitis – including itch, 
redness and watering, is typical of allergic rhinitis, as opposed to non-allergic rhinitis. Patients 
with troublesome rhinitis may also complain of sleep disturbance, snoring, dry mouth, and 
throat-clearing (Scadding GK, 2008). Co-existing or previous history of atopic diseases such as 
asthma, eczema and food allergy make a diagnosis of allergic rhinitis more likely, as does a 
strong family history of atopy. Whilst allergic rhinitis can develop at any age, onset is typically 
in the first 3 decades; however, relocation from areas of low prevalence to areas of high 
prevalence in adult life can result in first presentation of AR at older ages. Similarly, certain 
occupations may lead to the development of allergic rhinitis dependent on length of time in 
the job (i.e. duration of allergen exposure), rather than age (Hytonen M, 1997).  
Clues to a diagnosis of allergic rhinitis on examination include mouth breathing, sniffing, use 
of tissues, transverse nasal crease and/or an ‘allergic salute’. The presence of eczema, 
periorbital skin darkening (‘allergic shiners’) and conjunctivitis also point toward the 
diagnosis. Examination of the nasal mucosa by anterior rhinoscopy or endoscopy typically 
reveals a congested, pale mucosa, with a clear mucous discharge. The presence of nasal 
polyps, sinus discharge, or marked crusting and bleeding suggest alternative/additional 
diagnoses. The chest should be examined for signs of asthma in patients presenting with 
rhinitis as approximately one third are likely to have clinically overt lower airway involvement 
(Leynaert B, 2004), whilst an even higher proportion may have subclinical bronchial hyper-
reactivity. Clinical examination may be normal in patients with seasonal allergic rhinitis if 
examined outside of usual seasonal allergen exposure. 
A diagnosis of allergic rhinitis requires a suitable history plus demonstration of specific IgE 
against one or more plausibly causative allergens. This can be done by either skin prick testing 
or serum IgE testing (the latter now most commonly performed by the ImmunoCAP technique 
developed by Phadia, now part of ThermoFisher Scientific). In clinical practice, a range of 10-
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12 geographically relevant allergens is usually sufficient, but the history may at times 
implicate less common triggers. If no demonstration of allergen specific IgE can be made on 
skin and serum testing, but a suspect allergic trigger is identified, then confirmation of (local) 
allergic rhinitis can be made by properly controlled, blinded nasal allergen challenge (Rondon 
C, 2009). Additional tests which may be used in the assessment, rather than diagnosis, of 
allergic rhinitis include tests of the nasal airway such as peak nasal inspiratory flow, 
rhinomanometry and acoustic rhinometry as well as tests of nasal mucosal inflammation such 
as nasal nitric oxide and nasal mucous eosinophil estimation, although these are 
predominantly used in research settings rather than routine clinical practice. Additional tests 
including blood tests and imaging (CT, MRI) are indicated only when alternative/additional 
diagnoses are considered. Finally, assessment of the lower airway by spirometry, peak 
expiratory flow or bronchial provocation (histamine, methacholine) may also be indicated.  
1.1.5 Treatment 
Several useful guidelines exist for the treatment of allergic rhinitis, both national – BSACI 
guidelines, 2008 (Scadding GK, 2008), and international – ARIA guidelines, 2001 and 2008 
(Bousquet J, 2001; Bousquet J, 2008). Figure 2 outlines the classification of allergic rhinitis 
according to ARIA, Figure 3 a step-wise summary of treatment recommendations. The 
effectiveness of allergen avoidance, particularly for house dust mite, remains controversial, 
with a Cochrane meta-analysis not supporting single avoidance measures (Sheikh A, 2010). 
Nonetheless, in principle, allergen avoidance can improve allergic airway symptoms (as 
exemplified by relocation of mite allergic children to an altitude above which mites do not 
inhabit (Peroni DG, 1994)), and this may also be possible in practice, albeit using multiple 
interventions (Morgan WJ, 2004). Reduction of outdoor, seasonal allergen exposure can be 
achieved through lifestyle modifications and by nasal filters (O’Meara TJ, 2005), although 
neither of these approaches is necessarily acceptable to most patients. Nasal douching is well-
tolerated and useful for clearing nasal mucous and residual allergen. Similarly, frequent 
showering and hair-washing may help during periods of pollen exposure.  
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The mainstay of treatment for allergic rhinitis is intranasal corticosteroids. These treat all 
major symptoms, including conjunctivitis (Scadding GK, 2008; Kaiser HB, 2007). Whilst oral or 
local nasal antihistamines may be adequate for mild symptoms, their predominant effect is 
on itch and sneezing, with little impact on congestion in particular. Intranasal corticosteroids 
have better efficacy than systemic or local anti-histamines, or a combination of anti-histamine 
and anti-leukotriene (Weiner JM, 1998; Wilson AM, 2004; Di Lorenzo G, 2004). With regards 
to anti-histamines, only second generation, non-sedating medications should be used. 
Sedating anti-histamines are associated with impaired work and academic performance 
(Walker S, 2007), as well as typical anti-muscarinic side effects, such as dry mouth and urinary 
retention. A number of different intranasal corticosteroids are available. Use of latter-
generation molecules with low systemic bioavailability is recommended, for example 
fluticasone propionate, fluticasone furoate and mometasone furoate; however, growth may 
still need to be monitored in young children, particularly if using  corticosteroids at other sites 
– skin, inhaled – in addition. Low volume sprays are used preferentially, however higher 
volume nasal drops may be used for brief periods in some patients, particularly where there 
is troublesome nasal congestion (Scadding GK, 2008).  
Additional treatment options include eye-drops (chromones or anti-histamines), anti-
leukotrienes in patients with co-existent asthma and brief use of intranasal decongestants. 
Short courses of oral prednisolone may be used in patients with particularly troublesome 
seasonal allergic rhinitis, but depot intramuscular steroids are not recommended (Scadding 
GK, 2008; Bousquet J, 2008). Combined single intranasal spray with steroid (fluticasone 
propionate) and anti-histamine (azelastine) has been found to have benefit over either drug 
alone (Carr W, 2012) and may have a place in the treatment of individuals not adequately 
responding to an intranasal corticosteroid. Finally, it should be emphasised that education of 
patients and careful instruction on how and when to use medication is essential. This should 
be done at first consultation and subsequently if required, alongside questions about 
adherence to prescribed medications.  
Whilst most patients will respond well to these measures, a significant proportion continues 
to have inadequately controlled symptoms or unacceptable side effects from medications. In 
such individuals allergen-specific immunotherapy may be indicated.  
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1.1.6 Allergic rhinitis and asthma 
Rhinitis is strongly associated with asthma: 74-81% of asthmatics report symptoms of rhinitis 
(Leynaert B, 2004); rhinitis is a strong risk factor for new-onset asthma (Guerra S, 2002; 
Settipane RJ, 1994; Shabaan R, 2008). (Whilst this link appears strongest with allergic rhinitis, 
it is also apparent for non-allergic rhinitis). The presence of rhinitis impairs asthma control, 
increases beta-agonist use, physician visits and risk of hospitalisation (Thomas M, 2005; 
Sazonov Kocevar V, 2005; Clatworthy J, 2009; Magnan A, 2008). Treating allergic rhinitis with 
intranasal corticosteroids improves both upper and lower airway symptoms during seasonal 
ragweed exposure (Welsh PW, 1987) and can reduce lower airway hyperreactivity, as 
measured by methacholine provocation (Dahl R, 2005; Corren J, 1992). Treatment of allergic 
rhinitis with intranasal corticosteroids reduces the risk of both Accident and Emergency visits 
and hospitalisation for asthma (Corren J, 2004; Crystal Peters J, 2002; Adams RJ, 2002). A 
recent systematic review with meta-analysis of the efficacy of intranasal corticosteroids on 
asthma outcomes in patients with both allergic rhinitis and asthma demonstrated overall 
significant beneficial effects in several outcomes – FEV1, bronchial hyperreactivity, asthma 
symptom scores, and rescue medication use (Lohia S, 2013).  However, the results were 
driven by studies involving patients not on concurrent inhaled cortiocsteroids, with no such 
effects seen in the three trials which included patients also taking inhaled corticosteroids 
regularly. Moreover, effect sizes were small, with perhaps limited clinical relevance. 
Conversely, only mild asthmatics were studied, and exacerbation rates were not evaluated 
whereas measurement of the latter has proven the most sensitive outcome in several recent 
studies of interventions for more severe asthma (Busse W, 2011; Nair P, 2009; Haldar P, 2009; 
Wenzel S, 2013).  
 
1.2 Allergen-specific Immunotherapy 
Allergen-specific immunotherapy is the process of repeatedly administering an allergen 
extract to an individual with IgE-mediated disease caused by that allergen, with the aim of 
reducing symptoms on future re-exposure to the allergen, improving quality of life and 
inducing long-term tolerance (adapted from Alvarez-Cuesta E, 2006). In the UK, 
immunotherapy is indicated for pollen-induced seasonal allergic rhinitis inadequately 
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controlled by intranasal corticosteroids and/or anti-histamines, for individuals having had 
systemic IgE-mediated reactions to hymenoptera venom stings, and for individuals with 
perennial allergic rhinitis to house dust mite or animal allergens where allergen avoidance 
measures and optimal pharmacotherapy are inadequate to control symptoms (Walker SM, 
2011). The practice of immunotherapy for allergic disease has been around for over a century 
(Noon L, 1911). In some countries, including the UK, the practice of allergen immunotherapy 
passed from specialist centres into general practice during the 1970s and 1980s. However, 
this coincided with a number of fatalities, resulting in a report by the Committee on Safety of 
Medicines (CSM update, BMJ 1986;293:948) in which recommendations were made that 
immunotherapy should only be undertaken in facilities where full cardiorespiratory 
resuscitation are immediately available, and patients should be kept under medical 
observation for at least two hours after injections. This led to a dwindling of immunotherapy 
use in the UK. Whilst services have subsequently increased, immunotherapy remains 
underused in comparison to other parts of Europe and the USA. Conversely, the safety of the 
practice has undoubtedly improved.  
Sublingual immunotherapy emerged as an alternative to classical subcutaneous treatment 
from the 1980s onwards. The first double-blind placebo controlled trial was published in 1986 
(Scadding and Brostoff); the first successful double-blind placebo controlled trial of grass 
pollen sublingual treatment was published in 1994 (Sabbah A). The approach received 
recognition by the WHO in 1998 and was incorporated into the ARIA guidelines in 2001 
(Bousquet J, 2001). A meta-analysis of sublingual immunotherapy trials published in 2005 
confirmed a positive treatment effect (Wilson DR).  
1.2.1 Current approaches to allergen-specific immunotherapy 
Subcutaneous immunotherapy is administered as a series of gradually increasing doses of 
purified allergen extract in solution with or without an adjuvant, such as aluminium 
hydroxide. Up-dosing schedules vary between manufacturers and clinics, but a typical 
regimen includes weekly injections over 2-4 months until a maintenance dose is reached, 
followed by repeat injections of this dose every 4-8 weeks over a period of 3-5 years. Current 
practice in the UK is for patients to be monitored for an hour after each injection, as this is 
the time period during which systemic reactions are most likely to occur. Up-dosing schedules 
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and even the final maintenance dose may be adjusted in the event of local or systemic 
reactions to injections.  
Sublingual immunotherapy was initially administered in drops, taken sublingually and held in 
the mouth before swallowing. In 1998 the first study using oro-dispersible tablets was 
published (Passalacqua G); since then, tablet administration has become the preferred 
method. Whilst early studies undertook a brief up-dosing schedule, most now simply involve 
once daily administration of a single, high dose. In the UK, the first tablet is taken under 
supervision in a specialist centre, with observation for one hour afterwards. Subsequent 
doses may then be taken at home. The standard treatment period is for 3 years (Walker SM, 
2011).  
1.2.2 Efficacy of current treatments 
A Cochrane meta-analysis of subcutaneous immunotherapy studies for allergic rhinitis 
(Calderon MA, 2007) included 15 studies and found a significant effect versus placebo, with a 
standardised mean difference in symptom scores of -0.73 (-0.97, -0.50) and heterogeneity of 
63%. A meta-analysis of sublingual immunotherapy for allergic rhinitis was published in 2005 
and updated in 2011 (Wilson, 2005; Radulovic, 2011). The update gave a standardised mean 
difference in symptom scores of -0.49 (-0.64, -0.34) with heterogeneity of 81%. Of note, the 
most recent, large-scale trials of grass pollen allergen immunotherapy have produced 
relatively similar effect sizes for both subcutaneous and sublingual immunotherapy, with an 
approximate 30% reduction in seasonal symptoms and 40% reduction in medication use 
(Frew, 2006; Dahl, 2006). High quality, direct head to head comparisons of the two treatment 
modalities are lacking. A study by Khinchi et al (Khinchi MS, 2004) of birch pollen 
subcutaneous versus sublingual immunotherapy versus placebo showed both treatments to 
be effective compared to placebo, but a trend toward a greater effect from subcutaneous 
treatment. A systematic review of both treatments, with an adjusted indirect comparison 
between the two also found a trend towards greater efficacy of subcutaneous treatment, but 
concluded that superiority could not be confirmed based on the currently available data 
(Dretzke J, 2013). There is a paucity of direct comparative studies between either form of 
allergen-specific immunotherapy and pharmacological treatments for allergic rhinitis, but 
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indirect comparisons suggest a far greater effect than anti-histamines and anti-leukotrienes, 
and an equal or superior effect compared to intranasal corticosteroids (Matricardi PM, 2011).  
1.2.3 Safety 
There is a possibility of systemic reactions, including life-threatening reactions, with allergen 
immunotherapy. The risk of such reactions depends on patient factors, particularly the 
presence of asthma, and clinic/administration factors, particularly clinical experience with 
allergen immunotherapy. It was problems with the latter, as well as injudicious patient 
selection, which led to the near collapse of the use of this treatment in the UK in the 1980s. 
Nonetheless, even with optimum clinical practice and care, such reactions will occasionally 
occur, in which case the emphasis is on the administrating clinic to have the capacity to deal 
with them effectively and safely. Analyses have determined a systemic reaction rate of 1 per 
1,000 injections, with life-threatening, grade 4 reactions (as per World Allergy Organisation 
grading) occurring at 1 per 1,000,000 injections, and fatalities at 1 per 2-2,500,000 injections 
(Abramson MJ, 2010). Sublingual immunotherapy undoubtedly has the edge in this regard, 
with one serious adverse reaction per 384 treatment years and a total of just 12 systemic 
reactions (all non-fatal) published to date (Makatsori and Calderon, 2014). Conversely, local 
side effects are common with this form of administration: oral pruritus, intraoral oedema, 
throat irritation and ear pruritus affect at least 5% of patients (Dahl R, 2006; Didier A, 2007; 
Bufe A, 2009). However, the majority of these symptoms subside within 2 weeks of beginning 
treatment (Ibanez MD, 2007).  
1.2.4 Long-term effects of immunotherapy 
A major advantage of immunotherapy over pharmacotherapy for allergic rhinitis is the 
potential for long-lasting symptom reduction after discontinuation of treatment, indicative of 
immune tolerance. Induction of clinical tolerance by subcutaneous immunotherapy for grass 
pollen was demonstrated by Durham in 1999 (Durham SR, 1999). In this double-blind, 
placebo-controlled study, three years treatment provided a further 3 years of effective 
symptom relief following discontinuation, equivalent to that of individuals continuing active 
treatment for a further 3 years, and significantly better than a control allergic group.  
Tolerance induction by sublingual immunotherapy with grass pollen tablets has been 
demonstrated in two large double-blind, placebo-controlled studies, both demonstrating 2 
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years sustained improvement after discontinuation of 3 years of treatment (Durham SR, 2012; 
Didier A, 2011). Open studies have suggested longer initial durations of treatment may give 
longer periods of tolerance (Marogna M, 2010). Further open studies have suggested 
subcutaneous immunotherapy for allergic rhinitis in children may reduce the incidence of 
asthma and new sensitisations (Des Roches A, 1997; Jacobsen L, 2007), findings repeated in a 
number of sublingual studies (Novembre E, 2004; Marogna M, 2008). These preventative 
effects have yet to be confirmed in fully blinded, controlled, prospective studies.  
1.2.5 Novel approaches to immunotherapy 
Whilst immunotherapy is a highly effective treatment in well-selected patients, room for 
improvement remains. First, standardisation of allergen content and purity in vaccines is 
essential. Obtaining high doses of good quality allergen is expensive and the resultant cost to 
patients and health-services is great. Novel approches include the production of recombinant 
proteins for immunotherapy, potentially overcoming problems with allergen sourcing and 
purification (Jutel M, 2005; Pauli G, 2008). Next, subcutaneous treatment in particular carries 
the risk of inducing IgE-mediated systemic reactions. Production of hypoallergens by genetic 
engineering or chemical disruption of IgE-binding sites may reduce such reactions whilst still 
maintaining sufficient immunogenicity to induce a protective immune response 
(Niederberger V, 2004; Meyer W, 2013). Use of short peptide fragments, by-passing antibody 
recognition but maintaining T-cell immunogenicity, might also reduce systemic reactions 
(Oldfield W, 2002; Worm M, 2011) and has recently shown efficacy for cat allergen (Patel D, 
2013). Finally, attempts have been made to improve immunogenicity of vaccines, with the 
aim of allowing shorter treatment courses and/or longer duration of efficacy. This has 
included use of adjuvants, such as Toll-like receptor agonists (Creticos PS, 2006; Drachenberg 
KJ, 2001), carrier proteins to improve immune-cell targeting (Marth K, 2013; Senti G, 2012), 
and co-administration with immune modulating molecules, such as anti-IL-4, anti-TSLP and 
anti-IgE (Casale TB, 2006). In addition, novel routes of administration have also been 
investigated, including intralymphatic injections (Senti G, 2012; Witten M, 2013), intradermal 
injections (Slovick A, 2013) and epicutaneous application (Senti G, 2012b). 
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1.2.6 Mechanisms of immunotherapy 
Considerable progress has been made in understanding the mechanism of immunotherapy as 
a model of acquired antigen-tolerance (Figure 3b). Relevant immunological effects appear to 
include an early inhibitory effect on basophil activation (and, by extrapolation, mast cell 
degranulation) (Novak N, 2012; Shamji MH, 2015), albeit with the strongest evidence coming 
from studies of hymenoptera venom (rather than aeroallergen) immunotherapy. Following 
this, there appears to be an induction of IL-10 production, which may be associated with the 
presence of T cells with a regulatory phenotype (Francis JN, 2003; Akdis CM, 1998; Radulovic 
S, 2008), although the exact type of cell(s) involved – natural or inducible T regs – remains a 
matter of debate. Alongside this, studies have demonstrated reduced allergen-induced T 
cell/peripheral blood mononuclear cell proliferation in vitro, alongside reductions in Th2 
cytokine production (Akdis CM, 1998), although this has not been an unequivocal finding 
(Francis JN, 2003). Induction of allergen-specific IgG antibodies, particularly IgG4, has been 
the most reproducible (and also dose-dependent) finding (James LK, 2011; Frew AJ, 2006; 
Shamji MH, 2012), with evidence in vitro for functional activity (Shamji MH, 2012). Induction 
of allergen-specific IgA has been less frequently reported, although a possible functional 
effect – stimulation of monocyte IL-10 release - has been demonstrated (Pilette C, 2007). 
Longer term effects include reductions in effector cell numbers at mucosal sites (Wilson DR, 
2001; Nouri-Aria KT, 2005) and Th1-skewing, with augmented IFN-γ production (Durham SR 
1996; Wachholz PA, 2002). A recent study suggested that immunotherapy selectively deleted 
allergen-specific Th2 cells, identified using MHC class II-peptide tetramers as CD27- CCR7-
CRTH2+CCR4+ cells (Wambre E, 2012). Most recently, subcutaneous grass pollen 
immunotherapy has been shown to prevent a seasonal increase in circulating phenotypic type 
2 innate lymphoid cells seen in untreated allergics (Lao-Araya M, 2014).  
Whilst the above studies concern subcutaneous immunotherapy, many of these mechanisms 
appear to be shared by sublingual treatment. Like subcutaneous immunotherapy, sublingual 
treatment leads to induction of allergen-specific IgG antibodies, including IgG4, with ability to 
competitively inhibit allergen binding to IgE and to inhibit B cell facilitated allergen binding 
(Scadding GW, 2010; Durham SR, 2012). Sublingual immunotherapy appears to have a more 
profound stimulatory effect on IgE levels early on in treatment; but this effect appears to 
correlate positively with later induction of IgG (Lima MT, 2002; Suarez-Fueyo A, 2013). 
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Interestingly, there may also be an early increase in T cell IL-4 production, at least in vitro 
(Suarez-Fueyo A, 2013). T cell effects are, however, overall less well-delineated than for 
subcutaneous treatment. A study of birch pollen sublingual treatment demonstrated an early 
(4 week) IL-4-dependent inhibition of peripheral blood mononuclear cell proliferation in 
response to allergen (Bohle B, 2007); a study of house dust mite sublingual immunotherapy 
showed a TGF-β-dependent inhibition of proliferation at 6 months (O’Hehir RE, 2009). Again, 
other studies have failed to identify any significant cellular immune effects (Bonvalet M, 
2012). A recent study of dual grass pollen and house dust mite sublingual immunotherapy 
identified phenotypic, functional regulatory T cells, associated with reduced methylation of 
CpG groups within the FOXp3 gene locus (Swamy RS, 2012).  
An open, randomised comparative study of sublingual and subcutaneous immunotherapy 
with grass pollen demonstrated a more gradual onset and generally lower magnitude of 
development of IgG4, inhibition of IgE-allergen binding and facilitated allergen presentation, 
and reduction in basophil activation in vitro with sublingual treatment.  Clinically, this was 
mirrored by (non-significant) differences in reduction of response to nasal allergen challenge, 
with subcutaneous treatment again showing a trend to superiority (Aasbjerg K, 2014).   
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1.3 Biomarkers of successful treatment 
The National Institutes of Health Biomarkers Definitions Working Group defined a biomarker 
as “a characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention” (Biomarkers Definitions Working Group, 2001). At present, the best predictive 
tool for a successful response to allergen immunotherapy is a combination of the patient’s 
history (typical symptoms on allergen exposure) plus the presence of relevant allergen-
specific IgE on skin or serum testing. The best biomarkers of a response to immunotherapy 
appear to be allergen-specific IgG4 induction and inhibition of B cell facilitated allergen 
binding in vitro.  
1.3.1 The need for biomarkers for clinical trials of immunotherapy 
The current gold standard is for immunotherapy field studies to be judged according to a 
combined symptom and medication-use score in well-powered, double-blind, placebo-
controlled trials (Bousquet J, 2011). This has been the case for grass pollen tablet treatments 
developed and tested over the past 10 years. Yet such trials, aside from being expensive, are 
subject to additional pragmatic challenges, such as the standardisation of allergen exposure 
between individuals, geographical locations, and seasons. A trial may fail due to poor weather 
and low pollen counts, making it hard to distinguish a treatment effect, especially given the 
large placebo effect noted in most immunotherapy trials. Additionally, studying the 
immunological mechanisms necessary for successful treatment in field studies is limited to 
comparison of in-season and out-of-season time-points, and is again hampered by lack of 
standardisation of allergen exposure. In the context of clinical trials, an ideal biomarker would 
be surrogate for response to treatment, feasible for investigators to measure/perform, 
acceptable to patients and inexpensive.  
1.3.2 Current putative biomarkers 
The most commonly used biomarker in trials of allergen immunotherapy is specific IgG (and, 
often, specific IgG4), however, absolute levels do not necessarily correlate with treatment 
success, rather with treatment dose. The ability of sera from currently treated and post-
treatment individuals to block allergen-IgE binding in competitive ELISA assays or assays of 
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facilitated allergen-binding to B cells appears to provide a closer correlation with clinical 
outcomes (Durham SR, 2012; James LK, 2011; Shamji MH, 2012), even though this functional 
activity has been shown to relate to the serum IgG4 fraction (Shamji MH, 2006). Moreover, 
this functional activity persists 1-2 years after completion of 3 years immunotherapy, 
alongside persistence of the clinical effect, whereas the absolute allergen-specific IgG4 level 
begins to decline within a year (James LK, 2011). It has been postulated that a high affinity 
fraction of the IgG4 persists, with loss only of antibodies with lower binding affinity. Further 
supporting a role for IgG4, bee keepers with no evidence of local or systemic reactions to bee 
stings, despite numerous stings each season (referred to as ‘naturally tolerant’), have high 
levels of venom specific IgG4 with functional activity (Varga EM, 2013). 
Basophil allergen-induced activation in vitro may provide an alternative functional biomarker 
for successful immunotherapy. Flow cytometry on freshly isolated peripheral blood samples 
demonstrated reduced CD63 expression in response to in vitro grass pollen allergen in 
immunotherapy-treated individuals (Shamji MH 2015a; Aasbjerg K, 2014). How this process 
relates to the impaired release of pre-formed and newly-formed mediators from basophils 
following rush venom immunotherapy is unclear (Jutel M, 1996; Novak N, 2012). The latter 
possibly involving a form of tachyphylaxis which appears less likely to be relevant in standard 
immunotherapy up-dosing protocols. Again, exactly how well these in vitro phenomena relate 
to clinical outcomes has yet to be confirmed.  
T-cell or peripheral blood mononuclear cell assays might also provide biomarkers for 
desensitisation and tolerance. Venom immunotherapy has been associated with increased 
cellular IL-10 production and reduced allergen-induced T cell proliferation in vitro, reversible 
by blockage of IL-10 (Akdis CA, 1998). A similar effect on stimulation of IL-10 production has 
been noted in a number of aeroallergen immunotherapy studies, including locally in the nasal 
mucosa (Francis JN, 2003; Radulovic S, 2008); but findings are not sufficiently consistent, and 
assays too complex, to allow these to be used as routine biomarker assays. It has recently 
been demonstrated that nasal allergen challenge with grass pollen leads to activation signals 
in several types of circulating immune cell, including basophils, T cells and dendritic cells: flow 
cytometric analysis showed an increase in basophil CD63 expression 6 hours after allergen 
challenge, plus an increase in activated, CD25-expressing T cells and CD80 and CD86 
upregulation on dendritic cells (Shamji MH, 2015b). Further confirmatory work is required to 
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determine whether these interesting findings can have a role as biomarkers in future clinical 
studies.  
A highly reproducible effect on intradermal cutaneous responses to allergen with 
immunotherapy has been demonstrated, with up to 90% reduction in size of the late phase 
skin response (Varney VA, 1993; Lima MT, 2002; Chaker A, unpublished data). Again, how the 
effect size compares with reduction of typical rhinoconjunctivitis symptoms remains unclear.  
1.3.3 Alternatives to field studies 
Controlled allergen exposure, either in the form of a nasal allergen challenge (NAC) or in an 
environmental exposure chamber/unit (EEC/EEU) may serve as surrogate for natural 
(seasonal) allergen exposure, and hence may be suitable for assessment of the efficacy of 
allergic rhinitis treatments, including immunotherapy. This has been demonstrated with EECs 
for grass pollen SLIT (Horak F, 2009; Baron-Bodo V, 2013), Fel d 1 (major cat allergen)-derived 
peptide SCIT (Patel D, 2013) and ragweed allergoid with MPL adjuvant (Patel P, 2014). 
Furthermore, tight correlations have been demonstrated between symptoms during EEC 
exposure and natural seasonal exposure (Jacobs RL, 2012). EECs therefore appear to 
represent a suitable alternative to field studies, reflected by the use of these facilities to test 
numerous pharmacological treatments besides immunotherapy. On the other hand, few such 
facilities exist, and the cost of developing and maintaining them is considerable.  
Nasal allergen challenge (NAC) describes the controlled application of allergen to the nasal 
mucosa in allergic or suspected allergic individuals, in order to provoke acute 
rhinoconjunctivitis symptoms. NAC has provided insight into the pathophysiology of allergic 
rhinitis, including both early and late phase inflammation (Pelikan Z, 1988 and 1989; Naclerio 
RM, 1985). Early (within seconds to minutes of exposure) symptoms of sneezing, itching, 
rhinorrhoea and blockage correspond to increased glandular secretion (Raphael GD, 1989), 
plasma extravasation (Meyer P, 1999) and mast cell and basophil degranulation (Schleimer 
RP, 1985; Castells M, 1988). Nasal congestion and general mucosal hyper-reactivity some 3-
11 hours after allergen exposure are associated with a cellular influx of eosinophils (Bascom 
R, 1989), basophils (Bascom R, 1988) and neutrophils (Pelikan Z; 1989). Subsequent studies 
have demonstrated increases in various cytokines and chemokines within nasal mucosal fluid, 
particularly Th2 mediators (Erin EM 2005a and 2005b; Wagenmann M, 2005; Linden M, 2000). 
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NAC has also revealed the extra-nasal effects of nasal mucosal allergen exposure, including 
naso-occular (Baroody FM, 2009), naso-sinus (Baroody FM, 2008) and naso-bronchial (Boot 
JD, 2007; Braunstahl GJ, 2001) responses, and has been essential in identifying patients with 
local allergic rhinitis in the absence of systemic sensitisation (Rondon C, 2009). 
NAC has previously been used to assess the clinical and immunological effects of treatments 
for allergic rhinitis, including anti-histamines, (Greiff L, 1995), corticosteroids (Linden M, 2000; 
Erin EM, 2005a; Rak S, 1994) and allergen immunotherapy. Creticos and colleagues showed a 
rightward shift in the allergen dose-response curve, plus reduced histamine and TAME-
esterase release, in ragweed-immunotherapy treated individuals (Creticos PS, 1985; Creticos 
PS, 1989). They also demonstrated reductions in early phase symptoms after NAC following 
ragweed immunotherapy (Iliopoulos O, 1991) and reduced eosinophil migration into the nasal 
mucosa (Furin MJ, 1991). Subcutaneous immunotherapy has been shown to reduce the 
response to cat allergen NAC (Nanda A, 2004), as has intralymphatic immunotherapy with 
recombinant major cat allergen, Fel d 1 (Senti G, 2012). Reduced reactivity to grass pollen 
NAC has been demonstrated in several studies of grass pollen immunotherapy (Amar SM, 
2009; Subiza J, 2008; Bousquet J, 1991). Most have revealed a right-shift in dose-response; 
others have reported an increased proportion of negative challenges to a single allergen dose 
(Pfaar O, 2011). Of note, one study demonstrated reduced reactivity to NAC despite a lack of 
effect on seasonal symptoms during field study (the latter attributed to a low pollen season) 
(Amar SM, 2009).  
Concerning the extra-nasal effects of NAC, that nasal allergen exposure enhances lower 
airway inflammation may help explain the link between allergic rhinitis and asthma, and the 
positive effect on asthma of treating allergic rhinitis, particularly using intranasal 
corticosteroids. Studies have demonstrated an almost reciprocal relationship between upper 
and lower airways – isolated allergen challenge at either site leading to inflammation both 
locally and at the distant mucosa (Braunstahl GJ 2000 and 2001). This argues against a 
simplistic model of inflammatory mediators or infection ‘dripping down’ the airway from nose 
to lungs. Alternative explanations include systemic immune activation, either by absorption 
of allergen from the mucosa into the bloodstream or by local immune cell activation followed 
by peripheral migration - for example activation of antigen presenting cells in the nasal 
mucosa, migration to regional lymph nodes and activation of effector cells which then pass 
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into the peripheral circulation. Conversely, neuro-immune mechanisms may be required: 
inflammation leading to activation of sensory nerves at one mucosa, with efferent stimulation 
at both mucosae. Allergic rhinitis has previously been hypothesised to have systemic 
inflammatory ramifications (Borish L, 2003). In mice, nasal mucosal allergen exposure has 
been shown to stimulate generation and trafficking of immune cells from the bone marrow 
(Gaspar Elsas MI, 1997). Similar data in human studies is understandably difficult to acquire. 
Nasal challenge has been shown to upregulate expression of the beta-subunit, FcεR1β, of the 
high affinity IgE receptor on basophils isolated from peripheral blood (Saini S, 2004). 
Moreover, eosinophil migratory capacity in vitro increases in cells isolated after in vivo nasal 
allergen challenge (Lönnkvist K, 2002). 
 
1.4 Rationale 
Adequately blinded and controlled clinical trials of therapeutic interventions are often 
complex and expensive. Treatments for allergic rhinitis are no exception. In fact, the seasonal 
and/or unpredictable nature of allergen exposure leaves trials at the mercy of the weather 
and participant lifestyle and behaviour. This means these trials require large numbers of 
participants, adding to their expense. Use of clinical surrogates for allergen immunotherapy 
trials is therefore an attractive proposition, assuming adequate surrogates can be developed. 
This provides the rationale for developing alternatives to field studies, for example nasal 
allergen challenge, where allergen exposure and timing can be standardised. Such surrogates 
should be relevant to normal clinical symptoms experienced by patients and show correlation 
with them. Moreover, changes in surrogate responses should be indicative of changes in usual 
symptoms on natural allergen exposure.  
In addition to clinical surrogates, laboratory biomarkers may also provide an objective 
indication of treatment efficacy, and may give information on the mechanisms involved. An 
ideal laboratory marker would not only be indicative of a clinical response to treatment 
(essential in venom immunotherapy, where the only alternative is the sting challenge), but 
might also allow prediction of treatment success, and hence enable improved patient 
selection. As allergic rhinitis is primarily a mucosal disease, there is good rationale to 
investigate the local nasal mucosa for biomarkers of allergen exposure and, subsequently, the 
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effect of treatment interventions. The development of increasingly sensitive immunological 
assays, requiring as little as 25µL of fluid for measurement of multiple analytes, means nasal 
fluid is an attractive substrate for analysis.   
Recent evidence of activation of circulating immune cells following nasal allergen challenge 
(Shamji MH, 2015b) suggests isolated mucosal allergen exposure has systemic immune 
consequences, a finding which may help explain naso-bronchial interactions. A nasal 
challenge study combining local and peripheral assays of the immune response would provide 
a comprehensive picture of the biology of the allergic response. Examination of this in the 
context of immunotherapy may highlight the mechanisms behind the immune-modulatory 
properties of this treatment, as well as identify potential biomarkers of treatment efficacy.  
In the UK, as in many temperate climates, grass pollen hay fever is extremely common and 
troublesome. As a result, it is the most common target for allergen-specific immunotherapy 
in routine clinical practice. Importantly, recruitment of individuals with grass pollen hay fever 
for clinical studies is achievable and relevant – hence the focus of the work presented here. 
In addition, perennial allergens are also extremely important causes of allergic rhinitis and are 
probably more relevant to asthma development than seasonal allergens. Cat allergen is one 
of the most pervasive allergens in countries where cats are common household pets. An 
option to extend the work on nasal allergen challenge to cat allergic individuals arose with an 
opportunity for funding from the Immune Tolerance Network – hence the chapter on cat 
allergen provocation.  
Following on from the above, the rationale for much of the work presented here was an 
Immune Tolerance Network funded study at Imperial College and The Royal Brompton 
Hospital –  a randomized, double-blind, single-center, placebo-controlled study of sublingual 
and subcutaneous immunotherapy in adults with seasonal allergic rhinitis (GRASS, 
ITN043AD). The techniques developed in the studies described here were subsequently used 
in this large prospective study where the primary outcome was the response to nasal allergen 
challenge one year after completion of 2 years of treatment. The pilot studies detailed within 
this thesis helped inform both the methods used and the interpretation of data arising from 
the trial. Furthermore, the data on cat allergen nasal provocation has been used in two 
additional ITN-funded studies, including a multi-centre study in the US.  
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1.5 Hypotheses 
 
1. Nasal allergen challenge provides a dose-dependent, reproducible means of assessing 
response to allergen exposure in allergic rhinitics. 
 
2. Nasal allergen challenge in allergic rhinitics is characterised by local and systemic Th2 
responses. 
 
3. Grass pollen allergen-specific immunotherapy suppresses the clinical response to 
nasal allergen challenge and reduces natural, seasonal allergic rhinitis symptoms. 
 
4. Grass pollen allergen-specific immunotherapy is associated with a decrease in local 
and systemic Th2 responses to nasal allergen challenge. 
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1.6 Aims and objectives 
 
The aims of the work described here may be summarised as follows:  
1. To standardise methods of nasal allergen challenge with grass pollen. 
2. To optimise collection of nasal mucosal fluid for analysis of inflammatory mediators. 
3. To investigate peripheral blood/systemic immunological effects of nasal challenge. 
4. To standardise a method of nasal allergen challenge with cat allergen. 
5. To assess the effects of allergen-specific immunotherapy on both clinical and 
immunological responses to nasal challenge.  
The primary objective was to evaluate whether nasal allergen challenge could be an adequate 
surrogate for future trials of immunotherapy vaccines.  
The secondary objective was to identify local and systemic biomarkers of the allergic response 
and the response to immunotherapy.  
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2. Materials and methods 
 
2.1 Clinical Procedures 
2.1.1 Nasal Lavage 
Nasal lavage was carried out prior to nasal challenge in order to clear mucous and pre-existing 
mediators from the nose. Boiled water, allowed to cool to lukewarm, was added to purpose-
made squeezable plastic 240 ml bottles (Sinus Rinse, NeilMed, USA). A single sachet of 
pharmaceutical grade sodium chloride and sodium bicarbonate was then added to the water 
and mixed to form a solution. After testing again to ensure a suitable temperature, the 
volunteer placed the nozzle of the bottle into their nose to form a seal, and, leaning forward 
over a sink, squeezed the bottle to allow a jet of solution to pass into one nostril and out of 
the other.  The process was then carried out in the other nostril and repeated several times 
until all of the solution had been used. 
2.1.2 Nasal allergen/diluent challenge  
Nasal allergen challenges were performed with either Aquagen SQ Timothy grass pollen, 
Phleum pratense, ALK-Abelló freeze dried extract or Alutard SQ cat hair, Felis domesticus, 
allergen extract (both ALK-Abello, Denmark). Freeze dried extract was reconstituted in 4.5ml 
of albumin-based diluent, as per the manufacturer’s instructions, to give a starting 
concentration of 100,000 SQ-U/ml (equivalent to 30,000 BU/ml and containing approximately 
20 µg major allergen, Phl p 5 per ml or 14.6 µg major allergen, Fel d 1 per ml). Subsequent 
dilutions were made in sterile normal saline. For diluent challenges, albumin-based diluent 
and normal saline were mixed in proportions matching those used in active allergen 
challenges. New freeze dried extract was reconstituted weekly; dilutions were made on a 
daily basis. Allergen solutions of the desired concentration were then added using a pipette 
to the glass chamber of nasal applicator devices (Figure 4 A, B; Bidose, Aptar Pharma/Pfeiffer, 
Germany). These disposable devices are certified to spray two applications of a standard 
volume (100µL) in a fine mist. One spray was applied to each of the participant’s nostrils. The 
participant was asked not to sniff or blow their nose for the next 2 minutes.  
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2.1.3 Sampling of nasal secretions 
Three different synthetic absorptive matrices (SAMs) were used in the following studies: 
Accuwik Ultra (fibrous hydroxylated polyester), 111 (100% cellulose fibres of plant origin), and 
Leukosorb (patented fibrous matrix material) (all from Pall Corporation, USA). These were 
pre-cut to 35mm x 7mm with a rounded anterior edge (Parafix Tapes and Conversion Ltd, 
West Sussex, UK). A single type of synthetic polyurethane sponge was used (RG 27 grau, 
Gummi-Welz GmbH & Co., Germany), pre-cut into 20 x 15 x 5mm pieces and sterilized by 
autoclaving for 20 minutes at 121°C in batches of 20 prior to use.  
SAMs/sponges were inserted under direct vision with a head-mounted light source (Welch 
Allyn Instruments, UK), using blunt-ended croc forceps and a nasal speculum (Phoenix Surgical 
Instruments Ltd, Hertfordshire, UK), with the patient sitting comfortably upright with their 
head facing forwards. The absorptive materials were placed into each nostril, posterior to the 
muco-cutaneous junction, in close proximity to the inferior turbinate. They were left in place 
for exactly 2 minutes before removal (Figure 4 C, D). Following removal, they were then 
placed into centrifuge tubes (a single sponge or paired SAMs per tube) above an indwelling 
0.22µm cellulose acetate filter (Costar Spin-X, Corning, NY, USA). Tubes were then kept briefly 
on ice before being centrifuged at 4,500 rcf at 4°C for 10 minutes. The volume of freed fluid 
was calculated using an electronic balance, by measuring the weight of a cryovial tube before 
and after the addition of the collected fluid (Figure 5). The isolated ‘neat’ nasal fluid was 
pipetted into Eppendorf tubes and stored at -80°C. In the studies employing an elution step, 
immediately prior to centrifugation 100 or 200µL of buffer (Milliplex Assay Buffer, Millipore, 
USA: PBS pH 7.4, BSA (1%), Tween® 20 (0.05%), sodium azide (0.05%)) was pipetted on top of 
the sponge/SAMs within each centrifuge tube (Figure 5). The total fluid volume extracted was 
calculated by weight as before, an estimation of ‘neat’ fluid was made by subtracting the 
elution volume added from the final volume recovered. Samples isolated from each nostril 
were either stored separately or pooled depending on the individual study protocol.  
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2.1.4 Clinical nasal responses 
a) Total nasal symptom score (TNSS) 
Allergic rhinoconjunctivitis symptoms during nasal challenge were scored according to a 
verified scoring system: total nasal symptom score (TNSS), a 12 point scale with 4 categories: 
sneezing, nose running, nose blockage, and itching, each rated from 0-3 (Appendix 1, Table 
1; Bousquet J, 1987). 
b) Visual analogue score (VAS) 
Participants graded their overall rhinoconjunctivitis symptoms at each time-point on a visual 
analogue scale (VAS) from 0 to 100mm, where 0 corresponds to no symptoms and 100 to 
maximum symptoms. 
c) Peak nasal inspiratory flow (PNIF) 
The best of three PNIF measures made using a modified Youlten peak flow meter (Clement 
Clarke, UK) was recorded at each symptom assessment. The peak flow meter was set to zero 
by the investigator and then given to the participant. The participant was asked to place the 
mask over their mouth and nose to form a good seal and then sniff in as strongly as possible, 
whilst keeping their mouth shut. The reading on the meter was then recorded by the 
examiner and the meter reset to zero.  
d) Peak expiratory flow rate (PEFR) 
The best of three efforts made using a standard peak flow meter was recorded at each time 
point.  
e) Seasonal symptom questionnaires 
Volunteers made an assessment of their symptoms during the previous year’s grass pollen 
season (May-July 2012) using two proformas. In one, volunteers rated their symptoms in 
comparison to previous summers (either most recent or most recent before receiving 
immunotherapy) on a scale of -3 (much worse during the most recent season) to +3 (much 
better). Non-atopic volunteers without hay fever rated their symptoms as 0 (unchanged). The 
second proforma involved an overall seasonal symptom score, an 18-point scale, with 6 
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categories: blockage, running, sneezing, itching, eye itching, eye watering/redness, each rated 
0-3, with a total score of 0 (symptom free) to 18 (worst symptoms). 
2.1.5 Intradermal skin tests 
Intradermal skin tests were performed by injecting 0.02ml of allergen diluted in albumin-
based diluent into the skin of the outer surface of the forearms, using an insulin syringe. A 
total of 10 BU (0.02ml of 500 BU/ml, equivalent to 7ng major grass pollen allergen) was 
injected into the left forearm, 1 BU (0.02ml of 50 BU/ml, equivalent to 0.7ng major grass 
pollen allergen) into the right. A negative control injection of 0.02ml of normal saline was 
injected on the outer surface of the wrist on the right. Wheal response was recorded at 15 
minutes and late phase infiltration at 8 hours, using a pencil-friction technique described 
previously (Lima MT, 2002). Briefly, an HB pencil is drawn along the skin beginning distally 
and moving toward the injection site. The extent of swelling is picked up by increased 
resistance to the passage of the pencil. The spot is marked with a biro and the process 
repeated, approaching the injection site from a different angle. Once an approximate 
circumference is mapped, marks are joined in washable pen. An imprint of the marked area 
is then made by applying strips of ScotchTM tape across the skin, before removal and sticking 
on paper. The longest diameter and perpendicular diameter at its midpoint are then 
measured and their mean calculated.  
2.1.6 Nasal epithelial brushing 
Nasal brushing was performed in one nostril using a Cytosoft cytology brush (Medical 
Packaging Corporation, USA). The volunteer was sat comfortably in a chair facing forward, 
with head tilted slightly back. Local anaesthetic (5% lidocaine hydrochloride, 0.5% 
phenylephedrine) was applied to one side of the nose and 2 minutes allowed for onset of 
anaesthesia. The examiner then inserted a cytology brush through the nasal vestibule, along 
the floor of the nasal cavity, until alongside the inferior turbinate. The brush was then rolled 
laterally, under the inferior turbinate, then rotated through 180° clockwise and anti-
clockwise, then rolled away from the turbinate and removed from the nose. The brush was 
then placed into a 2mL culture tube containing RLT buffer plus β-mercaptoethanol (Qiagen, 
West Sussex, UK) and gently agitated for 4 seconds. The brush was then cut off at its handle, 
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allowing the bristled end to fit within the culture tube. The tube was then capped, labelled, 
and stored at -80°C.  
2.1.7 Nasal biopsy 
Two 2mm2 biopsy samples were taken under direct vision from the inferior turbinate of the 
nostril which had not undergone nasal brushing. After instillation of 5% lidocaine 
hydrochloride/0.5% phenylephedrine by nasal spray to decongest the anterior nasal mucosa, 
up to 1mL of 10% cocaine hydrochloride was inserted on small pieces of cotton wool onto the 
mucosa, adjacent to the inferior turbinate. Ten to 15 minutes were allowed for the 
anaesthetic to take effect. Prior to biopsy, anaesthesia was checked by probing the inferior 
turbinate with the tip of a pair of croc forceps. Following this, biopsy samples were taken 
using Fokken’s biopsy forceps (Phoenix Surgical Instruments Ltd, Hertfordshire, UK). One 
sample was deposited in RLT buffer plus β-mercaptoethanol, another in 4% 
paraformaldehyde (further details of processing are given below). Haemostasis was achieved 
by packing the nose with cotton wool balls soaked in 0.5mL of 1:1000 adrenaline. These were 
removed after 15 minutes and the nose examined for sites of bleeding - these were cauterised 
with silver nitrate if indicated.  The patient was given 500-1,000mg paracetamol PO and 
observed for a further 15 minutes. The patient was then discharged with advice regarding 
prevention of bleeding and course of action to take in the event of bleeding. A 24 hour contact 
telephone number for advice was provided. 
 
2.2 Laboratory procedures 
2.2.1 Immunohistochemistry 
a) Processing of nasal biopsy specimens 
Freshly collected biopsy tissue was placed into 4% paraformaldehyde in 0.1 M PBS, pH 7.4, 
for 2 hours at room temperature. The tissue was then dehydrated with two washes in 15% 
sucrose in 0.1 M PBS, the first for 1 hour, the second overnight, until mounting the following 
day. For mounting, a Dewar was first half-filled with liquid nitrogen. Twenty millilitres of 
isopentane was poured into a beaker with a long wire holder and lowered into the liquid 
nitrogen-filled Dewar, ensuring no direct mixing of fluids. Alongside this, small pieces 
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(approximately 1cm X 2cm) of matt index card were cut and labelled. A drop of OCT mounting 
medium (Tissue Tek, Sakura, UK) was placed onto the centre of the card. Using clean 
watchmaker forceps, the biopsy tissue was retrieved from the 15% sucrose and lowered into 
the OCT. As the isopentane began to freeze within the Dewar, the beaker was removed from 
the liquid nitrogen, and the biopsy frozen by lowering the card with forceps slowly through 
the vapour of the isopentane and into the liquid. Once the biopsy was frozen it was 
transferred into a labelled bijou tube and stored at -80°C.  Six µm cryostat sections were cut 
and air-dried for one hour, then fixed by immersion in a mix of acetone and methanol (60:40) 
for 7 minutes. After a further 1 hour of air-drying, slides were wrapped in aluminium foil and 
stored at -80°C until immunostaining. Sections were kindly cut and mounted by Dr Mikila 
Jacobson. The biopsy samples placed in RLT buffer plus β-mercaptoethanol were stored at -
80°C until transfer to Dr Louisa James at King’s College for analysis of immunoglobulin gene 
segment rearrangements (not discussed here).  
b) Immunostaining 
Tissue staining was carried out using an alkaline phosphatase detection system (Vectastain 
ABC-AP Kit, Vector Laboratories, Burlingame, CA, USA). Slides were removed from storage at 
-80°C and kept on the bench on dry ice before removal of aluminium foil and drying in air. 
Once dry, individual tissue sections were circled in wax and labelled according to the planned 
primary antibody staining. After three 5-minute washes in PBS, avidin was applied in drops to 
each specimen and left to incubate for 15 minutes, followed by two further 5-minute washes 
in PBS. Biotin was then added to the specimens and left to incubate for 15 minutes, followed 
by two further 5-minute washes in PBS. Blocking serum (normal horse serum (Vectastain), 3 
drops (approximately 150 µl) in 10ml PBS) was then added to specimens and left to incubate 
for 30 minutes before being gently tipped and blotted off. Primary antibodies (see below) and 
isotype controls, diluted in 5% normal human serum at appropriate concentration, were then 
added and left to incubate for 1 hour. Slides were then washed three times for 5 minutes each 
in PBS. Secondary antibody, biotinylated anti-mouse immunoglobulin (1 drop (approximately 
50 µl) in 10ml 10% normal human serum), was then added for 30 minutes. During this time, 
the Vectastain ABC-AP reagent was prepared for use by adding first 2 drops of Reagent A 
(Avidin DH), then 2 drops of reagent B (biotinylated alkaline phosphatase H) (both 
approximately 100 µl) to 10ml of PBS, and left to stand for 30 minutes. Secondary antibody 
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was removed from slides with three washes in PBS before incubation with ABC-AP reagent 
for 30 minutes. During this time, alkaline phosphatase substrate solution was prepared: Fast 
Red (TR/Naphthol AS-MX, Sigma, St Louis, Missouri, USA), one gold tablet (for Tris buffer 
preparation) was dissolved in 10ml distilled water, followed by one silver tablet (TR/Naphthol 
AS-MX), followed by addition of two drops (approximately 100 µl) of levamisol, then filtered 
through a 0.2 µm filter and the filtrate stored in the dark until use.  After three washes to 
remove excess ABC-AP reagent, Fast Red substrate solution was added to specimens for 20 
minutes in the dark. The reaction was stopped by gentle immersion and washing in water. 
Background tissue staining was then achieved by immersion of slides in filtered haematoxylin 
(Gill 1 hematoxylin, Thermo Scientific) for 5 seconds before washing off excess in water. Slides 
were dried before mounting (Faramount aqueous medium, Dako, UK) and addition of 
coverslips. Primary antibodies were as follows: monoclonal mouse anti-human mast cell 
tryptase clone AA1 (Dako) (1 µg/mL), mouse IgG1 (Dako) (10 µg/mL), mouse anti-human 
basophil 2D7 clone (Biolegend) (10 µg/mL), mouse monoclonal anti-human eosinophil major 
basic protein (Bio Rad) (2 µg/mL), mouse monoclonal anti-human CD3 (Dako) (10 µg/mL).  
Slides were examined under a light microscope at 200 x magnification by two independent 
blinded examiners (GS plus one of Dr Aarif Eifan or Dr Mikila Jacobson). The number of red-
stained cells within a 10 by 10 grid area across the subepithelium of each specimen was 
counted. The specimen was then moved to view the immediately adjacent area and a further 
count made. In this way the immediate subepithelial section of the whole specimen was 
covered. The total number of cells counted was then divided by the total grid area to give the 
mean number of cells per grid, followed by multiplication by a magnification correction factor 
to give the number of cells per mm2. The counts of the two examiners were compared by 
Bland Altman correlation using a software package (Graphpad Prism); discordant results were 
recounted by both examiners or by a third independent examiner. Mean values were 
established for concordant results before decoding and assignment into relevant groups.   
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2.2.2 Nasal fluid analyses 
a) MSD human Th1/Th2 7-plex plate assay 
In the first two pilot experiments (see below) measurement of IFN-γ, IL-2, IL-4, IL-5, IL-10, IL-
12p70, and IL-13 were performed using MSD Human TH1/TH2 7-Plex, 96-well plate, Ultra-
Sensitive Kits according to the manufacturer’s instructions (MS6000 7 spot, Meso Scale 
Discovery, Maryland, USA). Briefly, after incubation of plates with diluent, 25µL of samples, 
calibrators, and high and low standards were added to appropriate wells and incubated on a 
plate-shaker for 2 hours. Plates were then washed in PBS plus 0.05% Tween-20 using an 
automated washer (Aquamax 2000). Twenty-five microliters of detection antibody at 1µg/ml 
was added to wells, followed by incubation on a plate-shaker for 2 hours in the dark. Plates 
were then washed 3 times as before. One hundred and fifty microliters of Read Buffer T were 
then added to each well before plates were read on an MSD SECTOR® 6000 instrument. All 
measurements were performed on undiluted nasal fluid samples in duplicate and reported as 
mean values. The manufacturer’s quoted lower limits of detection were: IL-4, 0.16; IL-5, 
0.070; IL-13, 1.3; IL-10, 0.51; IL-2, 0.43; IFN-γ, 0.55; and IL-12p70, 2.0 pg/mL. Values below the 
lower limit of detection were given a value of 0. Assays were performed at the laboratories 
of ALK-Abello in Horsholm, Denmark, initially by Gitte Konsgaard Koed, then by GS under 
guidance of Gitte Konsgaard Koed. 
In vitro spiking experiments 
To investigate the recovery of cytokines after absorption by the different synthetic absorptive 
matrices and sponges, recombinant proteins for each of the 7 human cytokines listed above 
were diluted in assay diluent or in pooled pre-challenge nasal secretions and applied to the 
different materials. Fluid was recovered by centrifugation as described above and analysed 
by the 7-plex MSD cytokine assay. Cytokine concentrations of 0, 55, 167, and 500 mcg/ml 
were investigated and samples were analysed in duplicate. Spiking experiments were 
performed by Gitte Konsgaard Koed at ALK Abello, Horsholm, Denmark. Results are provided 
in Appendix 2, Figure 1.  
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b) ImmunoCAP Tryptase and ECP 
Tryptase and Eosinophil Cationic Protein (ECP) in nasal fluid were measured using an 
ImmunoCAP 100 machine (Phadia/Thermo Scientific, Uppsala, Sweden) according to the 
manufacturer’s instructions. In the first pilot studies and the cat allergen nasal challenge 
study, 20 microlitres of nasal fluid samples were diluted 1 in 10 in assay diluent (ImmunoCAP 
IgE/ECP/Tryptase Diluent, Thermo Scientific), and added to sample slots as directed by the 
automated system, alongside calibrators and curve controls. Tryptase- or ECP-conjugate (β-
galactosidase-labelled mouse monoclonal antibody), development solution and stop solution 
(all Thermo Scientific) were added to reagent ports as directed. ImmunoCAP anti-tryptase or 
anti-ECP caps were added according to the number of samples being analysed. Assay range 
was 1-200µL for both tryptase and ECP. Values below the lower limit of detection were given 
a value of 0, values above the upper limit were given a value of 200. In the cross-sectional 
study, 20 ml of nasal samples were diluted 1 in 5 in assay diluent and processed as above. 
Samples for the first pilot study were run by Gitte Konsgaard Koed at ALK Abello, Denmark; 
samples from the cat allergen nasal challenge study were kindly run by Miss Orla McMahon; 
samples from the cross-sectional study were run by GS.  
c) Human cytokine/chemokine magnetic bead panel 96-well plate assay 
In the latter pilot studies, the cat allergen study and the cross-sectional study nasal fluid was 
analysed for cytokines and chemokines using a human cytokine/chemokine magnetic bead 
panel 96-well plate assay (Milliplex Map Kit, Millipore, MA, USA) and a Luminex xMAP Magpix 
platform (Millipore), according to the manufacturer’s instructions. Briefly, antibody-
immobilised beads were sonicated, mixed in bead diluent and vortexed. Quality controls were 
reconstituted in deionised water, serial dilutions of the standard mix were made in deionised 
water, and wash buffer prepared. Plates were prepared by incubation with Assay Buffer for 
10 minutes on a plate-shaker at room temperature before removal of the Assay Buffer. 
Twenty-five microliters of standards and controls were added to relevant wells, followed by 
25μL of Assay Buffer to all wells, before addition of nasal fluid samples to relevant wells. 
Following this, 25μL of the premixed antibody-immobilised beads were added to each well. 
Plates were sealed, wrapped in foil and incubated overnight (16-18 hours) on a plate-shaker 
at 4°C. Plates were then washed twice using Wash Buffer and a hand-held plate magnet. 
Twenty-five microliters of Detection Antibodies were added to each well, followed by 
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incubation at room temperature on a plate-shaker for 1 hour. Twenty-five microliters of 
streptavidin-phycoerythrin were added to each well, the plates covered in foil, then incubated 
for a further 30 minutes. The plates were then washed twice, as before, followed by addition 
of 150 μL Drive Fluid to each well. Plates were then placed on the shaker for 5 minutes before 
being run on the Magpix machine and analysed with Xponent software. The mean of duplicate 
results was calculated after spurious results were excluded. Results below the lower limit of 
assay detection were given a value of 0. 
Neat nasal fluid (from one volunteer participating in the final pilot study) at two time points 
(2 hours and 6 hours, representing low and high concentrations of nasal fluid Th2 cytokines) 
was serially diluted in assay buffer: undiluted, 1 in 2, 1 in 4, 1 in 8, 1 in 32, 1 in 64, and run in 
duplicate as a further control.  
d) Allergen-specific antibodies in nasal fluid 
Phleum pratense (Timothy grass) specific IgE and IgG4 antibodies were measured in nasal fluid 
using an ImmunoCAP 100 machine (Phadia/Thermo Scientific) according to the 
manufacturer’s instructions. Briefly, for specific IgE, 40 μL of each nasal fluid sample was 
added to individual 1.8mL round-bottom Cryotube vials (Thermo Scientific) and loaded into 
the sample carousel as indicated alongside Specific IgE Calibrators, Control and Negative 
Control. Specific IgE conjugate (β-galactosidase-labelled mouse monoclonal antibody), 
Development Solution and Stop Solution were added to reagent ports as directed, before 
ImmunoCAP specific IgE, Timothy grass IgE and control IgE caps were added to the cap port. 
After successful completion of the first run with acceptable calibration curve, subsequent runs 
required Curve Controls to be run in place of Calibrators. For specific IgG4, 40 μL nasal fluid 
samples were added in Cryotube vials into the sample carousel alongside IgA/IgG sample 
diluent, as directed, along with Calibrators and Controls. Specific IgG4 conjugate (β-
galactosidase-labelled mouse monoclonal antibody), development solution and stop solution 
were added to reagent ports as directed, before ImmunoCAP specific IgG4, Timothy grass and 
control caps were added to the cap port. After successful completion of the first run with 
acceptable calibration curve, subsequent runs required Curve Controls to be run in place of 
Calibrators. 
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Phleum pratense (Timothy grass) specific IgA1 and IgA2 antibodies in nasal fluid and plasma 
were measured by Dr Charles Pilette and Bruno Detry at the Unit of Pneumology, University 
of Louvain, Brussels, Belgium, using a sandwich ELISA according to previously published 
methods (Pilette C, 2007). Briefly, samples were incubated on plates coated with major 
Timothy grass allergen (Phl p 5, 10µg/mL) after dilution in PBS. Mouse monoclonal antibodies 
to human IgA1 and IgA2 were added, followed by horse-radish peroxidase-conjugated anti-
mouse IgG. Plates were then analysed after incubation with hydrogen peroxide and 
tetramethylbenzidine in phosphate-citrate.  
2.2.3 Leukocyte and serum assays 
a) Processing of blood samples 
Whole blood was collected from participants at baseline and 6 hours after allergen challenge 
in both the cat nasal challenge study and cross-sectional grass pollen challenge study. In the 
cat allergen study, a single 10mL lithium-heparin tube was collected, and blood used for 
basophil flow cytometry (see below). In the cross-sectional study, 150mL of blood was 
collected: 140mL in lithium-heparin tubes, 10mL in a plain tube for serum isolation. In both 
studies, samples were transported to the laboratory within 30 minutes of venesection. In the 
cross-sectional study, after 1mL of whole blood was taken for flow cytometry, the remaining 
blood was centrifuged at 2200rpm for 10 minutes at room temperature to allow removal of 
plasma (subsequently stored at -20°C). Peripheral blood mononuclear cells were then 
separated from the remaining blood by Ficoll density separation before re-suspension in RPMI 
and three wash steps. Live cells were counted on a haemocytometer after staining with 
Trypan Blue before the final wash and resuspension in buffer (RoboSep Buffer, Stem Cell 
Technologies) at 50 million cells per ml. CD4+ cells were then separated using an EasySep 
CD4+ cell enrichment kit (Stem Cell Technologies) by negative selection, according to the 
manufacturer’s instructions. Briefly, cells were incubated in 5mL polystyrene tubes with an 
enrichment cocktail containing a range of anti-CD antibodies coupled to anti-dextran 
antibodies for 10 minutes before addition of dextran-coated magnetic particles for 5 minutes. 
Tubes were then placed into EasySep magnets for a further 5 minutes before inversion and 
collection of the negatively selected fraction (CD4+ cells) and resuspension in tissue culture 
medium (TCM, 5% human AB serum, 1% penicillin-streptomycin in glutamate +ve RPMI) at 
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500,000 cells per millilitre. Positively selected cells (CD4-) were resuspended in TCM at the 
same concentration after removal of tubes from the magnets, and then irradiated at 3000 
rads (irradiation performed by Dr M Shamji and Dr J Charlesworth). GS is grateful to Dr 
Mongkol Lao-Araya who assisted with PBMC processing and cell separation. 
b) Whole blood flow cytometry 
One hundred microliters of heparinised whole blood was stained, away from direct light, with 
fluorescent-labelled antibodies, at the manufacturer’s recommended concentrations: anti-
CD294 PE, anti-CD303 APC (both Miltenyi Biotec, Germany), anti-CD3 PE-Cy7 (BD Biosciences, 
CA, USA),  anti-CD203c PerCP-Cy5.5, anti-CD107a Pacific Blue, anti-CD63 FITC (all BioLegend, 
UK) or isotype controls, for 40 minutes. Following this, red blood cells were lysed by 
incubation with 2mL of BD Lysing Solution (BD Biosciences) for 10 minutes. Supernatant was 
removed after centrifuging at 200g for 5 minutes and cells washed with 3mL of PBS. Cells 
were fixed in 450µL Cell Fix solution (BD Biosciences). Additionally, further 100 μL blood 
samples were immunostained as above before incubation with allergen (1µg/mL Phleum 
pratense or cat hair allergen extract, Alutard SQ, ALK-Abello, Denmark) or anti-IgE (1 µg /mL) 
for 15 minutes at 37°C, followed by red cell lysis and fixation as before. Cells were then 
analysed using a BD FACSCanto II flow cytometer (BD Biosciences), gating for expression of 
CD63, CD107a and CD207c on basophils (CD3-CD303-CRTH2+ cells). Cell staining and 
acquisition by flow cytometry for the cat challenge study and the cross-sectional study was 
kindly performed by Miss Amy Switzer and Miss Orla McMahon.  
c) CD4+ cell – irradiated CD4- cell co-culture 
CD4+ and irradiated CD4- cells were co-cultured in 96-well plates and assayed for 3H-
thymidine incorporation and dual IL-10/IL-4 Fluorospot.  
For 3H-thymidine incorporation assays, CD4+ and irradiated CD4- cells were added to 96-well 
round bottom plates, both at 250,000 cells/well, with 0, 1, 10 or 30µg/mL Phleum pratense 
allergen, 10µg/mL PHA, or 3µg/mL PPD, in triple or quadruple, with a final volume of 200µL 
per well. Plates were incubated at 37°C, 5% CO2 for 5 days. On the 5th day, cells were pulsed 
with 3H-thymidine diluted 1 in 20 in glutamate +ve RPMI, 20µL per well, for 16 hours at 37°C, 
5% CO2. Incorporation was then terminated by placing plates at -20°C until harvesting. After 
thawing, DNA was extracted from plates onto glass fibre filters (Filtermat) using a cell 
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harvester (Tomtec Harvester 9600 Mach III), according to the manufacturer’s instructions. 
Filtermats were then removed and allowed to dry at room temperature. Once dry, Filtermats 
were placed into plastic sample bags (Perkin Elmer Ltd), and sealed along the long axis using 
a heat-sealer. A small hole was cut in the short axis to allow addition of 4mL of scintillation 
cocktail (Beta Plate Scint, Perkin Elmer), followed by even distribution across the Filtermat 
using a roller. The open short end was heat-sealed, and the plastic trimmed as necessary to 
fit within a holding cassette. Cassettes were loaded into the plate reader (1450 MicroBeta 
Trilux). Analysis was then performed using MicroBeta Windows Workstation software. The 
mean of the three or four replicates for each condition was calculated, after excluding 
anomalous values. Results were expressed as each condition minus unstimulated (0mg/mL 
Phleum pratense) cells.  
For dual IL-10/IL-4 Flourospot assays (Diaclone, Besancon, France), 96-well PVDF-bottomed 
plates (Millipore MultiScreen) were pre-treated with 35% ethanol for 30 seconds, then 
washed in PBS. Capture antibody mix was prepared by adding 100µL of each capture antibody 
stock solution (anti-IL-4 and anti-IL-10) to 10mL of 1xPBS, followed by mixing, as per 
manufacturer’s instructions, leaving concentrations of both at approximately 10µg per ml of 
PBS. Plates were then coated with 100µL of the mix, before incubation overnight at 4°C. The 
following day, wells were emptied and washed with PBS, before incubation with 100µL RPMI 
+ 10% FCS for 2 hours. Wells were then emptied and washed in PBS.  CD4+ and irradiated 
CD4- cells were then added, both at 500,000 cells/well, with 0, 1, 10 or 30µg/mL Phleum 
pratense allergen, 10µg/mL PHA, or 3µg/mL PPD, in triple or quadruple, with a final volume 
of 200µL per well. Plates were incubated at 37°C, 5% CO2 for 42 hours. Following this, plates 
were emptied and washed in PBS-0.05% Tween 20. Biotinylated IL-4 and FITC-conjugated IL-
10 detection antibodies in PBS plus 1% BSA were added and incubated for 90 minutes at room 
temperature. Wells were then emptied and washed in PBS plus 0.05% Tween 20. One 
hundred microliters of anti-FITC-green fluorescence conjugate/streptavidin-phycoerythrin in 
PBS plus 1% BSA were added to each well before plates were sealed and incubated for 1 hour 
in the dark. Wells were then emptied and washed in PBS plus 0.05% Tween 20. Plate bottoms 
were then peeled off and the revealed membrane washed under running distilled water. 
Wells were dried in the dark before reading on an Elispot reader under a UV light source (AID 
iSpot reader, Autoimmun Diagnostika GmbH, Strasbourg, Germany). Positively stained 
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cells/spots - IL-4, red; IL-10, green; dual, yellow - were counted automatically. Means of triple 
or quadruple repeats were calculated after exclusion of anomalous values, data were 
expressed as each condition minus unstimulated (0mg/mL Phleum pratense) cells. 
d) Analysis of nasal brush samples by RT-PCR 
Nasal brush tips, in 2mL Eppendorf tubes with RLT buffer (Qiagen, West Sussex, UK) plus 1% 
β-mercaptoethanol, were thawed and agitated to remove material from the brush. RNA 
extraction was then performed from 600 µL of each sample using an RNeasy mini kit and QIA 
cube (both Qiagen), according to the manufacturer’s instructions. Following this, samples 
were tested for RNA concentration using a Nanodrop spectrophotometer ND-1000 
(Nanodrop) and mRNA converted to cDNA by reverse transcription using a thermo cycler 
(SensoQuest labcycler). Briefly, 11.5µL of each sample mRNA was combined with 4µL of 5 x 
RT buffer (250 mM Tris-HCL, 375 mM KCL, 15 mM MgCl2, 50 mM DTT), 2µL dNTP mix (dATP, 
dCTP, dGTP, dTTP, each at 10 mM), 1µL RevertAid reverse transcriptase (200 U/µL), 0.5 µL 
RiboLock RNase Inhibitor (40 U/µL) (all Thermo Fisher Scientific) and 1µL random hexamere 
primer (100 mM) (Fermentas Life Sciences).  Samples were then run according to the 
following protocol: 25°C for 10 minutes, 42°C for 60 minutes, 70°C for 10 minutes, then kept 
at 4°C. Forward and reverse primers to the following genes were obtained: GAPDH, 18S, 
Foxp3, CCL11, CCL17, BAFF, APRIL/TNFSF13, IL-4, IL-5, IL-9, IL-10, IL-13, IL-17A, IL-21, IL-25, IL-
33, POSTN (periostin), TSLP, ST2 (IL-33 receptor), soluble ST2 (all Sigma Life Sciences), plus 
Annexin A1 and its receptor FPR2 (kindly supplied by Professor Mauro Perretti, Queen Mary, 
University of London). After reconstitution in RNase free water, matched forward and reverse 
primers were combined and diluted 1 in 20 in RNase free water. Primer pairs were mixed with 
SYBR green (Power SYBR Green PCR Master Mix, Applied Biosystems) in the ratio 1.6 : 5 in 
1.5ml Eppendorf tubes and added in appropriate slots to an epMotion 5075 automated 
pipetting machine. cDNA samples at 1 in 20 dilution in RNase free water in 1.5mL Eppendorf 
tubes were then added to relevant slots and the machine run according to the programmed 
plate layout, with each primer added to triplicate cDNA samples on 384 well-plates. Plates 
were then run on an SDS 7900 HT real-time PCR machine (Applied Biosystems) according to 
the manufacturer’s instructions and standard protocol (40 cycles of 15 seconds at 95°C and 
60 seconds at 60°C) and analysed by SDS 2.4 software (Applied Biosystems by Life 
Technologies). Relative gene expression was calculated using the comparative threshold cycle 
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(CT) method, with GAPDH and 18S gene expression as internal controls. Data were expressed 
as fold change (2-∆CT) versus the two house-keeping genes and comparisons made between 
participant groups.  GS is grateful to Dr Gilda Varricchi for assistance with sample processing.  
 
2.3 Statistical analyses 
Analyses were performed using a commercial software package (Graphpad Prism Version 
5.04) and Microsoft Excel spreadsheets. Normally distributed data are presented as mean ± 
standard error; non-parametric data as median ± interquartile range. Within group 
comparisons were made by paired t-test or Wilcoxon matched-pairs test; between group 
comparisons by unpaired t-test, Mann-Whitney U-test, or one-way ANOVA with correction 
for multiple comparisons. Correlations were made using Pearson’s or Spearman’s correlation 
coefficient. P-values <0.05 were considered statistically significant.  
For the pilot studies, no formal power calculations were used and end points were 
exploratory. For the cross-sectional study, the primary outcome was pre-specified: the 
combined, equally weighted early (0-1 hour) and late (1-8 hour) phase total nasal symptom 
score (TNSS) area under the curve (EPR AUC + LPR AUC/7). A combined early and late phase 
score was chosen for several reasons, despite the predominance of symptoms within the first 
2 hours post challenge in pilot studies. First, allergen immunotherapy has a more profound 
effect on allergen-induced skin late phase (8 hour) responses than on early phase (15 minute 
responses) (Lima MT, 2002). Secondly, it has also been shown to have a powerful suppressive 
effect on the bronchial late phase response (Warner J, 1978). Thirdly, whilst overall mean 
scores for TNSS and PNIF showed no evidence of a biphasic response in pilot studies, a 
minority of participants did have a secondary wave of increased symptoms after hour 4. 
Finally, this study itself was in many respects a pilot for a large, double-blind, prospective 
immunotherapy study (GRASS, ITN043AD) with the same combined score proposed as the 
primary outcome, largely for the first two reasons stated above.   
The primary outcome was powered based on unpublished data concerning 12 subjects with 
grass pollen allergic rhinitis who underwent a grass pollen nasal allergen challenge and 
monitoring over 6 hours (Durham S, unpublished data). This data was analysed by a 
statistician (Miss Jackie Turner) and power calculations undertaken (detailed in the table 
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below). Based on these data, and assuming equal power over 0-8 hours as over 0-6 hours, 
recruiting 14 patients per group would provide at least an 80% power to detect a 50% 
difference between groups in the primary outcome. The primary comparison was to be 
between immunotherapy-treated and untreated grass pollen allergics.  
 
Total Nasal Symptom Score Number of Patients 
needed per group 
Parameter Mean s.d. Difference 
between groups 
Effect Size 
(mean/SD) 
80%  
Power 
90% 
Power 
AUC 0 - 6h 
 
24.7  10.42 50% = 12.35 1.19 13  16 
AUC 0 - 1h 
 
6.6  2.29 50% = 3.28  1.44 9  12 
AUC 1 - 6h 
 
18.1  8.47 50% = 9.06 1.07   15 20 
Mean  AUC 
0 - 1h & 1-6 
12.4  5.38 50% = 6.20  1.15 13  17 
 
 
Secondary outcomes included the equivalent combined, equally weighted early and late 
phase change from baseline PNIF (∆PNIF) AUC, and separate early and late phase AUCs for 
TNSS and ∆PNIF. Intradermal early and late phase responses to allergen were also secondary 
outcomes. Based on previous studies (Varney VA, 1993; Lima MT, 2002; Francis JN, 2008), up 
to a 90% reduction in surface area of the late phase skin response is expected after at least 3 
months immunotherapy. Based on these previous results, 14 participants per group would 
give greater than 90% power to detect a 50% difference between groups. 
Exploratory outcomes included global evaluations of seasonal allergic rhinitis symptoms, local 
nasal fluid and histological biomarkers, and all peripheral blood biomarkers.  
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3. Validation of methods: pilot nasal challenge studies 
 
3.1 Dose-finding and reproducibility 
3.1.1 Introduction 
This first pilot study had several objectives: to determine the sensitivity of total nasal 
symptom scores (TNSS), visual analogue scales (VAS), and peak nasal inspiratory flow (PNIF) 
in measuring the response to grass pollen nasal allergen challenge (NAC); to determine dose-
response characteristics during NAC; to determine the reproducibility of NAC; and to measure 
putative early and late phase mediators in nasal fluid. With regards to the last, two types of 
absorptive filter strips, made from different synthetic absorptive matrices (SAMs), and open 
cell polyurethane sponges were compared with the aim of evaluating which was superior for 
the collection of nasal fluid and measurement of inflammatory mediators.  
3.1.2 Participants 
Twenty volunteers were recruited from the allergy clinic and staff at the Royal Brompton 
Hospital, London. Inclusion criteria were a history of grass-pollen induced seasonal allergic 
rhinitis for at least two years and positive skin prick test (>3mm wheal diameter to Phleum 
pratense extract, ALK-Abello, Denmark) and Timothy grass specific IgE (>0.35 IU/ml). 
Exclusion criteria were perennial rhinitis, chronic or recurrent sinusitis, current smoking or >5 
pack year smoking history, perennial asthma, FEV1 (forced expiratory volume in 1 second) 
<70% predicted at screening, and previous allergen immunotherapy. The study was 
conducted outside of the UK grass pollen season. Participants had not used corticosteroids or 
other anti-allergy medications for at least 2 weeks prior to each study visit. The study was 
approved by the Cambridgeshire 3 Research Ethics Committee and performed with 
participants’ written informed consent. 
3.1.3 Study Design 
The study consisted of 4 visits, each separated by at least 3 weeks (Figure 6). Visit 1 included 
a screening medical history and examination, plus skin prick tests to Timothy grass (Phleum 
pratense) and 11 other common aeroallergens, and blood sample for Timothy grass-specific  
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IgE and total IgE. Following screening, eligible candidates undertook a graded up-dosing nasal 
allergen challenge with purified extract of Phleum pratense. Allergen extract was 
reconstituted at 100,000 SQ-U/mL before dilution in normal saline at the following 
concentrations: 0, 30 (0.02 µg/mL major allergen), 100 (0.067 µg/mL), 300 (0.2 µg/mL), 1000 
(0.67 µg/mL), 3000 (2.0 µg/mL) and 10000 (6.7 µg/mL) BU/mL. Participants received one 
spray, 100µL, to each nostril. Increasing concentrations of allergen were given every 10 
minutes until completion or onset of troublesome symptoms. Participants recorded their 
TNSS, VAS and PNIF at baseline and after each allergen application.  
Visit 2 involved a single nasal challenge with the cumulative dose which first provoked a TNSS 
of ≥5 in each volunteer at visit 1. At baseline participants recorded TNSS, VAS and PNIF. This 
was followed by a nasal lavage, then repeat TNSS, VAS and PNIF 30 minutes later. Nasal 
challenge was performed a further 10 minutes later, with TNSS, VAS and PNIF recorded at 5, 
15 and 30 minutes after challenge, then hourly to 6 hours. At each time point, after the above 
recordings, two Accuwik synthetic absorptive matrix (SAM) strips (Pall Corporation, USA; cut 
round-ended, 35 x 7 mm) were placed back to back and inserted into the one nostril under 
direct vision using croc forceps and a Thuddicum’s nasal speculum (both Phoenix Surgical 
Instruments Ltd, Hertfordshire, UK). Two 111 SAMs (Pall Corporation, USA) of the same 
dimensions were placed into the other nostril. SAMs were placed onto the nasal mucosa, 
beyond the nasal vestibule, and alongside the inferior turbinate. SAMs were left in place for 
2 minutes before removal, and then added to 2mL centrifuge tubes with indwelling 0.22µm 
cellulose acetate filters (Costar Spin-X, Corning, NY, USA). Tubes were kept briefly on ice 
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before being centrifuged at 4,500 rcf at 4°C for 10 minutes. The isolated fluid was pipetted 
into Eppendorf tubes and stored at -80°C.  
Visit 3 was similar to visit 2, except that the nasal challenge was given with the cumulative 
allergen dose provoking a TNSS of ≥7, rather than 5, at visit 1. Also, at each time point, a 
20x15x5mm piece of sterile synthetic polyurethane sponge (RG 27 grau, Gummi-Welz GmbH 
& Co., Germany) was inserted into the right nostril and two 111 SAMs into the left nostril. For 
fluid isolation, the sponges and 111 SAMs were then centrifuged as at visit 2. 
Visit 4 was identical to visit 3, except that only nasal sponges were used to collect nasal fluid.  
3.1.4 Results 
a) Participant demographics 
Twenty volunteers were recruited. One patient attended only the screening visit (visit 1), then 
withdrew due to pregnancy. Another completed only visits 1 and 2 due to a move abroad. 
The remaining 18 completed all study visits. Table 1 summarizes the demographic data of the 
participants.  
b) Up-dosing titration nasal allergen challenge (visit 1), clinical data 
Fifteen volunteers were challenged up to and including 10,000 BU/mL. Four reached a 
maximum of 3,000 BU/mL and one only 1,000 BU/mL before the challenge was stopped due 
to troublesome symptoms. Doses of 1,000 BU/mL and 3,000 BU/mL were sufficient to 
provoke TNSS of ≥5 and ≥7 in the majority of patients, respectively. Overall, just 100 BU/mL 
gave a detectable significant increase from baseline TNSS (Figure 7A).  
The 1,000 BU/mL dose produced a significant fall in PNIF versus baseline (Figure 7B), with 
further decline at higher allergen doses. The 300 BU/mL dose produced a significant increase 
in VAS from baseline (Figure 7C). TNSS and VAS strongly correlated, r=0.87, p<0.0001; there 
was an inverse correlation between TNSS and PNIF, r=-0.62, p<0.0001 and an inverse 
correlation between PNIF and VAS, r=-0.60, p<0.0001. 
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c) Single-dose nasal challenges (visits 2-4), clinical data 
The TNSS was maximal 5 minutes post-challenge at each visit (Figure 8A). PNIF was lowest at 
15-30 minutes after challenge (Figure 8C). Peak TNSS was greater at visits 3 and 4 than visit 
2, p=0.002, p=0.048, paired t-test (Figure 8B). Area under the curve 0-6 hours was greater at 
visit 3 than visit 2, p=0.017, AUC paired t-test. There were no differences in TNSS or PNIF 
between visits 3 and 4. TNSS levels returned to near baseline levels by 4 hours, without a 
distinct late phase response. PNIF levels remained reduced versus baseline at 6 hours after 
visits 3 and 4, both p<0.01 (Figure 8D).  
d) Single-dose nasal challenges (visits 2-4), biomarker data 
Visit 2, Accuwik vs 111: Nasal fluid tryptase peaked at 5 minutes, followed by fall back to 
baseline values by 2 hours (Figure 9A). ECP levels peaked at 5 hours (Figure 9B). 111 SAMs 
recovered higher concentrations of both mediators, despite collection of similar volumes of 
neat nasal fluid.  Th2 cytokines IL-4, IL-5 and IL-13 all peaked at 4-6 hours (Figure 9C, D); IL-10 
followed a similar pattern. Again, 111 SAMs provided greater recovery of mediators 
(Appendix 1, Table 2). 
Visit 3, polyurethane sponge vs 111: A similar pattern in mediator release was seen as at visit 
2 for tryptase, ECP (Figure 10A, B) and Th2 cytokines (Figure 10C-F). Polyurethane sponges 
proved superior for mediator recovery than 111 SAMs for tryptase, ECP, IL-4, IL-5, IL-13 and 
IL-10, but no different for IFN-γ (Appendix 1, Table 3). Interferon-γ levels themselves were 
highly variable, without a clear pattern in response to nasal allergen challenge. Polyurethane 
sponges recovered a larger volume of nasal fluid (p<0.01 vs 111, AUC, Wilcoxon matched pairs 
test). Nasal fluid IL-5 and IL-13 correlated strongly (r=0.94, p<0.0001); there were also 
significant correlations between IL-5 and IL-4 (r=0.79, p<0.0001), and IL-5 and ECP (r=0.72, 
p<0.0001). 
Visit 4, polyurethane sponge vs visit 3, polyurethane sponge: Only cytokine levels were 
recorded in nasal fluid collected at visit 4, not tryptase and ECP. Levels followed a similar 
pattern after challenge at both visits (Figure 11A-D), without significant differences in 
concentrations of recovered cytokines between the two visits (Appendix 1, Table 4).  
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3.1.5 Summary of results 
 Mean TNSS and VAS increased, whilst PNIF decreased, after NAC with increasing grass 
pollen allergen concentration, up to and including 10,000 BU/ml (6.7 µg/mL major 
allergen).  
 Cumulative doses up to 1,000 BU/ml and 3,000 BU/ml were sufficient to provoke a 
TNSS of at least 5 and 7, respectively, in the majority of participants.  
 TNSS, VAS and fall in peak flow were maximal during the first hour after challenge, 
with the effects mainly confined to the first 3 hours, without evidence of a distinct late 
phase response.  
 Challenge with the same allergen dose at visits separated by 4 weeks produced 
reproducible clinical responses (visits 3 and 4).  
 For the majority of biomarkers of interest, polyurethane sponges proved superior to 
synthetic absorptive matrices.  
 Nasal fluid tryptase peaked 5 minutes after challenge, with no biphasic/late-phase 
response.  
 Th2 cytokines, IL-5 and IL-13 in particular, were elevated 4-6 hours after challenge, too 
late to contribute to early phase symptoms 
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3.2 Control (diluent-only) nasal challenge  
3.2.1 Introduction 
The first pilot study revealed a dose-response to nasal allergen challenge. However, a control 
(diluent-only) challenge study was necessary to account for the potential effects of the 
phenol-albumin diluent (and/or trace bacterial components), trauma caused by repeat 
insertion of absorptive materials into the nose, diurnal variation, and re-accumulation of 
mediators in nasal fluid following lavage.    
3.2.2 Participants 
Fifteen volunteers were recruited from the allergy clinic and staff at the Royal Brompton 
Hospital, London. Inclusion and exclusion criteria were as previously. Six of the volunteers had 
also taken part in the first study. The study was approved by the Cambridgeshire 3 Research 
Ethics Committee following an amendment to the approved protocol and performed with 
participants’ written informed consent. 
3.2.3 Study Design 
The study consisted of 2 visits - a screening visit and a diluent nasal challenge visit. Screening 
included a medical history and examination, plus skin prick tests to Timothy grass and 11 
other common aeroallergens, and blood tests (ImmunoCAP) for Timothy grass-specific IgE 
and total IgE. Following screening, eligible candidates were asked to return and undertake a 
single diluent nasal challenge, plus collection of nasal fluid using polyurethane sponges. Nasal 
challenge was undertaken with albumin-based diluent (ALK-Abello) diluted in normal saline 
in the same ratio as would be used to give the equivalent grass pollen solution of 5,000 
BU/mL. TNSS, VAS and PNIF were recorded at the following time points: 10 minutes after 
arrival, 30 minutes after nasal lavage, 40 minutes after nasal lavage, 5, 15, 30 and 60 minutes 
after challenge, and then hourly to 10 hours.  
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3.2.4 Results 
a) Participant demographics 
The demographic data of the fifteen volunteers are summarised in Table 2. Total IgE, Timothy 
grass specific IgE and skin prick to Timothy grass were not significantly different from those 
of the preceding pilot study.  
b) Clinical outcomes 
Diluent-only nasal challenge did not cause any change from baseline in TNSS, PNIF or VAS; nor 
was there an increase in nasal fluid volume, in contrast to the effects of nasal allergen 
challenge (Figure 12A-D). Area under the curve analyses showed highly significant differences 
between active (Pilot 1) and diluent challenges in all parameters (TNSS, p<0.0001; PNIF, 
p=0.009; VAS, P<0.0001; recovered nasal fluid volume, p=0.002; Appendix 1, Table 5).  
c) Biomarkers in nasal fluid 
In contrast to active challenge, there was no increase in nasal fluid tryptase in the 60 minutes 
after diluent challenge (Figure 13A). Conversely, ECP levels were similar after both allergen 
and diluent challenges (Figure 13B). Th2 cytokines IL-4, -5, -13 and IL-10 showed significant 
differences between active and diluent challenges at peak level (6 hours, p<0.01, Figure 13C-
F) and trends to differences in total AUC comparison (IL-4, p=0.052; IL-5, p=0.085; IL-13, 
p=0.099, Appendix 1, Table 6).  
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3.2.3 Summary of results 
 Diluent-only challenge had no effect on TNSS or PNIF. 
 There was no increase in nasal fluid tryptase. 
 Effects on nasal fluid IL-4, -5 and -13 were small and significantly reduced compared 
to allergen challenge. 
 Nasal fluid ECP levels were similar after diluent-only and allergen challenges. 
 
 
 
3.3 Nasal fluid biomarker analysis (additional) 
3.3.1 Introduction 
A further pilot grass pollen nasal allergen challenge study was required for several reasons: 
first, another synthetic absorptive matrix, Leukosorb (Pall Corporation, USA), became 
available, having been unobtainable for the earlier comparative study. Second, having run 
assays for nasal fluid cytokines on MSD 7-plex plates at the laboratories of ALK-Abello, 
Denmark up to this point, the possibility of performing equivalent assays in-house on a 
Luminex Magpix machine had arisen. Finally, this pilot would allow investigation of use of an 
‘elution buffer’ (a mild detergent) to maximise recovery of proteins from the absorptive 
material during centrifuging and to ensure a minimum fluid volume at each time point. In the 
previous studies, at a number of time-points, insufficient fluid volumes had been recovered 
to allow the planned assays to be performed. 
3.3.2 Participants 
Six volunteers were recruited from the allergy clinic and staff at the Royal Brompton Hospital, 
London, using the same criteria as in previous studies. Three of the volunteers had also 
participated in one of the previous pilot studies.  
3.3.3 Study design 
The study consisted of 3 visits – a screening visit and 2 single dose nasal allergen challenge 
visits. During the first challenge visit, nasal secretions were collected using polyurethane 
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sponges bilaterally; during the second, sponges were used on one side, Leukosorb SAMs were 
used on the other. TNSS, VAS and PNIF were recorded as before; nasal lavage was performed 
as before. A single grass allergen dose of 5,000BU/mL was used; if TNSS at 5 minutes post-
challenge was less than 7, a further dose of 10,000BU/mL allergen was given. At the first 
challenge visit, neat (non-eluted) nasal fluid was recovered from sponges taken from one side 
of the nose, whilst sponges from the other side were processed with an additional elution 
step using 200µL of buffer (Milliplex Assay Buffer, Millipore: PBS pH 7.4, BSA (1%), Tween® 20 
(0.05%), sodium azide (0.05%)). At the second challenge visit, nasal fluid from both sponges 
and Leukosorb SAMs was recovered using 100 µL of elution buffer. 
 
3.3.4 Results 
a) Participant demographics 
Six grass pollen allergics were recruited. All participants completed the first visit, comparison 
of Leukosorb SAMs and polyurethane sponges; four of the six participants completed the 
second visit, comparison of recovery of mediators with and without an elution step (Appendix 
1, Table 7).  
b) Leukosorb versus polyurethane sponges 
Polyurethane sponges proved superior to Leukosorb regarding recovery of all cytokines and 
chemokines of interest (Figures 14 and 15). Area under the curve analyses showed significant 
differences for IL-4, IL-5, IL-13, IL-33, MDC and eotaxin, with a trend towards a difference in 
IL-9 (Appendix 1, Table 8).  
c) Elution versus neat nasal fluid 
The results of Th2 cytokines measured in neat and eluted nasal fluid are given in Figures 16-
18, alongside serial dilutions of nasal fluid at 2 and 6 hours from one volunteer. Whilst the 
magnitude of mediator recovery was diminished after elution in 200µL buffer, the pattern 
overall remained similar to that of neat fluid, with increases in Th2 cytokines up to 6 hours 
post challenge, but an earlier peak in IL-33. Serial dilution curves proved linear, with the 
exception of IL-9 at 2 hours (low concentration). 
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3.3.5 Summary of results 
 Polyurethane sponges proved superior to Leukosorb SAMs. 
 Nasal fluid analyte concentrations were reduced with elution, but still above minimal 
levels of detection with patterns of secretion maintained.  
 Serial dilutions of nasal fluid from one individual provided linear reductions in analyte 
concentration for most mediators.  
 
3.4 Discussion 
These studies determined dose-response and time-course characteristics for nasal challenge 
with Timothy grass allergen and confirmed reproducibility. Polyurethane sponges proved 
superior to the three synthetic absorptive matrices, both in terms of volume of fluid 
recovered and mediator concentration. Tryptase provided a signal for the early phase 
response, peaking 5 minutes after challenge, with no biphasic/late-phase response; IL-5 and 
IL-13 in particular were elevated 4-6 hours after challenge, marking the evolution of the late 
phase. 
Diluent challenges confirmed that clinical responses were due to mucosal allergen exposure, 
rather than the procedures themselves (phenol-based diluent; physical effects of insertion of 
polyurethane sponges into the nose; repeated peak nasal inspiratory flow attempts). 
Concerning nasal fluid analytes, some re-accumulation of mediators following nasal lavage 
did occur, independent of allergen exposure (most notably with ECP).  
Analytes were successfully measured using MSD 7-plex plates then Luminex Magpix plates, 
the latter allowing capture of a broader range of cytokines and chemokines. The use of an 
elution buffer solved the problem of ‘dry’ swabs (less than the minimum fluid volume 
recovered to run the planned immunoassays) without altering the pattern of analyte 
accumulation in nasal fluid or diluting below minimal levels of detection.  
3.4.1 Appraisal of study methods and limitations 
The primary outcome used was the total nasal symptom score (TNSS). Whilst this is a largely 
subjective score, it showed a tight, inverse correlation with peak nasal flow, an objective 
measure. Careful instruction and observation of each PNIF attempt by examiners resulted in 
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very consistent results for each individual participant. Whilst PNIF is effort dependent – in 
contrast to rhinomanometry or acoustic rhinometry – the number of participants and 
frequency of assessments would not have been possible with more time-consuming and 
laborious (not to mention expensive) measures. In order to control for the nasal cycle effect 
when comparing absorptive materials, participants were randomised 50:50 as to which side 
of the nose each material was applied.  
All the different materials used for collection of nasal fluid were acceptable to participants, 
without causing significant discomfort or bleeding. The possibility of repeat insertion of 
absorptive materials into the nose causing inflammation has been investigated previously. 
Riechelmann et al (2003) found that insertion of polyurethane sponges did not increase either 
alpha-2-macroglobulin or lactate dehydrogenase (markers of plasma exudation and tissue 
injury, respectively) in nasal fluid. It therefore seems that the gradual increase in some 
mediators within nasal fluid after diluent challenge represents a return to the normal state of 
the mucosa after lavage (perhaps particularly in polysensitised individuals), rather than an 
irritant or inflammatory response. This might have been less evident if solely grass 
monosensitised participants were used, but recruiting sufficient numbers of such participants 
is difficult. A further possible criticism is that the diluent challenges were not performed on 
all the same volunteers as the first allergen challenge study (6 of the 15 participated in both 
pilots). This might explain the lack of significant difference between active and diluent 
challenges for ECP, as each individual could not be used as his/her own control for 
comparison. 
Elution buffers have been used by other researchers (for example, Nicholson GC, 2013). 
Whilst this solves the problem of ‘dry’ swabs/low volume of recovered fluid, mediator results 
are no longer a true representation of in vivo concentrations. Some researchers have 
attempted to normalise results to albumin or other markers of transudation or exudation, but 
the majority have reported uncorrected results (Linden M, 2000; Erin EM, 2005a; Nicholson 
GC, 2013). An alternative option would be to multiply the concentration of each mediator by 
the volume of undiluted fluid recovered at each time point (Wagenmann M, 2005). This 
involves the assumption that the entirety of any elution buffer added to the sponge can be 
recovered after centrifugation. For the studies reported here, no adjustments were made, 
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but results of nasal fluid analysis were nonetheless reproducible – important for future 
interventional studies. 
3.4.2 Comparisons with published literature 
Previously, tryptase increases have been detected within 10-15 minutes of allergen challenge 
(Rondón C, 2009; Jacobi HH, 1998), with ECP elevated at 6 and 24 hours (Rondón C, 2009; 
Miadonna A, 1999). IL-5 has been increased at 6-9 hours (Nicholson GC, 2011; Linden M, 
2000); IL-13 at 6-8 hours (Erin EM, 2005a; Nicholson GC, 2011); and IL-4 at 5-6 hours 
(Wagenmann M, 2005). IL-10 levels also showed a trend to increasing by 6 hours, as has been 
described elsewhere (Bensch GW, 2002), as well as during seasonal allergen exposure 
(Benson M, 1997). Conversely, fewer IL-10 mRNA+ cells were found in the nasal mucosa of 
allergics than non-atopics after challenge (Pilette C, 2013).  Most previous studies, either post 
challenge or during seasonal allergen exposure, have not demonstrated changes in nasal fluid 
IFN-γ in allergic individuals (Gröger M, 2012; Klemens C, 2007; Benson M, 1997). But, of note, 
an increase in IFN-γ during seasonal grass pollen exposure was found in non-atopics, but not 
allergics (Benson M, 1997).  
Mean mediator levels at peak times in the first pilot were as follows: tryptase 43ng/ml at 5 
minutes, ECP 97ng/ml, IL-5 833pg/ml, IL-13 143pg/ml, IL-4 21pg/ml, IL-10 112pg/ml, and IFN-
γ 60pg/ml, all at 5 hours post challenge. These levels are generally somewhat higher than in 
previously published studies, likely principally due direct fluid absorption, rather than use of 
nasal lavage. For example, peak tryptase levels of less than 2ng/ml (Rondón C, 2009; Allocco 
FT, 2002), and ECP levels of 20ng/ml and 40ng/ml at 6 and 24 hours post-challenge 
respectively (Miadonna A, 1999) have been reported. (Much higher ECP levels have been 
reported in nasal polyp patients, approximately 300ng/ml (Gevaert P, 2006)). Regarding IL-5, 
our results are in-keeping with those of Linden et al (2000) where peak levels of  900pg/ml 
were found using absorptive filter papers; conversely, nasal lavage returned levels of 
approximately 10pg/ml (Erin EM, 2005a). Similarly, IL-13 levels peaked at 1pg/ml post-
challenge using nasal lavage (Erin EM, 2005a); but values of up to 500pg/ml were recorded 
using Accuwik Ultra filter strips (Nicholson GC, 2011). Median peak IL-4 levels of less than 
0.5pg (quoted as total amount rather than concentration) were reported by Wagenmann 
(2005). Concerning IFN-γ, levels of 7pg/ml were recorded in unchallenged allergics in season, 
increasing to 17pg/ml following birch pollen immunotherapy (Klimek L, 1999).   
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Elevated nasal fluid IL-33 has been described in house dust mite, Japanese cedar, grass and 
tree pollen allergic rhinitics (Sakashita M, 2008; Asaka D, 2012; Kamekura R, 2012; Glück J, 
2012), but another study failed to find an increase from very low baseline levels after nasal 
allergen challenge, although levels of its receptor, soluble ST2, were increased during 
seasonal allergen exposure (Baumann R, 2013). Notably, Haenuki at al (2012) found lower 
epithelial expression of IL-33 on immunohistochemical staining of turbinate tissue from 
allergic rhinitics (although IL-33 mRNA detected by in situ hybridisation was raised in pollen 
allergics biopsied in-season). 
Without standardisation of approaches between research groups – for both collection of 
nasal fluid and immunoassays - it is not possible to establish normal ranges for nasal 
biomarkers at present. For example, nasal fluid collected by filter strips gave 5-10 times higher 
concentrations of IL-5 and IL-13 than nasal lavage in the same patients, and IL-4 levels were 
below the limit of detection using the latter approach (Erin EM, 2005b). Riechelmann (2003) 
found sponges provided 10 times higher levels of most mediators than lavage.  
3.4.3 Significance of results 
The model presented here is consistent with a Th2-dominant response to nasal allergen 
challenge. The finding of a possible early increase in IL-33 – peaking at 1 hour – was intriguing, 
being consistent with the postulated role of this epithelial-derived cytokine in linking innate 
and adaptive responses to allergen, but required further confirmation. The advantage of nasal 
fluid analysis in the study of allergic rhinitis is that it is a non-invasive procedure that allows 
evaluation of responses at the relevant site. We found responses to be sensitive to allergen 
challenge and reproducible. The model appeared ready to use in an interventional situation, 
in this case to investigate the effects of allergen immunotherapy on clinical and biological 
responses to nasal challenge. Prior to that, however, the opportunity arose to extend the 
model to a perennial allergen – cat dander.   
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4. Cat Nasal Allergen Challenge Study 
 
4.1 Introduction 
Cat allergen is highly pervasive in countries where cats are common pets. Cat allergen can be 
found in homes without cats (Bollinger ME, 2005), day-care centres (Arbes SJ, 2005a) and 
schools (Almqvist C, 1999) at levels sufficient to affect asthma control (Almqvist C, 2001). An 
estimated 17% of the US population is sensitised to cat allergen (Arbes SJ, 2005b), rising to 
44% of inner-city, moderate-severe asthmatic children (Gruchalla RS, 2005), with sensitisation 
estimated to account for 29% of asthma cases (Arbes SJ, 2005b). Allergen control measures, 
such as the use of HEPA filters, have shown limited effects (Wood RA, 1998).  
Standardisation of cat allergen exposure in field studies may therefore be even more complex 
than for grass pollen. Moreover, without clear ‘on’ and ‘off’ seasons, examination of the 
exposed state in comparison with the normal, uninflamed state is limited. In the past a ‘cat 
room’ – usually a small-sized room housing one or more cats – has been used to study cat 
allergen exposure. Whilst this simulates real-life exposure, exposing the airway to particles of 
multiple sizes (Corren J, 2011; Wood RA, 1993), it provides highly variable levels of airborne 
allergen (Corren J, 2011, Sicherer SH, 1997). Alternatives include nebulised cat allergen 
(Arvidsson MB, 2007) and cat nasal allergen challenge (Hanf G, 2004; Nanda A, 2004; Sicherer 
SH, 1997). Recently, cat allergen exposure in an environmental exposure chamber has 
demonstrated efficacy of a cat allergen peptide immunotherapy vaccine (Patel D, 2013).  
The aim of this study was to use the techniques developed in the previous grass allergen NAC 
studies to study responses to cat allergen NAC, including symptom scores, PNIF changes, and 
local inflammatory mediators in nasal fluid. Concerning the latter in particular, very few 
previous studies have reported on local inflammatory mediators in the nose following cat 
allergen exposure. Additionally, the ability of NAC to activate basophils in the peripheral blood 
was assessed by flow cytometry, looking for evidence of a systemic effect of nasal mucosal 
allergen exposure. A previous study had indicated repeat nasal allergen administration 
caused increased expression of the beta-subunit of the high-affinity IgE receptor, FcεR1β, on 
mature basophils (Saini S, 2004); moreover, Dr Mohamed Shamji and colleagues at Imperial 
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College had shown up-regulation of basophil surface activation markers following grass pollen 
NAC (Shamji MH, 2015).  
 
4.2 Participants 
Eighteen volunteers were recruited from the staff at the Royal Brompton Hospital, staff and 
students at Imperial College, and by advertisement. Inclusion criteria were a history of at least 
one year of cat-induced rhinoconjunctivitis (with/without mild asthma); no resident cat in the 
home; positive skin prick test to cat allergen (≥5 mm greater than negative control); positive 
ImmunoCAP test to cat allergen of ≥0.70 KU/L. Exclusion criteria included pre-bronchodilator 
FEV1 <70% of predicted value at screening or any other indicators of poorly controlled 
asthma; a history of anaphylaxis on exposure to cat allergen; previous cat allergen 
immunotherapy; currently symptomatic allergic rhinitis during the study visits; chronic or 
recurrent sinusitis; and current smoking or >5 pack year smoking history. The study was 
approved by the National Research Ethics Service, Surrey, and by the Research Office of The 
Royal Brompton and Harefield NHS Foundation Trust. Written, informed consent was 
obtained before any study procedures were carried out. 
 
4.3 Study Design 
The study consisted of three visits. First, a screening visit where allergy history, medical 
history, spirometry and skin prick testing to cat allergen were performed and blood taken for 
ImmunoCAP to major cat allergen, Fel d 1. Participants meeting the inclusion/exclusion 
criteria were then invited to return for two nasal challenge visits, at least three weeks apart. 
The first challenge involved administration of diluent only, the second increasing doses of cat 
allergen (Alutard SQ cat hair allergen extract, ALK-Abello, Denmark). Following arrival and 10 
minutes acclimatisation, participants recorded TNSS, PNIF and PEFR, and nasal fluid was 
collected using polyurethane sponges bilaterally. Following this, volunteers underwent a 
nasal lavage. TNSS, PNIF and PEFR were recorded 10 minutes later. A further ten minutes 
later, participants began the challenge (see below). TNSS, PNIF, PEFR and nasal fluid were 
recorded/collected at 5 minutes after the final challenge dose, then again at 15, 30, and 60 
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minutes, and at hourly intervals to 8 hours. Additionally, 20mL of peripheral blood was 
collected in lithium heparin tubes at least 15 minutes prior to challenge, then 6 hours after 
the final challenge dose for the purpose of basophil activation studies.  
For the allergen challenge visit, cat allergen (Alutard SQ cat hair allergen extract, ALK-Abello) 
was reconstituted at 100,000 SQ-U/mL (equivalent to 30,000 BU/mL or 14.6 µg/mL of Fel d1) 
in albumin-based diluent (ALK-Abello). Dilutions in normal saline were then made at the 
following concentrations: 10,000 BU/mL (4.87µg/mL Fel d1), 5,000 BU/mL (2.43µg/mL), 1,500 
BU/mL (0.73µg/mL), 500 BU/mL (0.243µg/mL). For the diluent challenge, albumin-based 
diluent, in the absence of allergen, was diluted in normal saline in the same ratios as each 
concentration above. One 100µL spray was applied to each nostril, at each dose, using 
disposable Bi-dose nasal applicator devices. The challenge began at 500 BU/mL, with 
increasing concentrations administered at 10 minute intervals, with response (TNSS, PNIF and 
PEFR) recorded immediately before the next dose, continuing to 10,000 BU/mL (or, if the 
participant had not yet reached a TNSS score of 8 and was happy to proceed, and at the 
examiner’s discretion, to 30,000 BU/mL).  
 
4.4 Results 
4.4.1 Participant demographics 
Table 3 summarises the demographic characteristics of the 19 participants. Individual 
characteristics of the participants are given in Appendix 1, Table 9, including other allergic 
sensitisations. All participants completed all study visits.  
4.4.2 Clinical responses to nasal challenge 
The outcomes of diluent and active challenges on total nasal symptom score (TNSS) are shown 
in Figure 19. Diluent-only challenge did not provoke a response. On average, a significant 
response was seen to the first allergen dose, 500 BU/mL (p<0.0001 versus diluent), with a 
progressive increase to 10,000 BU/mL, but a plateau thereafter. Seven participants received 
a maximum allergen dose of 30,000 BU/mL, the rest 10,000 BU/mL. One participant had not 
reached a score of 8 or more at the 10,000 BU/mL dose, but did not  
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go on to receive the 30,000 BU/mL dose due to the development of a cough. Regarding the 
time-course of response, scores peaked 5 minutes after the final allergen dose, falling 
thereafter until reaching baseline levels by 4 hours.  
Peak nasal inspiratory flow (PNIF) response is shown in Figure 20. On average, PNIF fell after 
the initial dose of 500 BU/mL (p<0.001 versus diluent), with further falls at each subsequent 
dose. Trough PNIF values were seen at 5 minutes after final allergen challenge, but showed a 
partial recovery up to 3 hours, after which levels plateaued, remaining reduced compared to 
diluent challenge up to 8 hours (8 hours: p<0.01 versus diluent, p<0.0001 versus baseline).  
Peak expiratory flow rate (PEFR) was not significantly affected by nasal allergen challenge 
during the dose titration or during the following 8 hours (Appendix 1, Figure 1). Volunteer cat 
allergen specific IgE levels and cat allergen skin test size showed no correlation with clinical 
outcomes including overall (area under curve) TNSS and PNIF, peak TNSS and PNIF, or 
threshold dose giving TNSS ≥7.  
 
86 
 
 
87 
 
 
 
 
 
88 
 
4.4.3 Local nasal biomarker responses 
Tryptase concentration in nasal fluid was greatest at 5 minutes after the final allergen 
challenge (peak level, p<0.05 versus diluent and versus baseline, Figure 21A; AUC comparison, 
allergen vs diluent, Wilcoxon matched pairs test, p=0.18). ECP levels peaked at 8 hours post 
challenge (p<0.0001 versus baseline), with a trend to greater levels than after diluent 
challenge (peak comparison p=0.07, Figure 21B; AUC comparison, p=0.31).  
Concerning Th2 chemokines, eotaxin levels were greatest at 8 hours post challenge (peak 
level, p<0.05 versus diluent, Figure 21C; AUC comparison, p=0.04). MDC and TARC also 
peaked at 8 hours, narrowly missing statistical significance compared to diluent challenge 
(both, peak level comparison, p=0.09, Figure 21D, E; AUC comparisons: MDC, p=0.049; TARC, 
p=0.31).  
Concerning Th2 cytokines, levels of IL-4, -5, -9, and -13 increased gradually after nasal allergen 
challenge, peaking at 8 hours, significantly greater than after diluent (peak level, IL-9, p<0.05 
versus diluent; IL-4 and IL-13, p <0.01; IL-5, p<0.0001 Figure 22; AUC comparisons: IL-9, 
p=0.07; IL-4, p=0.001; IL-5, p=0.002).  
Interleukin-6 levels were maximal at 8 hours post challenge, with a trend to greater levels 
than after diluent (peak level, p=0.07, Appendix 1, Table 10; AUC comparison: p=0.43). 
Interferon-γ, IL-8, IL-10, IL-17A, IL-33 and RANTES levels did not significantly differ after 
allergen and diluent challenges (Appendix 1, Table 10); concentrations of TSLP were below 
the limit of detection in all samples; IL-25 was detected in only one participant at one time 
point (95pg/mL, 30 minutes after allergen challenge). 
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4.4.4 Clinical outcomes versus biomarkers 
Both IL-5 and IL-13 levels inversely correlated with PNIF after allergen challenge (IL-5, r=-0.79, 
p<0.0001; IL-13, r=-0.60, p=0.006, Figure 23). Overall, tryptase also inversely correlated with 
PNIF (AUC correlation, r=-0.62, p=0.004); but peak (5 minute) tryptase did not correlate with 
peak TNSS or minimum PNIF, nor were there significant correlations between peak (8 hour) 
cytokine/chemokine levels and TNSS or PNIF. Amongst local mediators, IL-5 and IL-13 
correlated very closely (r=0.86, p<0.0001). There were also strong correlations between IL-9 
and IL-13 (r=0.68, p=0.001), as well as moderate correlations between IL-5 and both IL-9 
(r=0.54, p=0.02) and eotaxin (r=0.53, p=0.02). 
4.4.5 Whole blood basophil flow cytometry 
Basophil CD63, CD107a and CD203c surface expression did not change pre and 6 hours post 
diluent. Conversely, CD63 expression was increased 6 hours post allergen versus pre-
challenge, both with and without in vitro cat allergen stimulation (p<0.05 and p<0.01, 
respectively, Figure 24; Appendix 1, Table 11). CD63 expression was also greater 6 hours post-
allergen challenge than 6 hours post-diluent challenge (p<0.001).  
Surface expression of CD107a was also increased at 6 hours after allergen versus pre-
challenge, in both the presence and absence of in vitro allergen stimulation (both p<0.05). 
CD203c expression was increased after allergen, but only following in vitro allergen 
stimulation (p<0.05).  
Conversely, no changes in surface marker expression as a consequence of anti-IgE stimulation 
(positive control) were seen in pre-challenge compared to post-challenge samples either after 
allergen or diluent challenges. Basophil surface marker expression did not show significant 
correlations with clinical outcomes (TNSS and PNIF, either by AUC or peak levels) or nasal fluid 
biomarkers. 
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4.4.6 Summary of results 
 As with grass pollen provocations, nasal fluid tryptase increased at 5 minutes after cat 
allergen challenge. 
 Th2 cytokines and chemokines peaked at 8 hours post challenge. 
 Individuals with lower PNIF after nasal challenge tended to have higher nasal fluid IL-
5 and IL-13 
 IL-33 was present in pg/ml levels in nasal fluid, but levels were similar after active and 
diluent challenges; TSLP and IL-25 were almost exclusively undetectable; IL-17A and 
IFN-γ were present at low pg/ml levels only. 
 Peripheral blood basophils express greater surface CD63 and CD107a 6 hours after cat 
allergen challenge compared to pre-challenge or 6 hours post diluent challenge.   
 
 
4.5 Discussion 
This study provided dose-response and time-course characteristics for cat allergen 
provocations. As with grass pollen, nasal fluid tryptase increased in the early phase, then Th2 
cytokines and chemokines in the late phase – particularly IL-4, IL-5, IL-13 and eotaxin. The 
relationship between nasal fluid mediators and clinical outcomes of nasal allergen challenge 
was illustrated by the inverse correlations between PNIF and nasal fluid IL-5, IL-13 and 
tryptase. Tryptase, as a marker of mast cell degranulation, might be expected to show such 
an inverse correlation – implying that greater mast cell degranulation is associated with 
greater impairment of nasal flow. Conversely, increases in IL-5 and IL-13 occur much later 
than the maximum fall in PNIF, so no causality can be implied. Instead, this correlation might 
suggest that a larger early phase response, associated with greater mast cell degranulation, 
results in greater levels of these Th2 cytokines during the late phase. There was little evidence 
for a contribution from the IL-17 family of cytokines or epithelial derived cytokines – IL-25, IL-
33, TSLP - in this model. The systemic effect of nasal allergen exposure was highlighted by the 
up-regulation of peripheral blood basophil CD63 and CD107a expression 6 hours after NAC.   
4.5.1 Appraisal of study methods and limitations 
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Allergen and diluent challenges were not performed blinded and the order of challenges was 
not randomised. However, the complete absence of response to diluent suggests that the 
nature of each challenge – active or diluent – would have been immediately obvious to both 
subjects and examiners even with blinding. The order of challenges was deliberately selected 
as diluent first to avoid any residual inflammation at the second challenge visit.  Only non-cat 
owners were recruited as chronic allergen exposure might have diminished early phase 
responses, augmented non-specific hypersensitivity, or, potentially, induced a degree of 
tolerance. Whether cat-owning, cat-sensitised individuals would respond in the same way 
remains to be seen. The cohort recruited did not include any patients currently using inhaled 
corticosteroids for asthma. Whilst no changes occurred in peak expiratory flow rate after 
active challenge, it cannot be guaranteed this would not be the case in cat allergic individuals 
with active asthma. 
4.5.2 Comparisons with published literature 
a) Nasal fluid analytes  
Cat NAC gave similar patterns of nasal fluid mediators to grass NAC. Few previous studies 
have measured local mediators following cat NAC. Studies investigating the effects of 
omalizumab on nasal cat allergen responses have found reductions in albumin (Hanf G, 2004) 
and PGD2 (Eckman JA, 2010) in nasal fluid; but in the latter study tryptase could not reliably 
be measured. Two further studies have investigated effects of cat allergen immunotherapy 
on nasal fluid, but levels of IL-4, -5, -10, IFN-γ and TGF-β were apparently unchanged following 
treatment and baseline values were not reported (Nanda A, 2004;  Ewbank PA, 2003).  
The absence of significant effects of allergen challenge on IL-17, IL-25, IL-33 and TSLP reflects 
the current limited evidence for a role for these mediators in allergic rhinitis. Elevated TSLP in 
nasal fluid of dust mite allergic individuals has been reported, even in the absence of allergen 
challenge (Xu G, 2010). Immunohistochemical staining and real time RT-PCR have revealed 
increased expression of TSLP protein and mRNA in turbinate tissue of allergic rhinitics 
(Kamekura R, 2009; Mou Z, 2009). A further study identified increased in vitro TSLP expression 
in human nasal epithelial cells derived from mugwort allergics in-season, compared to 
controls (Zhu DD, 2009). Conversely, none of 11 TSLP single-nucleotide polymorphisms in a 
Han Chinese population was associated with susceptibility to allergic rhinitis (Zhang Y, 2012), 
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although some showed gender-specific associations with nasal polyposis (Zhang Y, 2013). The 
mixed results concerning IL-33 have been discussed in the previous chapter.  
Increases in IL-17A in nasal fluid have been reported after pollen allergen challenge (Baumann 
R, 2013) and in unchallenged dust mite allergics (Xu G, 2010). Conversely, whilst IL-17 was 
raised during viral upper respiratory tract infection, no increase was seen during seasonal 
pollen allergen exposure (Klemens C, 2007). Dust mite perennial allergic rhinitics were found 
to have greater local IL-17A expression than non-atopics by immunohistochemistry, as well 
as up-regulation of IL-17A gene expression and a higher proportion of IL-17-expressing T-cells 
in tissue homogenates (Liu Y, 2013). Up-regulation of peripheral immune cell IL-17 expression 
has also been found: blood myeloid dendritic cells of grass pollen allergics induced T cell IL-
17 secretion in vitro (Pilette C, 2013); grass or birch pollen allergen-challenged peripheral 
blood mononuclear cells up-regulated IL-17 receptor (IL-17RB) gene expression whilst 
basophils upregulated IL-17RB protein (Wang H, 2010).  Of note, ethnicity of populations 
studied may be relevant if extrapolation can be made from nasal polyp patients: the IL-17 
family of cytokines appear to be over-expressed in the majority of nasal polyp patients in 
Chinese cohorts, but this situation is rare in European cohorts (Zhang N, 2008).  
b) Basophil responses to NAC  
This study demonstrated an effect of in vivo allergen exposure (NAC) on ex vivo basophil 
activation. This result repeats the findings of Shamji et al (2015b) where increases in basophil 
surface CD107a, CD63, and CD203c expression were detected by flow cytometry after nasal 
challenge with grass pollen.  
Basophil responses have previously been investigated in the context of cat allergy: cat 
allergen-induced basophil histamine release in vitro was a predictor of patient response to 
nasal allergen challenge (Paterniti M, 2011); treatment with omalizumab decreased both 
response to nasal challenge and allergen-induced basophil histamine release (Eckman JA, 
2010). Of note, we did not find a correlation between basophil response to cat allergen in 
vitro and clinical response to cat nasal allergen challenge, although the study may have been 
underpowered to do so. In contrast, Shamji et al (2015a) did find a correlation between 
basophil CD63 surface expression and retrospective seasonal rhinitis symptom scores. In a 
previous study, repeat nasal challenge with grass pollen or ragweed over 3 days was shown 
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to increase expression of the beta-subunit, FcεR1β, of the high affinity IgE receptor on mature 
basophils, as well as a trend to increased expression of IL-13 (Saini S, 2004).  
Taken together, these results indicate a truly systemic immune consequence of nasal allergen 
exposure. Of note, the migratory capacity of eosinophils extracted from peripheral blood was 
found to be increased in samples taken 2 hours after nasal allergen challenge, suggesting the 
effect is not limited to basophils (Lönnkvist K, 2002). In mice, nasal mucosal allergen exposure 
has been shown to stimulate generation and trafficking of immune cells from the bone 
marrow (Gaspar Elsas MI, 1997). The theory of rhinitis as a disease with systemic ramifications 
has been proposed (Borish L, 2003), accounting for the fact that nasal allergen challenges and 
seasonal exposure have been shown to induce lower respiratory tract (Braunstahl GJ, 2001; 
Corren J, 1992) and sinus inflammation (Baroody FM, 2008); furthermore, the reverse may 
also occur – segmental bronchial provocation was shown to cause nasal mucosal 
inflammation in allergic rhinitics (Braunstahl GJ, 2000). Such findings may help explain why 
intranasal corticosteroids can have a positive impact on asthma control (Corren J, 2004; Wood 
and Eggleston, 1995).  
It is possible to speculate how nasal allergen exposure has systemic immune effects. A simple 
explanation would be the direct absorption of allergen from nasal mucosa into the 
bloodstream, or passage to the nasopharynx followed by swallowing and absorption in the 
gut – the latter supported by a study using radio-labelled Parietaria allergen (Bagnasco M, 
1997). Alternatively, allergen-carrying antigen-presenting cells may migrate from nasal 
mucosa to local lymph nodes and encounter effector cells there; or effector cells resident in 
the mucosa may encounter allergen, become activated and pass into the circulation; or there 
may be a systemic overspill of locally produced Th2 cytokines or other mediators (although 
the pg/ml levels of mediators detected in nasal fluid after challenge would presumably be 
greatly diluted within the whole circulation). There are reports of elevated serum IL-5 and IL-
9 in allergics (Liu W, 2012; Ciprandi G, 2010). Beeh et al (Beeh KM, 2003) demonstrated an 
increase in plasma IL-5 24 hours after nasal allergen challenge with either grass or birch pollen 
extracts in 16 allergic rhinitics without asthma or bronchial hyper-reactivity; no such increase 
was seen after a placebo nasal provocation. Absolute levels, however, were modest, peaking 
at a mean of just 14.5pg/ml after active challenge. Notably, there was a correlation between 
sputum ECP and plasma IL-5 in a subgroup of participants post active challenge; but this in 
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itself is insufficient to prove that a rise in plasma IL-5 post nasal challenge causes activation 
of lung eosinophils.  
4.5.3 Biological and clinical relevance of results 
The nasal fluid analyte results presented here are consistent with the Th2 model of allergic 
inflammation. There is little evidence for a contribution from Th17 cells, as measured by IL-
17A in nasal fluid. Similarly, the early innate immune response, manifest by epithelial-derived 
cytokines such as TSLP, IL-25 and IL-33, does not appear relevant in this model, although IL-
33 may warrant further investigation. Given the postulated role of these cytokines early in 
inflammatory responses, it seems reasonable to suspect a longer duration of study, e.g. up to 
24 hours post challenge, is not necessarily indicated, but alternative scenarios – repeat 
provocations, provocations in the context of innate immune system adjuvants such as TLR 
ligands – might reveal a more pertinent role for these mediators.  
The source of the Th2 cytokines and chemokines needs further clarification. An influx of 
eosinophils and CCR4+ T-cells does occur as early as 8 hours after nasal allergen challenge 
(Banfield G, 2010), but levels of nasal fluid mediators were clearly increasing from 4 hours or 
even earlier, suggesting cells already resident in the mucosa may be the primary sources. 
Mast cells, basophils and, potentially, type 2 innate lymphoid cells, may be early sources of 
IL-4, IL-5 and IL-13; activated epithelial cells may also be an important source of chemokines 
such as eotaxin and TARC.  IL-4 and IL-13 will contribute to further B cell class switch to and 
secretion of IgE, with the latter also stimulating mucus production. IL-5 is essential in 
contributing to eosinophilic inflammation. In this way, these factors may prime the mucosa 
for further, heightened inflammatory responses on re-exposure to allergen, and contribute 
to on-going inflammation which may be associated with general nasal hyperreactivity. 
Whilst tryptase is surrogate for mast cell degranulation as the primary feature of the early 
phase response, it is not the most important biological mediator of this phase. Histamine has 
effects on sensory nerve endings, stimulating itch and sneezing and the release of 
neuropeptides including Substance P, Calcitonin Gene Related Peptide (CGRP) and Vasoactive 
Intestinal Polypeptide (VIP) (Mosimann BL, 1993). Along with cysteinyl leukotrienes, 
histamine also has effects on blood vessels, the latter causing increased vascular permeability, 
and the former vasodilatation. Prostaglandin D2 may also contribute to vasodilatation and is 
98 
 
important in chemotaxis of CRTH2-expressing cells, including Th2 cells, eosinophils and 
basophils. Whilst many of these other factors have been measured in nasal challenge models, 
tryptase has the advantage of being very stable and measurable with a well-validated 
commercially available system (ImmunoCAP).  
Whilst the effect of cat allergen NAC on basophils was small, it provides a potential 
mechanism by which nasal allergen exposure could cause inflammation at distal sites - lower 
airway inflammation in asthma; skin inflammation in eczema; sinus inflammation in 
rhinosinusitis; conjunctival inflammation in rhinoconjunctivitis. Consequently, it may also 
help explain why intranasal corticosteroids, at doses probably insufficient to have systemic 
pharmacological effects, may improve asthma control.  
This cat allergen nasal challenge study has provided important preliminary data informing the 
use of nasal provocation as an end point in an ongoing trial of cat allergen immunotherapy 
(Cat-NIP, ITN). Cat NAC will also be compared with aerosolised cat allergen exposure in an 
environmental exposure chamber (Cat EEC-NAC, ITN061AD). Aside from this, the work 
presented here has further validated the use of peak nasal inspiratory flow to measure 
changes in the nasal airway after allergen challenge. 
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5. Cross-sectional grass pollen nasal allergen challenge study 
 
5.1 Introduction 
Having established a technique for NAC and measurement of mediators in nasal fluid, and 
having found evidence of systemic immune effects – peripheral blood basophil activation – 
following cat allergen NAC, the next step involved investigating how specific allergen 
immunotherapy modified these responses. A cross-sectional study design was used, making 
use of a cohort of well-characterised patients receiving grass pollen immunotherapy in the 
Allergy clinic at the Royal Brompton Hospital. These patients were compared to well-matched 
controls – grass pollen allergics not receiving allergen immunotherapy (in effect, a positive 
control group), as well as a cohort of non-atopic individuals (a negative control group). As an 
addition, a group of patients who had completed grass pollen immunotherapy were studied 
with the hypothesis that these individuals should also have suppressed NAC responses, given 
the ability of immunotherapy to produce sustained allergen tolerance for at least 3 years after 
completion of treatment (Durham SR, 1999; Durham SR, 2012). Whilst a prospective, placebo-
controlled study was not possible on grounds of cost and time, recruitment of participants 
was undertaken by two research nurses, Andrea Goldstone and Rachel Yan, leaving the 
physicians performing the nasal challenges (GS assisted by Dr Aarif Eifan), collecting and 
processing samples, and analysing the data, blinded to the status of participants. 
In addition to the clinical outcomes, nasal fluid mediators, and basophil assays described in 
the previous studies, additional laboratory assessments were performed in order to gain 
further insight into the mechanisms of allergen immunotherapy. These included 
measurement of allergen-specific antibodies in nasal fluid. Serum allergen-specific IgG 
undoubtedly increases during immunotherapy, but whether the same increase occurs at the 
mucosal interface with allergen is less clear. Moreover, the effect of immunotherapy on IgA, 
a predominantly mucosal antibody, requires further clarification. Both classes of antibody 
might be relevant to mucosal allergen tolerance. The effect of NAC itself on local antibody 
levels was also of interest: in the context of local allergic rhinitis, NAC has produced increases 
in allergen specific IgE within 1 hour of allergen exposure (Rondon C, 2009; Lopez S, 2010). 
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Immunotherapy has effects at the T cell level, some of which may be important in contributing 
to specific immune tolerance. In vitro studies have demonstrated enhanced T cell allergen-
induced IL-10 production following immunotherapy (Akis CA, 1998; Francis JN, 2003), with IL-
10 appearing necessary for the suppressive action of some regulatory T cells (Bohle B, 2007). 
T cell function was studied in two ways in the study presented here: proliferation in response 
to allergen through 3H-thymidine incorporation and individual cell cytokine production 
measured by Fluorospot assay. As in the cat allergen NAC study, the effect of NAC was 
investigated by studying the responses of cells isolated from peripheral blood before and after 
NAC.  
Immunohistochemistry has been used extensively to study local mucosal effects of allergen 
exposure – either by comparison in and out of season, or between allergic and non-allergic 
individuals, or pre and post NAC – as well as the effects of treatments, including allergen 
immunotherapy (Wilson DR, 2001; Nouri-Aria KT, 2005; Banfield G, 2010; Cameron LA, 1998). 
Nasal biopsy of the inferior turbinate is a simple procedure that can be performed in the clinic 
under local anaesthetic. Biopsies were taken as the final intervention during NAC visits (8 
hours post allergen), providing tissue for immunostaining, allowing comparison between 
nasal fluid mediators and immune cell infiltration into the local tissue.  
Nasal brushings have been used to collect cytology samples from the nasal mucosa which may 
then be assessed by RT-PCR to detect gene expression of inflammatory mediators such as 
eotaxin (Paplińska M, 2012). Nasal brushings, using a commercially available cytology brush, 
were taken from the side of the nose not biopsied, also at 8 hours post-challenge, for 
assessment of gene expression by RT-PCR.  
 
5.2 Participants 
Forty-six volunteers were recruited from the allergy clinic at The Royal Brompton Hospital and 
by local newspaper advertisement. Four groups were recruited: grass pollen allergics; non-
atopic individuals; patients undergoing grass pollen immunotherapy; and patients having 
completed grass pollen immunotherapy 12 to 24 months previously. Inclusion criteria were: 
 Grass pollen allergic volunteers (‘untreated-allergics’): as per previous pilot studies.   
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 Patients undergoing allergen immunotherapy to grass pollen (‘SIT-current’): as per 
grass pollen allergic individuals in previous studies, plus good adherence and on-going 
treatment with either subcutaneous injections of purified grass pollen extract (having 
reached full maintenance dose) or once-daily sublingual pollen extract tablets (having 
received at least 3 months uninterrupted treatment), (Aquagen SQ , Phleum pratense, 
100,000 SQ-U/mL or Grazax 75,000 SQ-U, respectively, both ALK-Abello). 
 Non-atopic individuals (‘non-atopics’): no history rhinitis symptoms other than with 
colds within the last 10 years; negative skin prick test responses, defined as wheal 
diameter ≤ 2 mm, to a panel of common aeroallergens (Timothy grass, mixed grass, 
silver birch, mixed tree pollens, mixed weed pollens, cat, dog, horse, house dust mite, 
Alternaria, Cladosporium and Aspergillus), compared to a negative control (allergen 
diluent) and positive control (histamine 10 mg/ml); absence of specific IgE, defined as 
IgE ≤ 0.35 IU/mL against Timothy grass. 
 Completed immunotherapy group (‘SIT-completed’): as per immunotherapy (‘SIT-
current’) volunteers, except for immunotherapy treatment having been completed (at 
least 3 years of treatment) between 12 months and 24 months previously. 
 
5.3 Study Design 
The study consisted of 2 visits. Visit 1 was the screening visit. Visit 2 involved a grass pollen 
nasal allergen challenge, with procedures as described previously. Particular to this study, all 
participants received a single 10,000 BU/mL dose, 100µL to each nostril, giving a total 
exposure of approximately 1.3µg major allergen. A single pre-lavage recording was made, 
then two post-lavage baseline recordings, before allergen challenge. Post challenge time-
points were as before, with recordings continued to 8 hours. Outcome measures were as 
before. Nasal fluid was collected using polyurethane sponges with extraction involving elution 
with 100µL buffer per sponge. A baseline blood sample of 150mL was taken following nasal 
lavage and prior to allergen challenge (130mL for separation of peripheral blood mononuclear 
cells for T cell assays; 10mL for whole blood flow cytometry assays; 10mL for serum antibody 
assays, see below). A second blood sample of 150mL was taken at 6 hours post allergen 
challenge. Blood samples were taken to the lab within 30 minutes of collection. Participants 
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also recorded retrospective scores of their hay fever symptoms during the preceding summer 
using two proformas (see below). 
Participants underwent intradermal grass pollen allergen injections on the extensor surfaces 
of their forearms, 10BU (approximately 7 ng major allergen) to the left arm, 1BU (0.7ng) to 
the right arm, between 30 minutes and 1 hour after allergen challenge, with the early phase 
skin response recorded after 15 minutes and the late phase response recorded after 8 hours. 
After recording clinical scores and undergoing collection of nasal fluid at 8 hours post allergen 
challenge, volunteers underwent nasal brushing on one side of the nose, followed by a nasal 
mucosal biopsy, under local anaesthetic, from the inferior turbinate of the other side of the 
nose. Participants were then observed for a further 30 minutes after the biopsy, before being 
discharged home. They were given a 24-hour contact telephone number in case of bleeding 
or discomfort following the biopsy.  
 
5.4 Results 
5.4.1 Participant demographics 
Fourteen non-atopic individuals (‘non-atopics’), 14 untreated grass pollen allergics 
(‘untreated allergics’), 14 allergic rhinitics currently receiving Timothy grass pollen 
immunotherapy (‘SIT-current’), and 4 patients who had previously completed grass pollen 
immunotherapy (‘SIT-completed’) were recruited (Table 4). Of the 14 patients currently 
receiving immunotherapy, 6 were taking Grazax 75,000 SQ-U sublingual tablets once daily 
and 8 were receiving monthly injections of 100,000 SQ-U Aquagen SQ Timothy grass pollen 
extract (both ALK-Abello, Hørsholm, Denmark). Of the 4 patients who had completed 
immunotherapy, 2 had taken Grazax and 2 had received the Aquagen SQ vaccine (Appendix 
1, Table 12). (Co-sensitisations are given in Table 12b, Appendix 1).  
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5.4.2 Clinical response to nasal allergen challenge 
All 4 groups had similar baseline scores prior to allergen provocation. Non-atopics had no 
response to allergen, whereas the 3 allergic groups showed clear responses, maximal at 5 
minutes. The SIT-current group had reduced TNSS compared to untreated allergics (p=0.039, 
Figure 25) as well as reduced fall in PNIF (p=0.016, Figure 26). SIT-completed patients showed 
the smallest fall in PNIF and similar reductions in TNSS as SIT-current patients. The effect of 
immunotherapy was predominantly seen during the early phase (TNSS, Figure 27A; PNIF, 
Figure 27B).  
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5.4.3 Local nasal biomarkers 
Nasal fluid tryptase peaked at 5 minutes post-challenge in allergic volunteers (p<0.0001, 
untreated allergics versus non-atopics, Figure 28A; Appendix 1, Table 13). Peak levels were 
lower in SIT-current and SIT-completed patients than untreated allergics, 11.4 and 10.4 pg/mL 
versus 16.5 pg/mL, respectively; but differences did not reach statistical significance. Area 
under the curve analyses revealed a trend to reduced tryptase in combined immunotherapy 
groups (SIT-current + SIT-completed) compared to untreated allergics (p=0.07).  
Eotaxin levels increased to 8 hours post-challenge in the allergic groups. SIT-completed 
volunteers had lower 8-hour eotaxin levels than untreated allergics (p=0.017, Figure 28B); 
SIT-current volunteers showed a trend to lower levels (p=0.08). Area under the curve analyses 
revealed reduced eotaxin levels in combined immunotherapy groups versus untreated 
allergics (p=0.01).  
Untreated allergics showed a gradual increase in the Th2 cytokines IL-4, IL-5, IL-9, and IL-13 
post-challenge (Figure 28; Appendix 1, Table 13). At 8 hours, SIT-current volunteers had lower 
nasal fluid IL-4 (p=0.027) and IL-9 (P=0.049) than untreated allergics. SIT-completed 
volunteers had lower IL-4 (p=0.049) and IL-9 (p=0.024), than untreated allergics, as well as 
trends to lower IL-13 and IL-5 (both p<0.08). Area under the curve analyses for combined 
immunotherapy groups showed reductions versus untreated allergics for IL-4, IL-9, IL-13 and 
eotaxin (all p<0.05). 
Interleukins 8 and 10 were present at similar concentrations in nasal fluid in all groups. ECP 
and RANTES levels were significantly elevated at 8 hours in untreated allergics compared to 
non-atopics (p<0.0001 and p<0.01, respectively, Appendix 1, Table 14), but were not 
significantly reduced in either immunotherapy group. At 8 hours, MDC was greatest in 
untreated allergics (p<0.01 versus non-atopics, p<0.05 versus SIT-completed).  
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5.4.4 Cutaneous allergen response 
The early phase (15 minute) cutaneous wheal response to 1 BU intradermal grass pollen 
allergen injection was smaller in SIT-current patients than untreated allergics (27% smaller, 
p<0.0007, Figure 29A). Late phase cutaneous responses were significantly smaller in both SIT-
current and SIT-completed groups (51%, p<0.0001 and 55%, p<0.0007 versus untreated 
allergics, respectively, Figure 29B).  
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5.4.5 Seasonal symptom scores 
Overall, untreated allergics rated their seasonal rhinoconjunctivitis symptoms as unchanged 
compared with previous years (retrospective global evaluation, Figure 30A). Both SIT-current 
and SIT-completed groups rated their symptoms during the most recent season as improved 
compared to years before starting immunotherapy (p=0.0011 and p=0.0003, versus 
untreated allergics, respectively). Overall seasonal symptom scores were also significantly 
lower in the immunotherapy treated groups than untreated allergics (p<0.0001 and p=0.015, 
SIT-current and SIT-completed, respectively, Figure 30B).  
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In the three allergic groups overall, seasonal symptom scores correlated with TNSS and PNIF 
responses to nasal challenge and with skin late phase intradermal allergen response (r=0.52, 
p=0.003; r=-0.57, p=0.0007; and r=0.63, p=0.0001, respectively, Figure 31A-C). In untreated 
allergics, ∆PNIF response to nasal allergen challenge correlated with seasonal symptom 
scores (early phase, r=-0.59, p=0.021; combined early and late phase, r=-0.54, p=0.036, Figure 
31D, E). 
In untreated allergics, 5-minute tryptase correlated with 8-hour IL-4, eotaxin, IL-5 and IL-9 
(r=0.69, p=0.008; r=0.70, p=0.006; r=0.61, p=0.024; r=0.59, p=0.029, respectively); and total 
volume of nasal fluid collected after challenge showed a positive correlation with TNSS 
(r=0.574, p=0.032), and an inverse correlation with ∆PNIF (r=-0.591, p=0.026) after challenge.  
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5.4.6 Subgroup analyses 
No significant differences were detected between subcutaneous (SCIT) and sublingually (SLIT) 
treated participants with regards to the preceding clinical or biological responses to nasal 
allergen challenge, or seasonal symptom scores. There were no correlations between 
duration of treatment and clinical or biological outcomes. 
5.4.7 Allergen-specific antibodies 
SIT-current participants had significantly higher levels of serum grass-pollen specific IgA1 than 
untreated allergics (Figure 32A). Lowest levels were seen in non-atopics. Conversely, allergen-
specific IgA1 levels in nasal fluid were not significantly different between groups, although 
the median level was highest in the SIT-current group (Figure 32B). Nasal allergen challenge 
did not result in significant increases, compared to baseline, in serum or nasal fluid IgA1 in 
the three allergic groups; however there was a decrease in nasal fluid IgA1 at 6 hours post 
challenge in non-atopics, p=0.002 versus baseline, Appendix 1, Table 15. 
Serum grass-pollen allergen-specific IgA2 antibodies were significantly higher in both SIT-
current and SIT-completed groups than in untreated allergics and non-atopics (Figure 32C). 
Nasal fluid specific IgA2 was highest in SIT-current participants (Figure 32D), but only 
significantly so (compared to non-atopics) at 6 hours post challenge (Appendix 1, Table 16). 
Again, no significant changes were seen when comparing pre- and post-challenge levels 
within groups, except for non-atopics, where levels in nasal fluid were lower post challenge, 
p<0.001, Appendix 1, Table 16.  
Correlation between serum and nasal fluid levels of both IgA1 and IgA2 revealed only weak 
correlations, r=0.32, p=0.002 and r=0.30, p=0.04, respectively.  
Subgroup analysis of subcutaneous (SCIT) and sublingual (SLIT) immunotherapy-treated 
patients revealed significantly higher levels of specific IgA1 in nasal fluid and a trend to higher 
levels in serum in SLIT-treated individuals, p=0.034 and p=0.2, respectively, Figure 33A, B; 
Appendix 1, Table 17. Levels of IgA2 were significantly higher in serum of SCIT-treated 
individuals, but nasal fluid levels were no different between SCIT and SLIT, Figure 33C, D; 
Appendix 1, Table 17.  
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There were no changes in nasal fluid grass pollen-specific IgE levels following nasal challenge 
versus baseline in grass allergic patients, but there was a statistically significant decrease post 
challenge in non-atopic individuals, albeit of negligible magnitude (Appendix 1, Table 18).  
Grass-pollen specific IgG4 was significantly higher in the sera of SIT-current and SIT-completed 
participants compared to both untreated allergics and non-atopics, Figure 34A. Levels were 
also higher in nasal fluid, although the difference was smaller; significant differences were 
seen at 6 hours post challenge, but not at baseline (Figure 34B; Appendix 1, Table 19). 
Subgroup analysis of SCIT and SLIT-treated patients revealed greater serum sIgG4 levels in 
SCIT-treated participants, but similar nasal fluid sIgG4 levels (Figure 34C, D).  
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5.4.8 Immunohistochemistry 
Eosinophils (MBP +ve cells) were most abundant in untreated allergics, without significant 
differences between groups (Figure 35A; example of staining Figure 36A). Basophils (2D7 +ve 
cells) were absent or present at low density in the majority of biopsies, the exceptions being 
two untreated allergics (Figure 35B; Figure 36B).  Mast cells (tryptase/AA1 +ve cells) were 
present at similar levels in non-atopics, untreated allergics and SIT-current groups, and lowest 
in SIT-completed patients, without a significant difference between groups (Figure 35C; 
Figure 36C). T cells (CD3 +ve cells) were similar amongst the different groups (Figure 35D; 
Figure 36D).  
5.4.9 3H-thymidine incorporation 
CD4+ cell thymidine incorporation after 6-day T-cell–APC co-culture was greatest in patients 
currently receiving immunotherapy (SIT-current), with cells isolated at baseline (pre-
challenge) showing greater in vitro proliferative response to 3µg/mL grass pollen allergen 
than both non-atopics and untreated allergics (Figure 37A). The pattern was similar at 6 hours 
after challenge (Figure 37B), although the proliferative response in untreated allergics was 
greater, having significantly increased compared to baseline (Figure 37C). A similar pattern 
was seen at both 1 and 5µg/mL of grass allergen (Appendix 1, Table 20). Proliferative 
responses in vitro to PHA and PPD were not significantly different between groups.  
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5.4.10 IL-4/IL-10 Fluorospot 
Following in vitro stimulation with 3µg/mL grass pollen allergen, the increase in IL-4 spots 
compared to unstimulated conditions was significantly greater in all allergic groups – 
untreated allergics, SIT-current and SIT-completed – than in non-atopics (Figure 38A). IL-10 
spots were also least frequent in non-atopics, showing no response to in vitro allergen 
stimulation, and being significantly lower than both untreated allergics and SIT-current 
groups (Figure 38B). Dual IL-4/IL-10 spots were most abundant in SIT-current patients, being 
significantly greater than non-atopics, and greater than untreated allergics, albeit without 
reaching statistical significance (Figure 38C).  
At other concentrations of grass pollen – 1 and 5µg/mL – a similar pattern was seen. For IL-4, 
greatest numbers of spots were seen in the two immunotherapy-treated groups, with the SIT-
completed group showing significantly greater IL-4 spots than both non-atopics and 
untreated allergics at each allergen concentration at 6 hours post challenge (Appendix 1, 
Table 21). Conversely, there were no differences between groups in response to non-specific 
stimulation with either PHA or PPD. Of note, in the three allergic groups, responses to both 
allergen and non-specific stimuli were greater in cells isolated from peripheral blood taken 6 
hours after allergen challenge compared to pre-challenge (albeit without reaching statistical 
significance), whilst this was not the case for the non-atopics.  
Concerning IL-10 spots, again, no differences were seen in response to non-specific 
stimulation with PHA and PPD (Appendix 1, Table 22). The pattern of results was broadly 
similar with in vitro stimulation with 3 and 5µg/mL grass pollen allergen. Immunotherapy-
treated groups had greater responsiveness than untreated allergics at 1µg/mL, but this 
difference did not reach statistical significance. There was again a tendency for increased IL-
10 spots in cells isolated from blood post-challenge compared to pre-challenge, but this effect 
was most pronounced in non-atopics, in contrast with IL-4 spots, (and similarly did not reach 
statistical significance).  
Concerning dual-positive spots, greatest numbers were seen in the immunotherapy-treated 
groups at each allergen concentration used (Appendix 1, Table 23). No differences were seen 
in response to non-specific stimuli. Numbers of dual-positive spots also tended to be 
increased after allergen challenge, compared to baseline, in the two immunotherapy groups.  
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5.4.11 Whole blood basophil flow cytometry 
The gating strategy is illustrated in Figure 39. Basophils were isolated from the lymphocyte 
compartment by gating on CD3- CD303- CTRH2+ cells. Data are presented as expression of 
surface activation markers after in vitro stimulation with 1µg/mL grass pollen allergen minus 
expression on unstimulated cells (Figure 40); (no differences were seen between groups in 
unstimulated cells, data not shown). In pre-challenge samples, expression of CD63 and 
CD203c was significantly greater in the three allergic groups than in non-atopics; CD107a was 
also greatest in the allergic groups, but only significantly greater than non-atopics in the 
untreated allergic group (Figure 40A-C). Of the three allergic groups, surface expression of all 
three activation markers was lowest in the SIT-current group, but this only reached 
significance compared to non-atopics for CD203c post-challenge (Appendix 1, Table 24). No 
differences were seen between groups in response to anti-IgE stimulation. 
Responses to allergen post-challenge were also greater in the three allergic groups than non-
atopics. On comparison of pre- and post-challenge basophil responses, generally no change 
was seen in allergen response, although CD203c expression in the SIT-current group was 
significantly lower post-challenge than at baseline. Conversely, the response to anti-IgE 
stimulation was reduced in all groups in samples taken post-challenge compared to pre-
challenge, being significantly reduced for CD63 and CD203c for both non-atopics and 
untreated allergics (Appendix 1, Table 24).   
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5.4.12 Analysis of nasal brush samples by RT-PCR 
Relative to GAPDH expression, nasal brush-derived mRNA showed more abundant transcripts 
from the following genes: IL-13, IL-25, APRIL, Annexin 1, ST2, sST2 and periostin; lower 
expression of: IL-4, IL-5, IL-9, IL-10, IL-21, IL-33, TSLP, BAFF, Annexin 1 receptor, CCL17 and 
Foxp3; similar expression of: IL-17A and CCL11 (Appendix 1, Table 25). Whilst greater relative 
expression of ST2 was seen in the three allergic groups, and greater periostin in untreated 
allergics and SIT-current compared to non-atopics, these differences between groups did not 
reach statistical significance.  
Relative to 18S expression, more abundant transcripts were detected from the following 
genes: IL-13, IL-25, APRIL, Annexin 1, CCL11, ST2, sST2, periostin; lower expression of: IL-4, IL-
5, IL-9, IL-10, IL-33, Foxp3; similar expression of: IL-17A, IL-21, TSLP, BAFF, Annexin 1 receptor 
and CCL17 (Appendix 1, Table 26). No differences were detected between groups by one-way 
ANOVA with correction for multiple comparisons. Unpaired t-tests (without correction) 
showed greater expression of ST2 in untreated allergics versus non-atopics, and greater 
expression of periostin in SIT-current patients versus non-atopics (both p<0.05).  
 
5.4.13 Summary of results 
 Individuals receiving grass pollen immunotherapy had lower TNSS and improved PNIF 
following nasal allergen challenge. The effect was most apparent in the first 60 
minutes post NAC. 
 Immunotherapy suppressed the intradermal allergen response, particularly the late 
phase response.  
 Individuals having completed immunotherapy at least 12 months prior to NAC also 
had improved PNIF post challenge and reduced late phase intradermal response. 
 Retrospective seasonal symptom scores correlated with both response to NAC and 
intradermal allergen response. 
 Treatment with immunotherapy was associated with reduced nasal fluid eotaxin, IL-9 
and IL-4, plus trends to reductions in other mediators, including tryptase. 
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 Immunotherapy-treated participants had higher serum grass pollen specific IgG4, IgA2 
and, to a lesser extent, IgA1, than untreated grass pollen allergics. A smaller effect was 
seen in nasal fluid.  
 Nasal fluid specific IgA1 levels were higher in SLIT-treated participants than SCIT-
treated participants. Serum levels of specific IgA2 and IgG4 were significantly elevated 
in SCIT compared to SLIT. 
 Immunotherapy was associated with a trend to greater T cell in vitro proliferative 
response to grass allergen, as measured by 3H-thymidine incorporation.  
 Immunotherapy-treated participants had greater numbers of IL-4 or IL-10 producing 
T-cells, but differences did not reach statistical significance.  
 Surface expression of CD63, CD107a and CD203c on basophils was not significantly 
different in immunotherapy-treated participants. Nasal allergen challenge did not 
result in upregulation of basophil surface markers.  
 Real time RT-PCR analysis of nasal brush samples showed few differences between 
groups.  
 
 
5.5 Discussion 
There were blunted clinical responses to NAC with immunotherapy, particularly in the early 
phase, whereas the effect on intradermal allergen response was most marked in the late 
phase. Correlations between provocation responses and seasonal symptoms suggest NAC 
may be a useful clinical surrogate. Immunotherapy also reduced Th2 cytokines and 
chemokines in nasal fluid, suggesting their suitability as biomarkers of treatment response.  
Immunotherapy-treated patients had higher serum grass pollen specific IgG4, IgA2 and, to a 
lesser extent, IgA1; but the effect was less pronounced in nasal fluid, suggesting these 
antibodies are not predominantly produced locally. Whilst a SCIT-SLIT comparison was not a 
stated aim of the study, post hoc analyses did reveal differences between the two with regard 
to antibody responses: nasal fluid specific IgA1 levels were higher in SLIT; conversely, serum 
levels of specific IgA2 and IgG4 were greater in SCIT. This may be indicative of differences in 
the mechanism of action between the two treatments. 
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Immunotherapy did not have a consistent, strong effect on T cell responses. This suggests 
that its effect may be primarily mediated by changes in antibody levels or direct effects at the 
nasal mucosa, rather than in the circulating T cell compartment.  
Notably, immunotherapy did not have the expected inhibitory effect on basophils. Whilst 
mean levels of surface expression of CD63, CD107a and CD203c were lower in 
immunotherapy-treated participants than untreated allergics, the only significant difference 
was seen in CD107a expression in basophils at 6 hours post challenge. Similarly, in contrast 
with cat nasal provocation, NAC did not enhance basophil activation.  
5.5.1 Appraisal of study methods and limitations 
The study was performed with examiners blinded to the status of participants, although 
participants themselves were clearly aware of their own atopic and treatment status. 
Importantly, outcomes cannot be attributed to the immunotherapy volunteers simply having 
milder baseline disease – this group had higher mean grass specific IgE levels; moreover, only 
patients with very troublesome allergic rhinitis, with proven incomplete response to 
intranasal corticosteroids, are treated with allergen-immunotherapy in the UK, meaning 
these patients were likely to have had severe disease prior to beginning immunotherapy. A 
cross-sectional design has limitations, in particular the possibility of selection and recall bias, 
as well as the absence of baseline data. Additionally, both subcutaneous and sublingually-
treated immunotherapy patients were recruited; this, along with the variable durations of 
treatment undoubtedly introduced heterogeneity. Nonetheless, SCIT and SLIT have both been 
shown to be highly effective in treating grass-pollen induced seasonal allergic rhinitis, with 
the largest, best-controlled studies suggesting a similar magnitude of effect (Frew AJ, 2006; 
Durham SR, 2006; Dahl R, 2006). It is therefore not unreasonable to group them together in 
a pilot, proof of principle study. Even with the inherent heterogeneity, differences between 
treated and untreated groups were clearly detectable. The study was underpowered for 
comparisons between SLIT and SCIT, but this was never the intention. Post-hoc, subgroup 
analyses were carried out, and failed to give significant differences between the two, except 
in the case of local antibodies, where the results do suggest potential mechanistic differences 
between the two treatment modalities. Finally, the SIT-completed group is clearly 
underpowered at just 4 participants. It is also the group most likely to be subject to selection 
bias – patients having done well on treatment more likely to return to participate in the study. 
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Nonetheless, as proof of principle, this small group serves an important purpose, providing 
evidence of long-lasting tolerance and suppression of local inflammatory mediators.  
Measurement of nasal fluid mediators until 8 hours after challenge captures important data 
on both early and late phase responses; however, even later changes may be missed. Only a 
limited number of studies have looked beyond 8 hours. Erin et al saw little further increase in 
several cytokines between 8 and 24 hours post challenge, except for IL-8 which continued to 
increase to 24 hours (Erin EM, 2005a). Measurement of nasal fluid antibody concentrations 
at 6-8 hours post challenge is probably earlier than optimal - increases in allergen-specific IgE 
were detected in bronchoalveolar lavage fluid 24 hours after segmental bronchial 
provocation (Wilson DR, 2002). Conversely, nasal provocations in the context of local allergic 
rhinitis have revealed an increase in specific IgE in nasal fluid by 6 hours (Rondon C, 2009). 
Similarly, 24 rather than 8 hours may have been a better time to take nasal biopsies for 
immunohistochemistry (Rak S, 1994), although studies of both nasal and skin allergen 
challenge have yielded meaningful results by 6-8 hours (Nouri-Aria KT, 2000; Banfield G, 
2010). Interpretation of the immunohistology results is limited by the absence of baseline 
data, the same being true of the RT-PCR data. Nasal biopsy cannot be performed immediately 
prior to nasal challenge – at least 4 weeks would likely be required to allow mucosal recovery. 
A baseline biopsy was therefore not performed. Conversely, if the study could be repeated, 
inclusion of a baseline nasal brush 3-5 days prior to challenge would give baseline data and 
allow pre- to post-challenge comparisons of gene expression. Nasal brushing likely recovers 
relatively few immune cells, instead predominantly collecting epithelial cells; this may explain 
why T cell transcription factors and Th2 cytokine genes were expressed at low levels 
compared to house-keeping genes.  
5.5.2 Comparisons with published literature 
a) Effect of immunotherapy on NAC responses 
The effect of immunotherapy was greatest during the first 2 hours after provocation. 
Interestingly, a similar effect on challenge responses has been described following ragweed 
immunotherapy (Creticos PS, 1989). This could be due to greater suppression of early rather 
than late phase inflammatory mechanisms; but late phase mediators – IL-4, IL-9, eotaxin - 
were significantly suppressed. The absence of distinct late phase clinical responses following 
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nasal challenge (in contrast to bronchial allergen challenge, where late phase responses may 
occur in 50% or more and are suppressed by immunotherapy (Warner JO, 1978)) is in-keeping 
with several other published reports (Iliopoulos O, 1991; Gronberg H, 1993; Pastorello EA, 
1994). Whilst clinical late phase responses (i.e. elevations in symptom scores) have been 
demonstrated post NAC for both house dust mite (de Graaf in’t Veld C, 1997) and pollens 
(Naclerio RM, 1985), responses are less robust, and of considerably lower magnitude, than 
early phase symptom responses. One explanation for this is that studies of the effects of nasal 
challenge on the lower airway tend to focus on measures of airflow – FEV1 or PEFR – rather 
than subjective symptom scores. However, whilst measures of nasal airflow or resistance may 
be a more sensitive tool for detecting the nasal LPR (Pastorello EA, 1994), these too show less 
dramatic effects than the reductions in FEV1 seen in bronchial late responses. An obvious 
possible explanation for this is the absence of smooth muscle within the nasal airway, in 
contrast to the lungs. Both bronchial smooth muscle contraction and mucosal 
inflammation/mucus secretion likely play a major role in late falls in FEV1 in the lungs. In the 
nose, vascular engorgement and plasma leakage are paramount. In the model developed 
here, PNIF responses suggest a persistent, gradually weakening effect on nasal flow, rather 
than a bi-phasic profile. The contrast between skin LPR and nasal LPR responses is even more 
dramatic. This perhaps represents the capacity (or, more simply, the space) available for 
superficial inflammation in the skin in comparison to the ‘closed box’of the nose. Whilst skin 
LPR responses are impressive in diameter (and therefore an excellent tool for the researcher), 
they are generally unproblematic (and not infrequently unnoticed) by the participant, in stark 
contrast to the early skin response. The difference here probably represents the available 
scope of the two models, rather than the nature of the inflammatory response per se.  
Without a clear late phase clinical response there is little potential for recording suppression 
by immunotherapy. Notably, environmental exposure chambers give a different pattern of 
response, with symptoms increasing progressively during the first few hours within the 
chamber, usually reaching a plateau by 3 hours (Patel D, 2013) – hence this approach may be 
better suited to assessing suppression of the clinical late phase by immunotherapy.  
The literature on the effects of immunotherapy on nasal fluid mediators is small. Ragweed 
immunotherapy resulted in a rightward shift in the dose-response curve for both histamine 
and TAME-esterase in a prospective study, but with no accompanying reduction in clinical 
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responses to challenge (Creticos PS, 1989). A previous cross-sectional study had shown 
reductions in secretion of PGD2 and TAME-esterase in immunotherapy-treated patients 
compared to matched, untreated allergics (Creticos PS, 1985). A subsequent double-blind, 
placebo-controlled study of ragweed immunotherapy confirmed these results, as well as the 
inhibition of kinins in nasal fluid (Iliopoulos O, 1991). No effect of cat immunotherapy was 
seen on nasal fluid TGF-β, IL-10, IFN-γ, IL-4, and IL-5 (Nanda A, 2004); conversely grass pollen 
immunotherapy inhibited tryptase and ECP release after nasal challenge (Klimek L, 1999a). 
Finally, birch pollen allergoid immunotherapy resulted in an increase in nasal fluid IFN-γ and 
decrease in IL-5 during seasonal allergen exposure, in the absence of nasal allergen 
provocation (Klimek L, 1999b). Grass pollen immunotherapy reduced seasonal eosinophil 
infiltration and IL-5 mRNA in nasal tissue (Wilson DR, 2001), increased local IFN-γ:IL-5 mRNA 
ratio (Wachholz PA, 2002), and reduced seasonal IL-9 mRNA and c-kit+ mast cells (Nouri-Aria 
KT, 2005).  
The results presented here build on the current literature, showing for the first time an effect 
of immunotherapy on local nasal fluid Th2 cytokines and chemokines after allergen challenge. 
Given the absence of readily detectable epithelial cytokines (with the exception of IL-33) and 
Th17 family cytokines, the effect of allergen immunotherapy on these mediators – if such an 
effect exists – cannot be tested in this model at present. It is possible that alternative 
approaches, for example repeat allergen challenges with a priming effect, or use of an 
allergen such as house dust mite which has intrinsic protease activity, may give alternative 
results. Whilst increases in IL-10 production by peripheral immune cells in vitro have long 
been recognised as a feature of immunotherapy treatment (Francis JN, 2003; Akdis CA, 1998), 
IL-10 responses in the local mucosa have been studied less frequently. Increased nasal 
mucosal IL-10 mRNA has been reported during seasonal allergen exposure in 
immunotherapy-treated patients (Nouri-Aria KT, 2004), with evidence that this is produced 
by phenotypic regulatory T cells (Radulovic S, 2008). No such effect was seen in this study. In 
contrast to Klimek et al (Klimek L, 1999a), we did not identify a reduction in nasal fluid ECP 
with immunotherapy. Of note, besides eosinophils, neutrophils – perhaps relatively 
unaffected by immunotherapy - may also be a source of ECP (Monteseirín J, 2007). Klimek 
(1999a) reported inhibition of increases in ECP at just 15 minutes post allergen challenge – 
we could not detect increases in ECP so soon after allergen exposure.  
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How do these effects compare with other rhinitis treatments, particularly corticosteroids? 
Pipkorn et al (Pipkorn U, 1987) demonstrated that a short course of high dose oral 
prednisolone (60mg daily for 2 days) could abrogate the late phase response to nasal 
challenge, as measured by sneezing, histamine, TAME-esterase activity, kinins and albumin, 
but had limited effect on the early phase. They subsequently found one week of treatment 
with intranasal corticosteroids had a more impressive effect on the early phase (Pipkorn U, 
1987). Intranasal corticosteroids have been shown to decrease eosinophil infiltration into the 
nasal mucosa during seasonal allergen exposure (Masuyama K, 1998), reduce IL-5 in nasal 
fluid (Kita H, 2000; Benson M, 2000) and IL-5 mRNA in turbinate biopsies (Masuyama K, 1998), 
inhibit increases in nasal fluid IL-4, -5, and -13 after nasal allergen challenge (Erin EM, 2005a; 
2005b), and prevent seasonal increases in IL-4 (Cameron LA, 1998) and eotaxin (Pullerits T, 
2000). There may be less effect on neutrophilic infiltration (Benson M, 1999) and 
inflammatory/Th1 cytokines, including IFN-γ, IL-1β, and TNFα (Benson M, 2000); but 
intranasal fluticasone was able to reduce IL-1β, IL-8, IL-6, and MIP-1α in nasal fluid in response 
nasal allergen challenge in one study (Weido AJ, 1996). There is a dearth of head to head 
studies between immunotherapy and intranasal corticosteroids, although a recent meta-
analysis suggests a comparable magnitude of effect (Matricardi PM, 2011). Some studies have 
looked at mechanistic as well as clinical outcomes (Rak S, 2001). Very few have compared the 
effects of both treatments on local mediators and inflammation, although Rak et al (2005) did 
find intranasal budesonide to be more effective than birch pollen immunotherapy in 
preventing seasonal increases in CD1a+, IgE+ and Fc epsilonRI+ cells in the nasal mucosa.  
b) Nasal fluid antibodies, immunotherapy and NAC 
Antibody responses to immunotherapy have been studied extensively. Both subcutaneous 
and sublingual immunotherapy have been associated with increases in allergen specific IgG 
antibodies, particularly IgG4 (Francis JN, 2008; James LK, 2011; Scadding GW, 2010), with 
evidence of a functional effect (Shamji MH, 2012). Both total and allergen specific antibodies 
have been identified in nasal fluid. Platts-Mills (1979) looked at nasal fluid from rye grass 
allergic patients, finding allergen specific IgA, IgG and IgE. He found a higher proportion of 
allergen specific to total IgG and IgA in nasal fluid than serum, consistent with local antibody 
production. Of note, after subcutaneous immunotherapy, the same patients showed a clear 
increase in serum allergen specific IgG, but without a corresponding increase in nasal fluid 
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IgG. Since then, further studies have revealed a marked increase in ragweed specific IgA in 
nasal fluid following seasonal allergen exposure, but no increase in local specific IgE in the 
same period (Reed CE, 1991). Later, this seasonal IgA increase was not found to be suppressed 
by intranasal corticosteroids (Kita H, 2000). Conversely, Benson et al (Benson M, 2000) found 
topical corticosteroids reduced total IgE in nasal fluid during the pollen season, alongside 
decreases in eosinophils, ECP, IL-4, IL-6 and IL-10. They later looked at total and birch pollen 
specific antibodies in the nasal fluid of birch allergic patients and non-atopic controls in 
relation to seasonal exposure, finding elevated levels of total IgE and IgG in allergics, as well 
as detectable Bet v1 specific IgA and IgG. However, Bet v1 specific IgE antibodies were largely 
undetectable, even in allergics. Conversely, dust mite allergen exposure led to greater 
changes in nasal fluid specific IgE levels than serum levels in one allergic cohort (Sensi LG, 
1994). More recently, a study of dust mite immunotherapy has reported increases in allergen 
specific IgG1 and IgG4 in nasal fluid (Xiao SF, 2004). 
Whilst several studies have identified an effect of seasonal/natural allergen exposure on 
antibody levels in nasal fluid, fewer studies have investigated the effect of nasal allergen 
provocations in this regard. Grass pollen nasal allergen challenge led to the appearance of 
immunoglobulin epsilon heavy chain germ-line transcripts in mucosal B cells in biopsy 
samples taken 24 hours after nasal challenge, an effect suppressed with topical 
corticosteroids (Durham SR, 1997). This research, and subsequent studies, helped confirm the 
presence of both local IgE production and B-cell class switching in the nasal mucosa (Cameron 
L, 2003; Kleinjan A, 2000; Smurthwaite L, 2001; Takhar P, 2005). Evidence for an effect of 
allergen challenge at protein level was provided by a study of segmental bronchial allergen 
challenge and analysis of bronchoalveolar lavage fluid (Wilson DR, 2002). An increase of 
allergen specific IgE in BAL was seen at 24 hours post challenge, with no increase in IgE 
directed against an irrelevant (non-challenged) allergen to which participants also had pre-
existing sensitisation. Moreover, the effect persisted even after correcting for changes in 
albumin and total IgE, suggesting local IgE production, rather than simply plasma leakage. 
With regards to nasal challenge, evidence of increased nasal fluid allergen-specific IgE has 
now predominantly been demonstrated in the context of local allergic rhinitis. The 
phenomenon of local, allergen specific IgE in the absence of identifiable peripheral 
sensitisation has long been established (Merrett TG, 1976; Huggins and Brostoff, 1975), with 
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something of a renaissance of late due to the work of Rondon and colleagues. They 
demonstrated the presence of local specific IgE in a proportion of individuals with nasal-
provocation proven grass and/or dust mite sensitive local allergic rhinitis (Rondon C, 2009; 
Lopez S, 2010). Notably, they reported increases in local IgE at just 1 hour after allergen 
challenge, peaking at 24 hours. Whilst it seems plausible that plasma cell production of 
immunoglobulins may increase at 24 hours after allergen exposure, the earlier increase is 
likely accounted for by an alternative mechanism.  
In common with previous results, in this study the lowest levels of grass pollen specific 
immunoglobulins of all classes were seen in non-atopic individuals, suggesting that natural 
tolerance is not reliant on active antibody-mediated suppressive mechanisms. In contrast to 
corticosteroids, immunotherapy did not show any tendency to reduce local IgE levels. Serum 
IgA2 and IgG4 were increased in immunotherapy treated individuals, consistent with previous 
data (Pilette C, 2007), and particularly with SCIT. Conversely, nasal fluid specific 
immunoglobulins showed a less impressive response, and, of particular note, SLIT appeared 
to have a similar or even greater effect here than SCIT. Finally, we were unable to detect an 
effect of grass pollen nasal challenge on specific immunoglobulin levels in nasal fluid at 6-8 
hours after challenge, in contrast to studies of nasal provocation in local allergic rhinitis.  
 
c) Immunotherapy and T cell responses to allergen 
The effects of immunotherapy on T-cell allergen specific responses have been studied in 
considerable detail, both for subcutaneous (James LK, 2008) sublingual (Scadding and 
Durham, 2011) pollen immunotherapy and hymenoptera venom immunotherapy (Ozdemir C, 
2011). Outcomes associated with immunotherapy treatment have included reductions in 
peripheral blood mononuclear cell or T cell allergen-induced proliferation and a propensity 
for T-cells to produce greater IL-10 (Francis JN, 2003).  Other findings include inhibition of Th2 
cytokines and/or increased production of IFN-γ (Jutel and Pichler, 1995; Benjaponpitak S, 
1999). However, these effects have not been consistently reproduced in all studies. For 
example, Francis et al (2003) found that PBMCs from immunotherapy-treated patients 
showed a tendency to greater proliferation and production of IL-5, -4, and -13 in response to 
allergen stimulation in vitro. Regarding sublingual immunotherapy, suppression of T cell 
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proliferation has been shown to be either TGF-β (O’Hehir RE, 2009) or IL-10-dependent (Bohle 
B, 2007), with the latter study also demonstrating an increase in T cell IFN-γ production later 
during treatment. Yet, several other studies have failed to reproduce these results (Rolinck-
Werninghaus C, 2005; Dehlink E, 2006). Interestingly, a recent detailed time-course analysis 
of the immunological effects of grass pollen SLIT suggested an early (1 month) increase in 
peripheral blood mononuclear cell IL-4 production in response to allergen in vitro (Suarez-
Fueyo A, 2014). Most of these studies have not involved nasal allergen provocations. Shamji 
(2015b) observed subtle changes in T-cell proliferation and IL-4 production following in vitro 
allergen stimulation in cells isolated from blood immediately before and 6 hours after 
participants underwent nasal allergen challenge. Proliferation assessed by 3H-thymidine 
incorporation and number of IL-4 positive cells detected by Flourospot, were both increased 
at 6 hours versus baseline; importantly, no such changes were seen following a diluent-only 
challenge. 
The data presented here are only partially consistent with the current paradigm view of the 
mechanisms of allergen immunotherapy. Instead of a reduction in allergen-induced T cell 
proliferation with immunotherapy, proliferation tended to be increased. This is, however, not 
dissimilar to the results of Francis (2003). In-keeping with the results of Shamji (2015b), there 
appears to have been an effect, albeit modest, of in vivo nasal allergen challenge on in vitro T 
cell proliferative responses, with untreated allergics showing greater proliferation at 6 hours 
than pre-challenge. However, this response was only seen at 3µg/ml in vitro Phleum pratense 
(the same concentration reported by Shamji), not at 1 or 5 µg/ml. This effect was not apparent 
in non-atopics or immunotherapy-treated patients. IL-4 production, as assessed by 
Fluorospot assay, did not reveal a significant effect of in vivo allergen challenge, in contrast to 
the study by Shamji et al. Consistent with the results of Francis, there was no evidence of a 
decrease in IL-4 production in treated individuals – instead a trend to the opposite. 
Conversely, IL-10 producing cells were not increased with immunotherapy, in contrast to the 
results of Francis et al. There are several reasons why this might be. First, the assays used are 
different – a plate-based spot assay versus intracellular IL-10 staining assessed by flow 
cytometry and production measured by ELISA (Francis JN, 2003), plus different incubation 
periods. Second, the treated patients here consisted of both SLIT and SCIT patients, with 
different durations of treatment, whereas in the previous study only SCIT-treated patients 
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were involved and all had received treatment for at least 1.5 years. The results of the study 
by Suarez-Fueyo (Suarez-Fueyo A, 2014) (increased PBMC IL-4 at 1 month of SLIT) may be 
relevant here: whilst all our SLIT patients had completed at least 6 months treatment, their 
study highlights the fact that T cell responses to SLIT may be dynamic over the course of time 
– potentially relevant given the different durations of treatment in this study.  
d) Basophil responses to NAC and immunotherapy 
Immunotherapy is believed to induce rapid (hours to days) basophil hyposensitisation, at least 
in the context of (rush) venom immunotherapy (Akdis CA, 1998; Novak N, 2012). How this 
differs, at this early stage, from the temporary state of hyporesponsiveness seen after drug 
or food desensitisation is unclear. However, recently it has been suggested that basophil 
hyporeactivity may, in part, be mediated by the histamine receptor-2 pathway (Novak N, 
2012). Concerning pollen immunotherapy, both sublingual and subcutaneously treated 
patients showed reduced basophil activation in vitro in response to allergen (Shamji MH 
2015a). Moreover, the effect seemed to persist in a group of patients who had completed 
immunotherapy some months previously, suggesting this may represent a mechanism of true 
allergen tolerance rather than temporary hyposensitisation. Aasbjerg and colleagues (2014) 
performed an open, randomised study of SCIT, SLIT and matched untreated controls and 
recorded basophil responses over the course of 15 months. They found that, whilst both SCIT 
and SLIT suppressed allergen-induced basophil activation, the magnitude of effect was about 
twice as great with SCIT than SLIT. In the study reported here, there was no clear effect of 
immunotherapy on basophil reactivity in vitro, nor was there a definitive stimulating effect of 
in vivo nasal allergen challenge as was described by Shamji (2015b). The reasons for this are 
unclear. Whilst there was heterogeneity within the cohort of immunotherapy-treated 
participants (both SLIT and SCIT; different durations of treatment), Shamji and Aasbjerg 
demonstrated effects for both SCIT and SLIT. The shorter duration of treatment of some 
patients may have been a factor, particularly for the SCIT-treated participants; however most 
of the inhibitory effect seen with SCIT patients had been reached by 3 months treatment in 
Aasbjerg’s cohort, suggesting this should not have been a factor in the SCIT group here. The 
absence of an effect of in vivo nasal allergen challenge, in contrast to the Cat NAC study, might 
be due to delays in immunostaining of blood samples and capture by flow cytometry at 6 
hours: the observed reductions from pre- to post-challenge of anti-IgE-induced basophil 
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activation, not apparent in the cat NAC study, would tend to support this. Delays in the 
laboratory may have occurred due to the number of concurrent experiments performed on a 
twice daily basis for this cross-sectional study, with sample capture by flow cytometry proving 
slow, alongside several other studies on-going in the lab at the same time. In retrospect, the 
number of different assays performed may have been over-ambitious. Additionally, unlike the 
cat NAC study, there was no diluent challenge day to correct for effects seen after allergen 
challenge. 
e) NAC, immunohistochemistry and immunotherapy 
With regards to immunohistochemistry and cytology studies, eosinophils appear to be a 
sensitive indicator of either seasonal allergen exposure (Masuyama K, 1998) or nasal allergen 
provocation (Bascom R, 1989; Pelikan Z, 1988). Conversely, mast cells have remained 
unchanged in nasal lavage fluid (Pelikan Z, 1988) and even shown a trend to a reduction in 
biopsy specimens (Varney V, 1992) post NAC. Additionally, there may be differences 
depending on staining for tryptase or chymase positive cells (KleinJan A, 2000). Basophils have 
been shown to peak at just 1 hour after nasal allergen provocation in a biopsy study (KleinJan 
A, 2000), but also to be elevated up to 11 hours after challenge in nasal fluid cytospin slides 
(Bascom R, 1988a). Studies of T cells in the local mucosa during seasonal exposure or after 
allergen challenge have revealed increases in the numbers of activated CD25+ CD4+ cells or 
CCR4+ cells, rather than necessarily an increase in total T cell numbers (Varney V, 1992; 
Banfield G, 2010). Antigen presenting cell number and phenotype has also been shown to be 
affected by allergen exposure (Godthelp, 1996).  
The effect of corticosteroids on cellular influx in allergic rhinitis has been extensively studied 
and provides a comparator for the effects of allergen immunotherapy. Nasal eosinophils are 
highly steroid-sensitive (Bascom R, 1988b). Intranasal steroids have been shown to reduce 
the seasonal increase in eosinophils in the nasal mucosa (Masuyama K, 1998) as well as in 
response to nasal allergen provocation (Rak S, 1994; Holm A, 2001; Bascom R, 1988b). Whilst 
some researchers have not found a significant steroid effect on local mast cell numbers 
(Bradding P, 1995; Pipkorn U, 1987; Juliusson S, 1993), others have shown prevention of usual 
seasonal increases/increases in response to challenge (Gomez E, 1988; Rak S 1994; Holm AF, 
1999). Some studies also report suppression of T cell infiltration (Rak S, 1994) and basophils 
(Bascom R, 1988a) by intranasal corticosteroids. Allergen immunotherapy suppresses 
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eosinophil influx during seasonal allergen exposure (Wilson DR, 2001), but this effect is less 
marked than with prolonged treatment with intranasal corticosteroids. Immunotherapy 
reduces the seasonal increase in mast cell numbers in comparison to placebo, but does not 
completely ablate it (Nouri-Aria KT, 2005). Additionally, however, immunotherapy has 
systemic effects which are not achievable with local nasal corticosteroids (and perhaps not 
even with systemic corticosteroids), including suppressing T cell, eosinophil (Varney VA, 1993) 
and mast cell (Durham SR, 1999b) infiltration in the skin after intradermal allergen injection. 
The effect of immunotherapy on basophil infiltration in response to seasonal exposure or 
allergen provocation has been less frequently studied. Okuda et al (1989) report that 
immunotherapy reduced the number of local basophilic metachromatic cells in allergic 
rhinitics after allergen challenge; conversely, Iliopoulos et al (Iliopoulos O, 1991) found no 
significant effect of immunotherapy on basophil numbers after provocation despite changes 
in local histamine, kinins and TAME-esterases.  
In this study, immunotherapy-treated patients did not have significantly reduced local 
eosinophils after NAC compared to untreated allergics. The study was probably 
underpowered to detect a difference (if one indeed exists). Only relatively few individuals – 
all of whom were in the untreated allergic group – had high basophil counts, and no significant 
differences were found between groups. Again, the study appears underpowered in this 
regard, but the timing of the biopsy may not have been optimal, with the work of Kleinjan et 
al (2000) suggesting an earlier time point - as early as 1 hour - would have been preferable. 
Conversely, many other fruitful studies have examined biopsies as late as 24 hours post 
challenge (Holm AF, 2001). Clearly a single time point may not be optimal for all inflammatory 
cell types, but taking biopsies at multiple time points is difficult for both examiners and 
participants, and would interfere with non-invasive measures, such as nasal fluid collection. 
No definite effect was seen on mast cells (aside from a slight reduction in the small group who 
had already completed immunotherapy) consistent with the mixed results in the literature. 
Finally, there were no changes in overall T cell numbers, again, not necessarily at odds with 
the published literature. Overall, these results tend to suggest that other laboratory outcomes 
– nasal fluid Th2 cytokines and chemokines in particular – may be more sensitive measures of 
the effect of immunotherapy in the context of nasal allergen challenge, a result consistent 
with the study by Iliopoulos et al (1991).  
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f) Immunotherapy and nasal mucosal gene expression 
Gene expression has previously been studied in relation to seasonal allergen exposure and 
nasal allergen challenge, either by in situ hybridisation (Nouri-Aria KT, 2000) – technically 
demanding and time-consuming, but allowing morphology and cellular localisation of mRNA 
to be studied – or by RT-PCR of material derived by nasal biopsy or brushing/scraping of the 
nasal mucosa (Kitamura Y, 2012). In situ hybridisation has demonstrated increases in IL-4 and 
IL-5 mRNA in the nasal mucosa in-season (Cameron LA, 1998; Masuyama K, 1998; Kita H, 
2000) and after nasal provocation (Nouri-Aria KT, 2000). Elevated IL-10, IL-13, and RANTES 
mRNA after provocation (KleinJan A, 1999) and a trend toward increased IL-9 mRNA in-season 
(Nouri-Aria KT, 2005) have also been described. Reduced IFN-γ in allergics compared to 
controls in response to allergen challenge (Pilette C, 2013) and increased IL-17A mRNA in dust 
mite allergics (Liu Y, 2013) have been reported. RT-PCR has demonstrated increased 
expression of TSLP and IL-33 mRNA in homogenised turbinate tissue of allergic rhinitics (Mou 
Z, 2009; Kamekura R, 2012). In the study presented here, nasal brush samples were 
performed to investigate whether changes in gene expression could be detected for 
mediators, particularly epithelial-derived cytokines, for which either no changes in protein 
levels in nasal fluid could be detected after challenge or where levels appeared to be below 
the limit of assay detection. Results were disappointing, with only differences in ST2 (IL-33 
receptor) and periostin mRNA levels being significant – lower in non-atopics than untreated 
allergics and patients currently receiving immunotherapy, respectively. ST2 protein levels in 
nasal fluid have been found to be raised during seasonal allergen exposure (Baumann R, 2013) 
as have periostin levels (Ishida A, 2012), but these have yet to be studied in the context of 
allergen immunotherapy. Of note, asthmatics with higher serum periostin levels had better 
response to anti-IL-13 treatment than those with lower levels (Corren J, 2011). Periostin has 
subsequently been considered a good marker of Th2 inflammation. However, unlike Th2 
cytokines in nasal fluid, there was no evidence of reduced periostin at mRNA in 
immunotherapy-treated patients.  
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5.5.3 Biological and clinical relevance of results 
a) Effects of immunotherapy 
Immunotherapy reduced tryptase in nasal fluid without a clear reduction in mucosal mast cell 
density. This suggests an active suppression of mast cell degranulation with immunotherapy. 
Inhibitory antibodies – potentially both IgA and IgG classes – are candidates for mediating this 
effect, but alternative mechanisms, such as up-regulation of inhibitory surface molecules 
(perhaps histamine receptor-2 as has been suggested for basophils during venom 
immunotherapy (Novak N, 2012)) might also be relevant. The reductions seen in Th2 
cytokines and chemokines during the (biological) late phase response are consistent with the 
anticipated inhibitory effects of immunotherapy. Given the correlation described between 
early (5 minute) tryptase and late (8 hour) Th2 cytokines/chemokines in untreated allergics, 
some of this may be a direct downstream effect of reduced mast cell degranulation. 
Alternatively (or additionally), reduced activation (rather than reduced cell numbers) of local 
antigen presenting, T- and B-cells may result in lower Th2 cytokine and chemokine release. 
Local inhibitory factors, such as IL-10, cannot be said to have a definite role from the data 
presented here, but this is in contrast to other studies (Radulovic S, 2008). Overall, the results 
suggest that allergen immunotherapy has effects on both early and late phase allergic 
responses – similar to prolonged intranasal steroid use – with additional systemic effects, as 
also demonstrated by suppression of both early and late phase intradermal skin responses to 
allergen.  
It is not possible to conclude from these data that allergen immunotherapy has a profound 
effect on peripheral blood T cell responses to allergen. Conversely, recent studies have 
suggested that selective deletion of CD27- Th2 cells occurs during allergen immunotherapy 
(Wambre E, 2012). This might be expected to reduce the overall T cell proliferative and/or IL-
4 secretory response to allergen; yet this subtle signal may be drowned out by a larger, but 
less relevant response when T cells are assessed as a whole population. Alternatively, 
immunotherapy might be associated with stimulation of a regulatory T cell response (Swamy 
RS, 2012), which would be consistent with an increased T cell proliferative response to 
allergen, as hinted at here, and also an increased propensity to release inhibitory factors such 
as IL-10.  The data here suggest a discrepancy between local and systemic responses – 
particularly for IL-4. Despite this, it is clear that immunotherapy has a systemic effect in vivo, 
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as manifest by the suppression of responses to intradermal allergen injection. Why then this 
observed discrepancy? Nasal responses (and those in the skin) were assessed in vivo (or 
directly ex vivo regarding nasal fluid cytokines), whereas systemic T cell responses were 
assessed following in vitro culture. In particular, in vitro T cell responses were assessed at the 
exclusion of potentially suppressive/regulatory serum factors. The absence of a clear T cell 
regulatory response may also be an apparent rather than a true result. The Fluorospot system 
used here has not reproduced the effect seen with simple ELISA-based assays of T cell IL-10 
secretion (Francis JN, 2003; Akdis CA, 1998) suggesting the amount of IL-10 secretion overall 
may be relevant rather than an increase in the absolute number of cells secreting IL-10.  
These results suggest only a modest correlation between serum and nasal allergen-specific 
antibodies. Subcutaneous immunotherapy appears to have a marked effect on stimulation of 
specific antibody production in serum, but the effect on nasal fluid is smaller and similar to 
that of sublingual immunotherapy. This may be relevant given the similar effect size of the 
two treatments seen clinical trials (compare, for example, Frew AJ, 2006 with Didier A, 2007). 
Sublingual immunotherapy may stimulate local antibody production from regional lymph 
nodes or from T cell–B cell interaction in the mucosa itself. Conversely, subcutaneous 
treatment may produce a large plasma cell response in the blood, with overspill or active 
secretion of antibody into the nasal mucosa. Furthermore, these results suggest a more 
dramatic effect on local IgA, rather than IgG4, in sublingual immunotherapy, suggesting the 
former antibody class may be more important in this mode of treatment – consistent with 
results of a mouse model of SLIT where a 30-fold increase in BAL and nasal lavage fluid 
allergen-specific IgA was seen (Kildsgaard J, 2007). IgA levels may increase as a result of local 
class switching by B cells, or by activation of and secretion from memory IgA+ B cells. 
Functional studies are required to evaluate the activity of these local antibodies.  Of note, 
prophylactic intranasal administration of a monoclonal IgA antibody against ragweed in mice 
prevented induction of airways inflammation after nebulised challenge in an allergen-specific 
manner (Schwarze J, 1998).  
b) Impact on clinical practice 
The impact on clinical practice principally relates to clinical research studies. The same 
techniques have been used as the primary outcome in a prospective, double-blind, double-
dummy, placebo-controlled trial of sublingual and subcutaneous grass pollen immunotherapy 
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(GRASS, ITN043AD). In time, these studies may encourage use of nasal allergen challenge in 
more routine clinical care, for example, in judging the relative importance of different 
allergens in polysensitised individuals; assessing suitability for immunotherapy in individuals 
with sensitisation to perennial allergens such as house dust mite, cockroach or animal 
danders; and also in assessment of occupational allergen exposures. Biological markers of 
response – tryptase and Th2 cytokines/chemokines – may be of particular relevance in the 
latter case where a high level of evidence of causality may be required. Finally, it may be 
possible to assess the likelihood of response to different treatments in a prospective manner, 
depending on biomarker profiles in nasal fluid.  
Both TNSS and PNIF have their merits as choice of primary outcome in future, interventional 
studies. TNSS is, perhaps, the obvious choice given that this is what matters to patients and 
reflects what they experience during usual allergen exposure. TNSS was chosen as the primary 
outcome for the GRASS trial for this reason. On the other hand, PNIF looks a more sensitive 
tool for picking up a treatment effect, at least judging from the data from the cross-sectional 
study presented here. As a primary outcome this would provide more power to detect a 
treatment effect of an intervention, should one exist. However, it will likely be more of a 
challenge to convince regulatory authorities to approve any new treatment based purely on 
an effect on PNIF. The result is that both measures should be used in future studies, 
particularly as neither is difficult nor time consuming to perform. Recording of VAS was left 
out of later studies presented here as it added nothing beyond that seen with TNSS.  
Use of nasal allergen challenge in clinical trials has considerable advantages. First, it avoids 
the problem of variable allergen exposures encountered in field studies. Second, it allows 
investigators more freedom with regard to timing of trials, particularly with regard to seasonal 
allergens. Third, it likely provides greater power, for a given number of participants, to pick 
up a treatment effect compared to seasonal combined symptom and medication scores 
(SMS), thereby potentially lowering both cost and complexity of future studies. This final point 
does require further clarification before regulatory authorities are likely to approve of its use 
in phase III studies. Adequately powered studies with both NAC responses and combined 
SMS, allowing correlation between the two both during baseline seasons and in response to 
treatment (be that allergen immunotherapy, intranasal corticosteroids or other) are needed. 
In addition, correlation between NAC and EEC exposure is also required. The latter has now 
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been used in several phase II studies, with promising outcomes (Patel D, 2013; Patel P, 2014), 
and has been shown to have a reasonable correlation with symptom scores during usual, 
seasonal allergen exposure, such as for ragweed pollinosis (Jacobs RA, 2012). At present 
therefore, the EEC is a preferable surrogate for seasonal SMS compared to NAC, at least with 
regard to assessment of interventions for clinical use. NAC probably has the advantage when 
it comes to investigating pathomechanisms as the time-course of effects following allergen 
exposure is clearly set following a single, high-dose exposure.  
5.5.4 Future studies  
As mentioned previously, further validation of the NAC requires a prospective study. The 
GRASS should fulfil this requirement. The primary outcome there will be, as in this study, the 
equally-weighted EPR and LPR response to nasal challenge (in this case with adjustment for 
baseline, pre-treatment NAC response). The trial will also indicate how baseline, pre-
treatment characteristics, including clinical and biological responses to nasal allergen 
challenge, may predict response to immunotherapy. Seasonal symptom and medication 
diaries have been recorded prospectively, allowing correlation between symptoms in the field 
and nasal challenge responses. A strong correlation will further support the use of NAC as a 
surrogate for ‘real-life’ symptoms. 
Studies of the functional properties of nasal fluid antibodies are underway. Post-
immunotherapy nasal fluid can block IgE-mediated facilitated allergen binding to B cells (M. 
Shamji, unpublished data), although confirmation that this is mediated by the IgG4 fraction is 
required. IgA serum fractions have been shown to induce monocyte IL-10 secretion in vitro 
(Pilette C, 2007). Nasal fluid IgA may have similar properties, a possibility that Dr Pilette and 
colleagues are investigating using nasal fluid samples from this study. The source of allergen-
specific antibodies - stimulation of pre-existing plasma cells or class-switching from other 
antibody isotypes – is also of interest. Evidence for local class switching to IgE has already 
been provided (Thakar P, 2005; Coker HA, 2003; Smurthwaite L, 2001). The possibility of class 
switch from IgE to IgA2 exists given that the α2 heavy-chain constant region gene segment 
lies downstream of the ε segment. A longstanding collaboration with Dr Louisa James and 
Professor Hannah Gould at King’s College will be used to investigate these possibilities 
further, using PBMCs and nasal biopsy samples taken in this study.   
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The mechanism of peripheral blood basophil activation after NAC is unclear. To investigate 
the possibility that serum-based factors (such as allergen absorbed into the circulation or 
inflammatory cytokines) are responsible, serum taken pre- and post-challenge might be 
investigated for its ability to stimulate autologous basophils in vitro. Whether such an assay 
is feasible - in particular, the stability of basophils, presumably isolated pre-challenge, in 
assays run 6 hours later – remains to be seen. Alternatives would include looking for allergen 
in serum pre and post challenge (as has previously been described with radiolabeled allergen 
(Bagnasco M, 1997)) or direct measure of serum cytokines, both requiring highly sensitive 
assays.  
Undertaking nasal challenge with a longer period of observation post challenge would allow 
for assessment of responses beyond 8 hours. This may determine whether peak cytokine 
levels are reached by 8 hours. A later time point, perhaps 24 hours, might be better for 
identifying antibody responses to challenge. Finally, recording up to 24 hours (and even 
beyond) would provide information on resolution of inflammatory responses. Repeated 
provocations over a period of days would more closely model chronic allergen exposure. It 
would be interesting to review nasal fluid responses in this context, particularly whether other 
mediators, e.g. IL-17A, are more relevant than in a single challenge model.  
Paired studies of responses to nasal challenge in the upper and lower respiratory tract may 
shed further light on the mechanisms of naso-bronchial interaction. They may also provide 
information as to whether responses in the nose might be surrogate for those in the chest – 
beneficial if so, given the relative ease of access of the nasal mucosa and safety of nasal 
allergen challenge.  
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6. Conclusion 
The studies detailed here describe the process of developing a tool for use in clinical research, 
then testing it in an interventional scenario – allergen immunotherapy for seasonal allergic 
rhinitis. This has involved investigation of dose responses, time-course of responses, and 
methods of collection of biological material – principally nasal fluid – followed by laboratory 
assays, and, where possible, assessing the relationship of the latter with clinical responses. 
Polyurethane sponge was found to be superior to alternative methods of direct nasal fluid 
absorption; low volume elution with a detergent buffer avoided null (as opposed to negative) 
results without compromising validity. The early allergic response coincided with a rapid 
increase in tryptase in nasal fluid, a finding reproduced in each subsequent study. Several 
cytokines – IL-4, IL-5, IL-9 and IL-13 – and the chemokine eotaxin best represented the 
biological late phase response. There is evidence that these mediators are suppressed during 
(and after completion of) specific allergen immunotherapy, alongside improved clinical 
outcomes in response to NAC, and better seasonal symptoms. Concerning the last point, NAC 
may be a useful surrogate for usual seasonal symptoms in individuals with grass-pollen 
induced seasonal allergic rhinitis, although further clarification in prospective studies is 
required. The relationship between NAC responses and perennial (as opposed to seasonal) 
allergic rhinitis symptoms cannot be determined from these data and requires further study. 
Cat NAC provided important evidence of a systemic effect of nasal mucosal allergen exposure. 
Whilst the precise mechanism of this remains to be determined – and the relevance to clinical 
disease assessed further – it at the least provides a testable hypothesis as to why mucosal 
allergen exposure at one site might lead to inflammation at distant sites. Another novel result 
here is the relative difference in allergen specific antibody responses seen in subcutaneous 
versus sublingual grass pollen immunotherapy, although numbers of individuals in each sub-
group are small. The finding of similar, if not greater, allergen specific IgA1 and 2 levels in 
nasal fluid in sublingual immunotherapy, despite lower serum levels, suggests up-regulation 
of local rather than systemic anti-allergic mechanisms.  Again, these qualitative differences 
between sublingual and subcutaneous immunotherapy require further study.  
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